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ABSTRACT 
 
Macromolecular Crystallography: Crystallisation and Structural 
Determination.  
 
 
 
This thesis explores the protein crystallography in its crucial steps: from the crystallisation process 
to the resolution of the crystalline structure. The first chapter is a general introduction to 
macromolecular crystallography and crystallisation processes of, the parameters affecting it, are 
described with together the most used crystallisation techniques. The following three chapters 
report the research themes object of this PhD thesis to three themes strongly correlated to the 
crystallography of biological macromolecules: (1) The design and developing of engineered 
surfaces and tools to favor the crystallisation of biological macromolecules; (2) The three-
dimensional structure determination of toxins belonging to the RIPs family to be able to correlate 
their molecular structures to the biological activities; (3) The structural characterisation of adducts 
between model proteins and platinum-based anticancer drugs or, generally, metal ions.  
 
1. The success of structural analyses of biological macromolecules by X-ray crystallography 
depends on the availability of suitable single crystals. The second chapter illustrates the research on 
functionalised surfaces as protein nucleator. To crystallise model proteins, we have used two 
functionalised surfaces exposing ionisable groups: sulphonated polystyrene films and silanised 
mica. The results showed that for some proteins, those functionalised surfaces decreased the median 
waiting time and the starting protein concentration necessary to obtain crystals, with respect to the 
siliconised glass cover slips (reference) (Tosi et al., 2008).  
In order to compare the effect of the different surfaces, experiments must be done under similar 
conditions. We have tested the functionalised surfaces with together a modified essicator, the 
Crystallisation Mushroom (Triana S&T), to perform vapour diffusion experiments that allows the 
equilibration of more than 12 drops against a unique reservoir. Also in this case, the obtained results 
highlight the influence of ionisable groups, linked to the surfaces, on the nucleation and growth of 
protein crystals, confirming that functionalised surfaces decrease the nucleation induction-time with 
respect to the siliconised glass cover slips (Tosi et al., submitted). 
 
2. In the third chapter, the crystallisation studies on several toxins belonging to the family of RIPs 
(Ribosome Inactivating Proteins) are presented. In particular, the results obtained for two of them, 
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bouganin and lychnin, are discussed. The resolution of the three-dimensional structure of those two 
RIPs has allowed to compare them with other known RIPs (Fermani et al., submitted). It is showed 
that he overall structure of bouganin and lychnin is similar to the other considered RIPs and the 
typical RIP fold is conserved. The superimpositioning of their Cα atoms highlights some differences 
in the N-terminal and C-terminal domains. The studies of their structures has been carried out in 
parallel to the study of their adenine polynucleotide glycosylase activity and the comparison. It has 
been hypothesised that two conditions are needed to be present at the same time in a RIP to 
guarantee an efficient interaction with the substrate and an efficient catalysis. They are a negative 
electrostatic surface potential at the active site and several exposed positively charged residues in 
the region around that site.  
 
3. The fourth chapter explores the interactions between model proteins and platinum-based 
anticancer drugs or, generally, metal ions. The study of Pt-protein adducts is important both for 
drug’s activity and undesired side effects. The characterisation of protein-cisplatin adducts can give 
valuable information for designing new and better anticancer drugs and possibly overcome cisplatin 
resistance. As model of study, four proteins have been chosen: human ubiquitin and superoxide 
dismutase (SOD) for their biological relevance and their full characterisation in the native state, 
while Hah1 and CopC because they are proteins naturally involved in copper homeostasis and 
responsible for platinum drugs transport. Crystals of protein and cisplatin or other metal ions such 
as Cd, Cu, Hg, and Zn have been prepared by co-crystallisation or soaking of already formed native 
crystals. The crystallographic structures of ubiquitin with Cd, Zn, or Hg have confirmed that the 
protein has highly affinity for metal ions and have revealed which residues have greater propensity 
to bind metal ions and, likely, also cisplatin (Falini et al., 2008). 
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CHAPTER 1: THE PROTEIN CRYSTALLISATION 
 
 
1.1 INTRODUCTION 
 
The first protein crystals were grown from haemoglobin over 150 years ago in a laboratory in 
Germany and this was immediately recognised as an exceptional and valuable discovery. Their 
appearance signified purity, uniqueness and a connection between the living and the inanimate 
world from which life emerged (though evolution was not suspected). Since then protein crystals 
have evolved from objects of wonder, speculation and demonstration of molecular purity to 
essential intermediates in the discovery of macromolecular structure. Parallely, methods of 
crystallisation developed as well from empirical, trial and error approaches to the more rational, 
direct and physically characterised concepts of the past several years.  
The success of Human Genomics and the need of rational drug design have substantially 
accelerated protein structure investigations. Completion of the Human Genome Project offers the 
possibility to identify a host of genetic disorders and design therapies to treat them. Genes encode 
proteins, which are the targets of drugs. The function of proteins is determined by their three-
dimensional structure; thus, a detailed knowledge of protein structure becomes essential to develop 
therapeutic treatments and engineer proteins with improved properties. If the active site structure of 
a salient enzyme in a metabolic or regulatory pathway is known, then chemical compounds, such as 
drugs, can be rationally designed to inhibit or otherwise affect the behaviour of that enzyme.  
The secret of life is hidden in the structure of proteins and in the 1930s it was become to perceive 
that the technique, that would be able to unlock it, was X-ray crystallography. The work that firmly 
and finally established the value of protein crystallisation came with the early experiments of 
Crowfoot, Bernal and Fankuchen who applied X-ray diffraction to protein crystals.  
Max Perutz, the giant of the age, made indelible the extraordinary powder of X-ray crystallography 
through his classic investigation of haemoglobin crystals (Fig. 1). No technological advance has so 
revolutionised a field as X-ray crystallography has molecular and structural biology.  
Indeed, with X-ray crystallography it has been possible to study macromolecular assemblies as 
large as a nucleosome (Luger et al., 1997), viruses (Kim et al., 1989) or ribosome (Yonath et al., 
1980); while NMR application, despite having the advantage of being performed in solution, is 
limited to the study of proteins and polypeptides with molecular weight lower than 30 kDa. On the 
other hand, X-ray crystallography is totally dependent on the need for highly quality diffraction 
crystals and the obtainment of such crystals is the rate-limiting step to structure determination. The 
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crystal becomes the keystone element of the entire process and the ultimate determinant of its 
success. The quality of the final structural image is directly determined by the perfection, size and 
physical properties of the crystalline specimen. To obtain good structural data, crystals need to be 
single and have dimension of at least 10 µm3, preferably much larger (Chayen, 2004). It is said 
amongst crystallographers that crystallisation is an art, crystallography a science. 
 
 
 
 
 
                                    
 
 
 
Figure 1. Max Perutz (left) with his model of haemoglobin and John Kendrew (right)  with his model of 
myoglobin. 
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1.2 THE CRYSTALLISATION PROCESS 
 
Although comparable in their morphologies and appearance, there are substantial differences 
between crystals of low-molecular-mass compounds and crystals of proteins and nucleic acids. 
Crystals of conventional molecules are characterised by firm lattice forces, are relatively highly 
ordered, generally physically hard and brittle, easy to manipulate, can be usually exposed to air, 
have strong optical properties and diffract X-rays intensely. Macromolecular crystals are by 
comparison usually more limited in size, very soft and crush easily, disintegrate if allowed to 
dehydrate, exhibit weak optical properties and diffract X-rays poorly (McPherson, 2004). They are 
temperature sensitive and undergo extensive damage after prolonged exposure to radiation. The 
extent of the diffraction pattern from a crystal is directly correlate with its degree of internal order. 
The most vast the pattern, or the higher the resolution to which it extends, the more structurally 
uniform the molecules are in the crystal and the more precise their periodic arrangement is. The 
level of detail to which atomic positions can be determined by crystal structure analysis corresponds 
closely with the degree of crystalline order. Protein crystals contain very high solvent content (20-
70%) of the cell volume. The crystal can be considered as an ordered gel with big interstitial spaces 
through which the solvent and other small molecules can freely diffuse. This contributes in 
producing weak interactions and destabilising the crystal lattice. The interaction involved in the 
crystal packing can be specific (hydrogen bonds, electrostatic interactions and Van der Walls 
interactions) or non-specific (hydrophobic interactions). 
Crystallisation is a phase transition phenomenon involving different steps: nucleation, nuclei 
growth and cessation of growth (Kam et al., 1978). Nucleation is the key of crystallisation and it 
can be homogeneous in the bulk of the solution, or heterogeneous, which is caused by a foreign 
agent to the crystallisation solution (Chayen et al., 2008). Nucleation is the most difficult problem 
to address theoretically and experimentally because it represents a first order phase transition by 
which molecules pass from a wholly disordered state to an ordered one. Presumably this occurs 
through the formation of partially ordered or paracrystalline intermediates (McPherson, 2004). 
During the nucleation phase ordered nuclei are formed in solution as result of fluctuation of matter. 
Nuclei which exceed the critical size start to growth. The crystallisation of macromolecules in 
solution is a process influenced by the physical-chemical properties of the solvent, the solute and 
the solute-solvent interaction. It requires that a supersaturated state is achieved.  
The crystallisation process can be illustrated by a phase diagram, which indicates the stable state 
(liquid, crystalline or amorphous solid, i.e. precipitate) under a variety of crystallisation parameters 
(Fig. 2). The saturation limit line separate the undersaturated from the saturated region. Crystals 
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dissolve in the undersaturated region, where the protein concentration in solution is below the 
protein solubility curve, while they can grow in the saturated region. In principle, crystals will grow 
from an aqueous protein solution when the solution is brought into supersaturation and the protein 
concentration exceeds the solubility. In practice, crystals hardly form unless the concentration 
exceeds the solubility by a factor of at least three (Asherie, 2004). The large supersaturation is 
required to overcome the activation energy barrier that represents the free energy required to create 
the small microcluster of proteins, known as a nucleus, from which the crystal will eventually grow 
(Fig. 3). The crystallisation of molecules from solution is an equilibrium phenomenon and the 
specific kinetic and thermodynamic parameters depend on the chemical and physical properties of 
the solvent and solute involved. Under condition of supersaturation the system is driven toward an 
equilibrium state in which the solute is partitioned between a soluble and solid phase. Although the 
individual molecules lose rotational and translational freedom, thereby lowering the entropy of the 
system, they, at the same time, form many new, stable bonds which maximise the number of 
attractive interactions and minimise those dispersive or repulsive. This reduces the potential or free 
energy of the system and provides the driving force for the ordering process. The impetus for 
macromolecules to crystallise is the minimisation of free energy that occurs when the number of 
attractive interactions are maximised and the dispersive or repulsive interactions are minimised. For 
biological macromolecules, which exist predominantly in an aqueous environment, one free energy 
minimum is represented when they are fully solvated. In extremely concentrated solutions in which 
there is insufficient water to maintain hydration, the molecules may crystallise or they may 
aggregate as an amorphous precipitate. The supersaturation region can be divided in three zones: 
metastabile, labile and precipitation zone. In the labile zone the supersaturation is large enough that 
spontaneous nucleation is observable. If the supersaturation is too large, then disordered structures 
(such as aggregates, spherulites or precipitates) may form. An amorphous precipitate corresponds to 
one local energy minimum and frequently occurs when aggregation proceeds too rapidly. If the 
energy minimum is sufficiently deep, the molecules remain in that state. The precipitation zone is 
unfavourable for crystal formation, however, occasionally the energy barrier is small and, waiting 
for sufficient time, crystals may grow from the amorphous material. In the metastabile zone crystals 
can growth but being the supersaturation too small, no nuclei can form for any period of time.  
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                                                                                        Precipitant Concentration 
 
 
Figure 2. Schematic phase diagrams showing the solubility of a protein as a function of the concentration of 
the precipitant and the protein present in solution. 
 
 
Figure 3. Schematic phase diagram showing the free-energy profile during the crystallisation process. 
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In an ideal experiment, once nuclei have formed, the concentration of protein in the solute will 
drop, thereby leading the system from the labile into the metastable zone, where few crystals will 
grow. More often, either no crystals forms at all or excess nucleation occurs, whereby numerous 
clusters of tiny crystals are formed instead of a few sizeable ones. An additional frustrating problem 
is the formation of large single crystals that do not diffract.  
To induce macromolecular crystallisation and obtain crystals of high quality suitable for X-ray 
diffraction, it is necessary to bring the system very slowly toward a state of minimum solubility and 
thus achieve a limited degree of supersaturation by varying the concentration of precipitant, protein 
and additives, pH, temperature and other parameters (Table 1). It is well known that protein crystal 
formation requires interactions that are selective, highly directional and arranged in geometry that is 
appropriate for producing three-dimensional (or in some cases two dimensional) crystal lattice. If 
the transformation process from the liquid to the solid state proceeds too fast, the molecules have no 
time to order themselves properly.  
The protein crystallisation process is influenced by a large number of factors (Table 1) but far the 
most important is the property of the protein sample. Important requirements for a successful 
crystallisation are purity, homogeneity and stability. The higher the purity, the easier the 
crystallisation is. Even at 100% of chemical purity, the molecules can exist in different 
conformation states or in interchange between two or more conformational equilibrium states, that 
interfere with the formation of a highly ordered crystal (Durbin et al., 1996). The protein should 
usually be at least 97% pure to guarantee sufficient homogeneity of the sample. The failure to 
achieve crystals, the growth of poor diffracting crystals or low reproducibility usually suggest the 
impurity. Possible sources of impurity include: 
- variation in primary structure (genetic)  
-  post-translation modifications (glycosylation) 
- variation in secondary structure (misfolding, denaturation) 
- variation in tertiary structure (conformers, dynamic changes) 
- variation in quaternary structure (mixed oligomeric states) 
-  partial binding of ligands or ions 
-  mixed oxidation states of Cys residues, ligands or metals 
-  fragmentation (proteolysis).  
The solubility in a generic solution of a molecule of any type depends on the interactions of the 
molecule with the solvent molecules.  
There are hydrophobic and hydrophilic amino acids in protein molecules. After protein folding in 
aqueous solution, hydrophobic amino acids usually form unexposed hydrophobic areas while 
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hydrophilic amino acid interact with the surrounding solvent molecules through hydrogen bonds. If 
a sufficient  portion of the protein surface is hydrophilic, the protein can be dissolved in aqueous 
solutions. The protein solubility strongly depends on the ionic strength: at very low ionic strength a 
phenomenon called “salting in” takes place, i.e. in the presence of small amount of electrolyte 
proteins are more soluble then in pure water because of the interactions between the charged 
residues and the ions. The “salting in” effect does not depend on the nature of ions, but only on the 
ionic concentration. As the ionic strength is increased the protein solubility raises to a maximum 
and then decreases when the ionic concentration is such that the ions begin to compete with the 
solute (protein) for the surrounding water. The salt ions are more easily hydrated than 
macromolecules. This causes the removal of ions essential to satisfy the electrostatic requirements 
of protein molecules, which will try to balance their charge through interactions among themselves. 
Proteins molecules start to interact and aggregate. This process is known as “salting out”.  Different 
ions will affect the solubility of the protein in different ways. Small highly charged ions are more 
effective than large low charged ions in salting out.  
Along with ionic strength, pH is one of the most important variables influencing the solubility of 
proteins 
The solubility minimum corresponds to the isoelectric point of the protein, at which the net surface 
charge is zero and the solubility drops down. Below the isoelectric point proteins carry a net 
positive charge, above it a net negative charge. The isoelectric point is of significance in protein 
purification because it is the pH at which mobility in an electrofocusing system is zero (and 
therefore the point at which the protein will accumulate). 
Also the distribution of the charges, the dipole moment of the protein, its conformation and in many 
cases its aggregation state depend on the pH. The pH is also the most useful variable to investigate 
the growth of polymorph crystals with different habits or unit cell. 
The precipitant agents play an important role during the crystallisation process. They can be divided 
in four categories based on their mechanisms for promoting crystallisation: (1) salt, (2) organic 
solvents, (3) long chain polymers and (4) low molecular weight polymers and non-volatile organic 
compounds (Table 2) (McPherson, 2004). 
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Table 1. Parameters affecting the proteins crystallisation process. 
 
 
Salts influence the solubility of a protein through the salting out effect. Organic solvents bind water 
to themselves just as salt ions do and also significantly reduce the dielectric constant of the medium. 
The first of these effects decreases the capacity of the system to fully solvate the macromolecules 
while the second one reduces the effective electrostatic shielding between individual 
macromolecules. Ethanol is the most commonly used precipitant but acetone is often advantageous 
as it is somewhat milder. However, the high volatility of these solvents makes them difficult to 
handle and less volatile solvents, which are miscible with water, are preferable. Amongst these, 2-
methyl-2,4-pentanediol (MPD) has proved useful. MPD is a small polyalcohol which has properties 
midway between those of low molecular weight PEGs and organic solvents. MPD works as a 
precipitant by a combination of effects, including competition for water, hydrophobic exclusion of 
protein solutes, lowering of the solution's dielectric constant, and detergent-like effects. It is 
generally used in excess or in a concentration of 40% (v/v).  
Organic solvents often denature proteins and this should be minimized by working at low 
temperature. Polymers such as polyethylene glycols are very efficient and, unlike proteins, have no 
  1-  Ionic strength  
  2-  pH and buffer 
  3-  Concentration and nature of precipitant  
  4-  Temperature and temperature fluctuations 
  5- Concentration of macromolecule 
  6- Purity of macromolecules  
  7- Additives, effectors and ligands 
  8- Organism source of macromolecule 
  9- Substrates, coenzymes, inhibitors 
10- Reducing or oxidising environment 
11- Metal and other specific ions 
12- Equilibration and growth rate 
13- Surfactants or detergents  
14-Gravity convection and sedimentation 
15- Vibrations and sound 
16- Volume of crystallisation sample 
17- Presence of amorphous or particulate sample 
18- Surfaces of crystallisation vessels 
19- Proteolysis 
20- Contaminations by microbes 
21- Pressure  
22- Electric and magnetic fields 
23- Handling by investigator and cleanliness 
24- Viscosity and mother liquor 
25- Heterogeneous or epitaxial nucleating agents 
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consistent conformation, writhe and twist randomly in solution, occupy more space than they 
otherwise deserve. This results in less solvent available space for the other macromolecules which 
then segregate, aggregate, and ultimately form a solid phase, often crystals. Many protein structures 
have been solved using crystals grown from polyethylene glycols. Because of the larger molecular 
weight, polyethylene glycols probably do not even enter the crystals and therefore do not directly 
contact the interior molecules. Solutions of polyethylene glycols have mean electron densities 
roughly equivalent to water and do not generally interact in a deleterious manner with heavy atom 
compounds, thus making them particularly well suited for macromolecular crystallisation. PEG's 
with molecular weights less than 1000 are typically liquids and are generally used at concentrations 
above 40% v/v. PEG's with molecular weights above 1000 are generally solids and are used in the 
5-50% w/v concentration range. All PEG solutions should be made with the inclusion of ~0.l% Na 
azide (which, incidentally, is also highly toxic to humans) to prevent bacterial growth. PEG sizes 
from MW=400 to 20,000 Da are used but the most useful are the ones in the range of 2000-8000Da. 
 
 
Table 2. Precipitant used in macromolecular crystallisation. 
 
 
 
Most proteins vary in solubility as a function of temperature, and some are very sensitive. The 
dielectric constant decreases with increase of temperature and the entropy terms in the free energy 
of solution tend to dominate the enthalpy terms. Temperature coefficient of solubility varies from 
protein to protein and with the condition such as ionic strength and the presence of organic solvents. 
Crystallisation experiments are usually carried out at 4 °C or room temperature (25 °C). Several 
protein will denaturate at temperatures above 40 °C so temperature can be varied over only a 
Salts Volatile organic 
solvents 
Polymers Non-Volatile organic 
solvents 
Ammonium phosphate sulphate Ethanol Poly(ethylene glycol) 
1000, 1450, 3350, 4000, 
6000, 8000, 20.000 
2-Methyl-2,4-pentanediol 
Lithium sulphate Propanol and isopropanol Polyamine 2,5-Hexandediol 
Sodium or ammonium citrate 1,3-Propanediol Jeffamine T, Jeffamine M Ethylene glycol 400 
Sodium or potassium phosphate  Methanol   
Sodium or potassium or 
ammonium chloride 
Dioxane   
Sodium or ammonium acetate Acetone   
Magnesium or calcium sulphate Butanol   
Calcium chloride Acetonitrile   
Ammonium or sodium nitrate Dimethyl sulfoxide   
Sodium or magnesium formate    
Sodium or potassium tartrate    
Cadmium sulphate    
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limited region (i.e. 0-40 °C) (Wiencek, 1999). Low temperatures tend to limit degradation problems 
as well as bacterial growth. The solubility of proteins in salt solutions tends to increase at low 
temperatures, whereas in PEG and MPD solutions, protein solubility generally decreases with 
decreasing temperature. By increasing or decreasing precipitant or protein concentration, 
crystallisation should, at least in theory, be possible at either room temperature or 4 °C, although the 
kinetics of crystallisation can be expected to vary in accord with temperature. 
The protein concentration should be as high as possible. Crystals have been reported grown at 
concentrations from one to several hundred milligrams per millilitre, although the most common 
range seems to be from 5 to 30 mg/mL.  
Other parameters may be less important but often play crucial roles. It can not be predicted which 
variables may be of importance for a particular macromolecule. The methodology employed to find 
the experimental conditions that will lead a protein to crystallise is a strict empirical “trial and 
error” procedure. Once the crystallisation conditions have been identified, the second step involves 
their optimisation. This process refines the chemical and physical parameters identified during 
screening to produce crystals of as higher as possible quality that are suitable for X-ray analysis. 
Optimisation builds directly upon the success of the screening experiments. In the first step of 
optimisation the initial crystallisation conditions are taken and the concentration of the 
macromolecule or precipitant, or pH, or the growth temperature are varied.  
One of the paradoxes in crystallisation is that the optimal solution conditions for nucleation of the 
crystals are not the ideal ones to support their subsequent growth. This is because spontaneous 
nucleation is quite simply more likely to occur when the levels of supersaturation are high, whereas 
slow, ordered growth of large crystals is favoured by lower levels. The ideal experiment therefore 
must somehow uncouple nucleation from growth to satisfy the distinctly different requirements of 
the two events. Seeding (See page 25) is only one of many possible optimisation methods. Some 
alternatives to separate nucleation from growth, or to slow down the growth after nucleation has 
occurred, are presented in Table 3 (Bergfords, 2003). 
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Table 3. Easy optimisation strategies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Method  Comments Reference 
Filter the protein It removes dust, precipitated 
protein, particles that could be 
unintentional nucleation sites  
Blow et al. (1994) 
Cover the reservoir with oil 
(vapour diffusion) 
It slows the rate of equilibration Chayen et al. (1997) 
Evaporative dialysis  Useful for proteins with a 
narrow metastable zone 
Bunick et al. (2000) 
Temperature shifts It can work for proteins that 
exhibit temperature-sensitive 
solubility 
Blow et al. (1994) 
“Backing off”                       
(vapour diffusion)             
After nucleation has occurred, 
the cover slip is moved to a 
different reservoir for 
equilibration at metastable 
conditions 
Saridakis et al. (2000) 
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1.3 CRYSTALLISATION TECHNIQUES 
 
The methods used in macromolecular crystal-growth are continually being refined. Here the most 
used microtechniques which have been developed for use with small amounts of protein will be 
reported. 
 
1. MICROBATCH METHOD: This is the classical method described for early enzyme 
crystallisation (Blundel et al., 1976). The primary disadvantage of this method is the relatively large 
amount of material required and the difficulty in modifying conditions once vials are prepared. For 
this reason, since 1972 with the crystallisation of phycocyanin, the batch method has been adapted 
to the use of microliter quantities of material (Dobler et al., 1972). The micro-batch method is a 
variation of the simple batch crystallisation technique, in which the concentrated protein solution is 
mixed with concentrated precipitant in a closed vessel to produce a final supersaturated condition, 
which may eventually lead to crystallisation. The components are at their final concentration at the 
start of experiment. The objective of microbatch technique is to reduce the consumption of sample 
by generating crystallisation trials in very small volumes (Chayen, 1998). The protein is dissolved 
at low ionic strength so as to have a highly concentrated solution. The precipitating agent (salt or 
organic solvent) is then added to bring the solution to a state of low supersaturation. The protein 
sample and precipitant solution are dispensed into the well of a plate and the well is covered with 
paraffin oil or low-density oil to prevent evaporation, contamination and physical shock (Fig. 4). 
During the incubation period, the concentration of a precipitant agent remains constant since 
evaporation is limited and, therefore, the volume of the drop remains the same during the 
experiment. On the other hand, the concentration of the protein changes on formation of either 
crystals or amorphous precipitant. If the concentration of precipitant agent is chosen in such a way 
that the solution is in an undersaturated state, crystallisation will never occur. On the other hand, a 
turbidity or opalescence in the solution probably indicates that the point of low supersaturation has 
been passed. Nevertheless quite often an amorphous precipitate will redisolve and crystals will 
slowly form. This technique was used very successfully for the production of large crystals of 
lysozyme, ribonuclease and enzymes of the trypsin family, but it offers very few possibilities of 
crystal growth control. The main disadvantage of this method is that the equilibration occurs very 
rapidly, thus affecting the rate of crystal growth and consequently the quality of the obtained 
crystals. It is only useful for proteins whose nucleation and growth velocities are extremely low 
even at high supersaturation or for those ones which give well ordered crystals at even high growth 
rates. The second disadvantage is that the manipulation of the crystals from the drop covered by oil 
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is very difficult. However, since the use of very small volumes of protein solution can be made, the 
micro-batch technique is quite useful as an initial screening method. 
 
 
 
Figure 4. Microbatch method: A small drop of the sample combined with the crystallisation 
reagent is pipetted under a layer of oil. 
 
 
2. VAPOR DIFFUSION: This method uses the evaporation and diffusion of water between 
solutions of different concentrations as a means of approaching and achieving supersaturation of 
protein macromolecules. Different techniques based on the same principle can be used (Fig. 5): 
- hanging drop 
- sitting drop 
-sandwich drop. 
Simply, the hanging drop method differs from the sitting drop method for the geometry of the 
system. It is important to mention that both methods require a closed system. The system must be 
sealed off from the outside using an airtight container or high-vacuum grease between glass 
surfaces. In sandwich drop method, the sample solution mixed with the precipitant is placed in the 
middle of two siliconized glass cover slides. 
Typically, in vapour diffusion experiments the protein solution is mixed in a 1:1 ratio with a 
solution containing the precipitant agent at the concentration that needs to be achieved after vapour 
equilibration has occurred. The drop is then suspended and sealed over the well solution, which 
contains the precipitant solution at the target concentration, as either a hanging or sitting drop. The 
difference in precipitant concentration between the drop and the well solution is the driving force 
which causes water to evaporate from the drop until the concentration of the precipitant in the drop 
equals that of the well solution. Since the volume of the well solution is much larger than that of the 
drop (1-3 ml as compared to 1 - 15 µl), its dilution by water vapour leaving the drop is insignificant. 
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The volume of a hanging drop is limited to about 8 - 10 µl, since bigger volumes might cause the 
drop to fall out of the cover slip. This limitation is overcome in the sitting drop technique in which 
the drop sits on a pedestal (e.g. microbridge) above the reservoir solution. In the hanging drop 
technique the microdroplet is suspended from the underside of a microscope cover slip which is 
then placed over a small well containing the precipitating solution (Fig. 5). The cover slips must be 
thoroughly and carefully coated with nonwetting silicone to ensure proper drop formation and 
prevent spreading (McPherson, 1982). 
During a vapour-diffusion experiment, the protein will start to concentrate from an unsaturated state 
to reach a supersaturated state. As the first crystals appear, the concentration of protein will 
decrease. The crystal will then grow until the concentration of the protein in the drop reaches the 
solubility curve. 
Vapour-diffusion is the optimal technique for screening a large number of conditions. Furthermore, 
this method can be used to increase or decrease the concentration of protein in the equilibrated state, 
varying the ratio between protein and well solutions when the drop is initially set up.  
In the case of salt precipitating and non volatile organic solvents as MPD and PEG, the droplet of 
mother liquor must initially contain precipitant at a concentration lower than that one of the 
reservoir. The equilibrium occurs by distilling water out of the droplet and into the reservoir. In case 
of volatile organic precipitants, nothing has to be added initially to the droplet, as the distillation 
and equilibration proceed in the opposite direction. 
The rate of vapour-diffusion can also be controlled, to a certain extent; it greatly depends on the 
surface area of the drop. By reducing the surface area it is possible to slow the equilibration process 
dramatically. This can be achieved by means of the so-called 'sandwich drop' technique. A major 
advantage of the vapour diffusion method is the possibility of affecting the equilibrium rate of the 
trials and thus approaches the saturation more slowly, by varying the distance between the drop and 
the reservoir (Luft et al., 1994; Luft at al., 1996). The larger the distance which separate them, the 
slower the droplet equilibrates with the reservoir. The variation of the equilibrium rate with the 
distance droplet-reservoir is not linear. The rate is more sensitive to variations in the droplet-
reservoir separation at short distance. 
A further advantage of the vapour diffusion method is the possibility of altering the composition 
and/or the concentration of the components in the trial without touching the drop, by concentrating 
or diluting the reservoir (Yonath et al., 1982; Pryzbylska, M., 1989) or just transferring the cover 
slip with the drop from one reservoir to another (Chayen et al., 1989). A combination between the 
microbatch and water vapour diffusion methods is accomplished by placing a layer of a low density 
oil or a mixture of oils on the reservoir solution which will act as a barrier through which the vapour 
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phase will diffuse slowly (Chayen et al., 1997). The type of oil and the thickness of the oil layer 
situated above the reservoir will dictate the rate of vapour diffusion and consequently the speed of 
crystallisation. This can reduce the number of grown crystals and increase their size. 
 
 
HANGING DROP 
 
SITTING DROP 
 
 
SANDWICH DROP 
 
 
 
 
Figure 5. Vapour diffusion method: In hanging drop technique, the drops is suspended over the well solution 
(left), in sitting drop technique it sits on a pedestal (center), in sandwich drop technique it is placed in the 
middle of two siliconized glass cover (right). 
 
 
3. DYALISIS METHOD: This technique was first described by Theorell (1932) and used in the 
crystallisation of haemoglobin (Boyes-Watson et al., 1947). Dialysis techniques utilise diffusion 
and equilibration of small precipitant molecules through a semipermeable membrane as a means of 
slowly approaching the concentration at which the macromolecule solute crystallises. Initially, the 
protein solution is contained within the dialysis membrane, which is then equilibrated against a 
precipitant solution. Equilibration against the precipitant in the surrounding solvent slowly achieves 
supersaturation for the solute within the dialysis membrane, eventually resulting in crystallisation. 
A dialysis membrane can be used to cover the opening of a dialysis button, allowing diffusion of the 
surrounding solvent into the solute through the dialysis membrane (Fig. 6). Dialysis buttons 
themselves come in a variety of sizes from 7 µl to 200 µl. The protein solution at the start of the 
dialysis experiment is in an undersaturated state. The concentration of the precipitant agent slowly 
increases as its diffusion through the membrane takes place.  
The advantage of dialysis over other methods is that the precipitating solution can be varied, simply 
by moving the entire dialysis button or sack from one condition to another. Thus, the protein 
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solution can be continuously recycled until the correct conditions for crystallisation are found. This 
technique has been adapted to small amounts of material becoming a microtechnique in which no 
more than 5-50 µl are used in each trial. The microdialysis method first used in the crystallisation of 
alcohol dehydrogenase has been introduced by Zeppeneuer (Zeppeneuer et al., 1967; Zeppeneuer et 
al., 1968; Zeppeneuer et al., 1971). Samples of protein or nucleic acid solution are injected into 
glass short capillaries or tubes (McPherson, 1982). The capillaries have a piece of dialysis 
membrane stretched over one end that is held in place by a collar of PVC or surgical rubber tubing 
cut so as to provide support legs as well. The other end is sealed by a plug of dental wax or simply 
with a piece of parafilm. The entire system is then submerged in a test tube or other vessel 
containing the solution. Slow equilibration takes place across the membrane and crystallisation 
frequently occurs. 
 
 
 
 
Figure 6. Dialysis method: The protein is placed in a Dialysis Button which is 
sealed with a dialysis membrane and placed into a 
suitable container holding the precipitant or crystallisation media. 
 
 
4. BULK CRYSTALLISATION METHOD: A solid salt or a saturated solution of the salt is 
added to the solution containing the purified protein or nucleic acid until a visible opalescence is 
developed. Two of the first animal proteins crystallised, ovalbumin (Hopkins et al., 1898) and horse 
serum albumin (McMeekin et al., 1939) were obtained by this method. The solution is then 
centrifuged and the supernatant is stored for few days or weeks. Highly concentrated protein 
solutions (in a range from 10 to 100 mg/mL) are essential. 
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5. FREE INTERFACE DIFFUSION: If a macromolecule is differently soluble in two solvents 
and if one solution containing the dissolved sample can be layered carefully atop the other, transient 
conditions of supersaturation will be established in the region of the interface (Fig.7). As the two 
layers diffuse into one another toward equilibrium, nuclei are formed. This technique has been 
adapted to milligram quantities of starting material using small glass capillary (Salemme et al., 
1972; Weber at al., 1970). With this method applicable to either salt solutions or organic solvents, it 
is recommended that the protein or nucleic solutions are highly concentrated (50 mg/mL) and great 
care is taken to eliminate dust and debris from the system. The concentration of the precipitant 
solution has to be so that only a detectable turbidity forms at the interface. If a flocculent precipitate 
forms, that means that the concentration is too high. This technique is less frequently used than the 
sitting and hanging drop vapour diffusion but is one of the methods used by NASA (National 
Aeronautics and Space Administration) to perform protein crystallisation experiments in 
microgravity. The technique allows to screen a gradient of sample precipitant concentration 
combinations.  
 
                                         
 
 
Figure 7. The free interface diffusion technique as applied to microliter samples in small capillaries. 
 
6. LIQUID BRIDGE METHOD: This method is a variant of the previous one (McPherson, 1982).  
A microdrop of mother liquor and a drop of the precipitating solution are placed in close proximity 
on a glass slide. A fine needle is used to draw a thin liquid bridge connecting the two drop so that 
free diffusion can occur between them. The slides and droplets are then sealed from the air to 
prevent evaporation. By direct liquid diffusion across the bridge into the mother liquor, the 
precipitant induces crystallisation. 
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7. COUNTER DIFFUSION METHOD: Counterdiffusion (CD) techniques have been well 
investigated and explained for over 100 years since the first description of periodic precipitation 
pattern formation in gelled medium (Liesegang, 1897). In counter diffusion experiments, the 
interacting precipitating agent and protein solutions either contacts one another directly or is 
separated by an intermediate chamber working as a physical buffer (NG et al., 2003; Garcia Ruiz, 
2003) (Fig. 8).  
 
 
 
 
Figure 8. Geometry of a counter diffusion experiment showing the phenomenology of the technique with (a) 
or without (b) a buffer chamber. PA indicates precipitating agent. 
 
As soon as the two solutions come in contact, they will interact according to the solubility 
dependence of the protein on the precipitating agent concentration. The two processes working in 
the experiment, mass transport and precipitation, are consecutive. In the case of macromolecules, 
upon starting the experiment, the molecules of protein diffuse toward the left (in the geometry of 
Fig. 8) while the salt will diffuse toward the right 10 to 100 times faster than the protein molecules 
toward the left, invading the protein chamber. As the precipitant diffuses into the protein, it will 
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provoke the precipitation of the protein according to the solubility of protein. Once the salt ions run 
into the protein chamber, the system moves deep into the labile region provoking the immediate 
precipitation of an amorphous phase at the location x = x0 (Fig. 9). The precipitation of the protein 
occurs because its solubility varies with, for instance, the concentration of salt. In the diagram 
showed in figure 9 the starting protein concentration is indicated as 0M and the concentration of the 
salt as 0P. When these solutions come into contact, the system moves toward point E1 in the phase 
diagram. The supersaturation is very high. Therefore, the first precipitate could be an amorphous 
phase forming at x0. Its formation depletes the concentration of protein in the neighboring zones. As 
the salt continues to diffuse into the protein chamber, a new precipitation event takes place, this 
time at lower supersaturation eventually producing microcrystals (location x1 in the phase diagram). 
Iteration of this process provokes the precipitation at lower supersaturation as the precipitation front 
moves far from the precipitant chamber toward the protein chamber (x2, x3, … xe). This yields 
precipitation zones of fewer crystals of larger size and higher quality. Contrasting the classic drop 
and batch methods, the counterdiffusion technique explores a large number of crystallisation 
conditions in a single experiment. 
 
 
 
 
Figure 9. The solubility diagram showing how CD (Counter Diffusion) crystallisation works. 
 
From this phenomenological description, it is clear that the mechanism initiating pattern formation 
differs in counter diffusion from that in other crystallisation techniques. The counterdiffusion 
technique is an out of equilibrium precipitation system moving spontaneously toward equilibrium. 
One counter diffusion experiment is therefore equivalent to a large number of hanging drop or batch 
experiments across the phase diagram. The counterdiffusion crystallisation procedure is able to 
compose a continuous supersaturation gradient. During the diffusion process a supersaturation state 
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with respect to the protein can be attained in the labile region, while crystal growth can occur in a 
continuous range in the metastable area of the phase diagram. Hence, crystal formation is caused by 
the progression of a nucleation front resulting from the nonlinear interplay among mass transport, 
protein crystal nucleation and growth. 
García-Ruiz proposed applying the counterdiffusion techniques in gelled medium to the 
crystallisation of biological macromolecules as an alternative method to carry out a wide screening 
of experimental crystallisation conditions in a single experiment (Garcia-Ruiz, 1991). In 1993, 
García-Ruiz and collaborators developed the gel acupuncture method (GAME), in which the protein 
solution is confined in a capillary punched in a gel layer and the precipitating agent is poured on the 
gel layer (Fig. 10) (Garcia-Ruiz et al., 1993). The capillary acts as a long protein chamber and 
removes convection from the system. When the precipitating system contacts the protein solution, a 
wave of supersaturation is triggered. This wave travels along the protein chamber and screens 
different crystallisation conditions of progressively lower supersaturation values as it moves further 
from the lower end of the capillary. Unlike traditional methods, one of the main advantages of 
GAME is its ability to yield crystals obtained under different nucleation and growth conditions in 
every experiment. This implies that a single GAME experiment is equivalent to many experiments 
with traditional methods. GAME is the only technique that produces crystals that fill the capillary 
diameter and do not slip, allowing data collection at room temperature from the same capillary in 
which the crystals were grown. The use of capillaries is even more advantageous as it has been 
proven that crystals can be frozen into capillaries for cryocrystallography studies after diffusion of 
an appropriate cryoprotectant (NG et al., 2003). Additionally, the use of very thin capillaries of 0.1 
mm in diameter reduces the consumption of protein solution for screening purposes.  
 
 
Figure 10. The gel acupuncture method (GAME) with capillaries of different diameters. In the image on left 
1 is the capillary, 2 the precipitant, 3 the agarose gel. 
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The crystallisation by counter diffusion is a very efficient technique for obtaining high quality 
crystals. A prerequisite for the use of counter diffusion techniques is that mass transport must be 
controlled by diffusion alone. Sedimentation and convection can be avoided either by working in 
gelled systems or in the absence of gravity (Snell et al., 2005; Zegers et al., 2006). Since the early 
eighties, several thousands of crystallisation experiments were performed in space on board 
NASA's Shuttle, on board automatic platforms like the European Retrievable Carrier (EURECA) 
platform, or on board the Russian Mir Space Station (Kundrot et al., 2001). The crystallisation 
experiments performed on the ISS (International Space Station) have allowed to visualise the 
growth of crystals in capillary counter diffusion investigating the microgravity effect. Crystal 
perfection has been shown to be higher for crystals grown in non-convective environments 
compared with that one of crystals grown in convective environments. 
 
8. HIGH-THROUGHPUT PROTEIN CRYSTALLISATION: Several projects have recently 
been initiated to construct automated systems able to rapidly performing a large number of 
crystallisation trials, with the intent of ‘industrializing’ protein crystallisation (Yon et al., 2003; 
Huia et al., 2003). Technical advances have been made in crystallisation and an increasing number 
of robotic systems have been described that allow hundreds or thousands of crystallisation 
experiments to be carried out (Khun et al., 2002). Commercially available systems include IMPAX 
and Oryx robots from Douglas instruments (http://www.douglas.co.uk) (Fig. 11), Cyberlab from 
Gilson (http://www.gilson.com) and those from Cartesian (Fig. 12) (http://www.cartesiantech.com). 
Higher-density formats have become common for sitting drops with the marketing of microplates 
for 96-well sitting drops (Hampton Research, http://www.hamptonresearch.com). Microbatch 
crystallisation under oil is being practiced at high-throughput. The Hauptmann–Woodward group 
has developed a system based on 1536-well plates and a customized 384-channel Hydra liquid-
handling robot from Robbins Scientific (Luft et al., 1999). The robot sets up the following 
experiment in each well: 200 nl of protein and 200 nl of screening solution are independently 
dispensed into 5 µl of paraffin oil. Low-speed centrifugation ensures mixing of the protein and 
buffers and settlement of the mixed drops onto the bottoms of the wells.  
Also the biotechnology company Syrrx (http://www.syrrx.com) and the Genomics Institute of the 
Novartis Research Foundation (http://web.gnf.org) have pioneered the use of automation to set up 
nanolitre-scale crystallisation drops (20–100 nl) (Stevens, 2000; Goodwill et al., 2001).  Nanolitre 
crystallisation has the significant advantages of allowing extensive crystallographic screens to be 
performed with much less protein (making the task of protein production easier) and of reducing 
crystallisation times. The practical limitation of this approach is the resulting crystal size-up to 50 
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µm. In September 2003, at the EMBL (European Molecular Biology Laboratory) of ESRF 
(European Synchrotron Radiation Facility) of Grenoble, a high-throughput crystallisation platform, 
the HTX Lab, has been set up with the aim to increase the success rate and speed up the process of 
crystal structure determination. In this platform the whole process of crystallisation screening is 
automated through the introduction of liquid handling, crystallisation and crystal imaging robots. It 
allows to perform experiments using extremely low volumes of sample, which makes it possible to 
perform extensive screening even when the amount of sample is limited. Screens of large numbers 
of crystallisation conditions can now be rapidly carried out, analysed and, if required, followed up 
with fine screening to optimise conditions. With sufficient investment in robotics like the systems 
mentioned above, preparing crystal trials is not a problem; however, every crystallisation 
experiment has to be inspected to score the drops, to determine the optimisation strategy, and to 
capture the time at which a crystal appears optimal. Increased numbers of crystallisation 
experiments have driven the development of systems to store crystallisation trays and capture and 
analyse images of the crystallisation wells (e.g. the Robomicroscope II from Robodesign and the 
CrystalScore™ imaging system developed by Diversified Scientific Inc.). Most labs rely on human 
inspection, but there have been advances in imaging that promise to alleviate the challenge and 
tedium of inspecting thousands of protein drops every week. Automated image capture offers 
various advantages over human inspection, namely ergonomics and throughput. With an image 
capture system, most protein drops can be examined on a computer with the microscope. Using 
automated methods, the drops can be inspected more frequently and each observation time-stamped 
precisely. Moreover, digitised images of protein drops can be analyzed using a myriad of artificial 
intelligence techniques which, though not yet competitive with human expertise, can be trained to 
recognise patterns not obvious to the human eye.  
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Figure 11. Oryx robot of Douglas instrument to perform microbatch and vapour diffusion experiments. 
 
 
 
    
 
 
Figure 12. Cartesian instrument, Honeybee 961, a dedicated sitting drop system that fills reservoirs as well 
as shelves. 
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8. SEEDING TECHNIQUE: Seeding is a powerful tool for the separation of nucleation and 
growth (Bergfors et al., 2003). In this technique, previously nucleated crystals are used as seeds and 
introduced into new drops equilibrated at lower levels of supersaturation. Seeding techniques can be 
classified into two categories based on the size of the seeds: 
• Microseeding—transfer of submicroscopic seeds, too small to be distinguished individually. 
• Macroseeding—transfer of a single crystal, usually 5–50 µm. 
Microseeding is an easy method and therefore the type of seeding to try first. Macroseeding (also 
called seed transfer) is much more labour intensive. It requires tedious transfers of the parent crystal 
through multiple washes, although the effort can be worth it, especially in terms of increasing the 
size of the crystal. However, in most seeding situations, a whole seed is not required; microseeds 
will suffice. The disadvantage to microseeding is that it is difficult to control the number of seeds 
that are transferred. Microseeds can be made and introduced into the new drop in many different 
ways. Foe example, the crystals can be pulverized (smashed) into crystalline particles by tissue 
homogenizers, sonication, vortexing, seed beads, glass rods, or other utensils. 
Not all precipitates are equal: it is important to distinguish the precipitates of denatured protein 
from amorphous and non-amorphous precipitates and recognize submicroscopic crystals which look 
like amorphous precipitate. One quick assay for microcrystallinity of precipitates is streak-seeding 
(Stura, E. et al., 1991). In this method, the precipitate is streak-seeded into a new drop and the 
results are examined after 2–7 days. Amorphous precipitates will generate only more precipitate 
along the streak line, whereas crystalline precipitates will generate microcrystals. Sometimes the 
seeds generated along the streak line are large enough to use without further refinements. 
Seeding can be used in conjunction with other optimisation measures such as fine-tuning the 
precipitant and protein concentrations, adjusting the pH, and screening additives. This approach is 
usually applied when crystals of inadequate quality or crystalline precipitate have been obtained 
from initial crystallisation trials. The advent of microfocusing synchrotron beams now makes it 
possible to collect data from crystals of less than 100 µm but the need for large crystals still exists. 
Seeding can be used to grow larger crystals or get them to grow singly, improve their diffraction 
quality, save protein, reduce long waits for spontaneous nucleation, and cross-seed other proteins. If 
no crystals or microcrystals are forthcoming in the initial crystallisation screening, seeding can be 
attempted with any solid phase that has resulted. It is obvious that spherulites represent some kind 
of semiordered aggregation, but even oils and precipitates can exhibit short-range order and 
therefore act as nuclei (ordered aggregates) for further crystal growth (Stura et al., 1991). For these 
solid states of the protein, streak-seeding is the method of transfer. 
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The main difficulty is to find a suitable fibre to use, cat’s whiskers are excellent. A parent crystal is 
stroked to pick up invisible seeds. Then the seeds are introduced into a fresh drop by stroking the 
fibre in a straight line through the drop. Crystals will grow along the streakline. Sometimes new self 
nucleated crystals in parts of the drops farther away from the streakline will appear (Fig. 13) . 
 
 
 
                                    
 
 
 
Figure 13. Crystals grown in a drop in which streak-seeding has been carried out using a cat whisker. 
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CHAPTER 2: HETEROGENEOUS CRYSTALLISATION 
 
 
2.1 INTRODUCTION 
 
In proteins crystallisation, either getting no crystals at all, or even more frustrating, getting crystals 
that are not of high enough quality to allow structure determination is a real problem. The ultimate 
means to obtain good crystals is to control their conception stage, i.e. the nucleation stage which is 
the first step that determines the entire crystallisation process. This is not an easy task, hence, the 
holy grail is to find a ‘universal’ nucleant, a substrate that would induce crystallisation of any 
protein. Anecdotally, protein crystals have been often observed to grow on the surface of fortuitous 
impurities in the drop, such as dust particles and fibres. This has led to more systematic studies of 
the benefits of including heterogeneous nucleation agents in protein crystallisation. Heterogeneous 
nucleation involves the introduction of a solid material termed the heterogeneous nucleating agent, 
nucleant or seed. It is the formation of critical nuclei on particles or surfaces that facilitate the 
process by attracting the molecules electrostatically, hydrophobically or via more specific 
interactions, reducing the critical nuclear size or inducing crystalline order through epitaxy. 
Heterogeneous nucleation can therefore take place at metastable conditions. In fact, nucleation 
occurs on the surface of the nucleant material, which creates a higher local concentration of 
macromolecules, lowers the energy barrier for nucleation and bypasses the high kinetic barrier of 
spontaneous nucleation. A lower level of supersaturation is required under such circumstances for 
the nucleation step to occur, compared to homogenous nucleation (Chayen et al., 2006). Recent 
notions on protein crystal nucleation
 
have stressed this idea known for long time ago (Nanev, 2007). 
A search for a “universal nucleant” for biological macromolecules has been ongoing for 2 decades 
(Saridakis et al., 2008) and the main lines of research have involved studies of epitaxic nucleants 
(McPherson et al., 1987; McPherson et al., 1988), lipid layers (Edwards et al., 2004; Hemming et 
al., 1995) and a lot of natural materials. 
The most obvious way to attract molecules to each other is through electrostatic interactions. 
Charged nucleation-promoting surfaces have been therefore engineered for the purpose of 
facilitating nucleation. For example, a silicon substrate with microlithographically etched alternate 
stripes of n- and p-doping was able to promote nucleation only on those surface regions that were 
oppositely charged to the protein of interest and nucleation elsewhere was suppressed. A p-doped 
silicon (p-Si) surface in contact with an electrolyte at pH<7 will accumulate positive charge, 
whereas it will be neutral when in contact with an electrolyte at pH>7. Conversely, the n-Si surface 
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potential will be almost zero at pH<7 and negative at pH>7. Experiments performed with lysozyme 
on such patterned surfaces, as well as on unpatterned SiO2, Si3N4 and Al2O3 surfaces, showed that 
they were able to induce nucleation, which depended on the surface potential of the material and the 
charge of the protein at a given condition of pH, buffer concentration and ionic strength (Sanjoh et 
al., 1999; Sanjoh et al., 2001). 
Polymeric films containing ionisable groups, such as sulfonated polystyrene, cross-linked gelatin 
films with adsorbed poly-l-lysine or entrapped poly-l-aspartate and silk fibroin with entrapped poly-
L-lysine or poly-L-aspartate, have been tested as heterogeneous nucleant surfaces for crystallising 
concanavalin A and chicken egg-white lysozyme (Fermani et al., 2001). It was found that the 
crystallisation of concanavalin A by the vapour diffusion technique was strongly influenced by the 
presence of ionisable groups on the film surface. Both the induction time and protein concentration 
necessary for the crystal nucleation decreased whereas the nucleation density increased on going 
from the reference siliconised cover slip to the uncharged polymeric surfaces and even more to the 
charged ones. The authors proposed that non-specific attractive and local interactions between the 
protein and the film surface might promote molecular collisions and the clustering with the due 
symmetry for the formation of the crystal nuclei. Moreover, chemically modified mica sheets, a 
natural mineral that can be cleaved to present atomically flat surfaces, have been tested as 
heterogeneous nucleant surfaces for lysozyme, concanavalin A and thaumatin (Falini et al., 2002). 
They have shown be able to promote nucleation not only through non-specific electrostatic 
attraction but also through local interactions between exposed charged residues of the protein and 
ionisable groups attached to the mica surface. These local interactions can become more important 
than the net-charge effect of the whole protein molecule. Chemical modifications of mica by 
silanisation reactions could not only change the density of charged groups on its surface but also 
somewhat modify its wettability and roughness. An increase of the wettability and the roughness of 
the sheet surface has been also suggested to contribute to the observed enhanced nucleation-
inducing properties. Furthermore, Nanev's group has reported that glass coated with positively 
charged poly-L-lysine promoted the nucleation of crystals of ferritin, which, at the given 
crystallisation conditions, is negatively charged, whereas the glass suppressed the nucleation of 
crystals of the positively charged lysozyme (Nanev, 2007; Nanev, 2007; Tsekova et al., 2002). 
For crystallising proteins, favourable protein–protein interactions involving precisely defined areas 
(‘patches’) on the surface of the protein molecules are needed. A surface made of the protein to be 
crystallised itself is therefore a good candidate for a heterogenenous nucleant. Pechkova and 
Nicolini have pioneered protein-crystal growth on so-called Langmuir-Blodgett (LB) protein thin 
films (Pechkova et al., 2004). Microcrystals of two previously uncrystallisable proteins, the human 
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protein kinase CK2 catalytic α subunit and bovine cytochrome P450scc, were obtained on those LB 
thin films. Two possible mechanisms have been proposed for such a nucleation induction by LB 
films. The first explanation assumes that a high electrostatic potential is induced at the film surface, 
which is caused because the charged protein molecules are oriented in the same way in the thin 
film. The film therefore attracts the molecules from solution and orients them in a way that favours 
protein–protein attractive electrostatic interactions. The second mechanism involves the migration 
of film fragments, which constitute tightly packed ordered molecules of the protein to be 
crystallised, into solution, in which they have the role of seeds (Nicolini et al., 2004). 
Porous materials have been designed that have greater universality in their nucleation-inducing 
effects (Chayen et al., 2008). Two materials of different chemical composition, but sharing a wide 
distribution of pore sizes on the same order of magnitude as protein molecules, have proven 
successful: porous silicon with pore sizes of 5–10 nm (Chayen et al., 2001) ( that has been shown 
experimentally to be an effective nucleation-inducing material for protein crystals: five of six tested 
proteins crystallised from metastable solutions in its presence) and mesoporous bioactive gel-glass 
material ('bioglass') with pore sizes of 2–10 nm
 
(Chayen et al., 2006). Both have been successful in 
producing crystals with reduced mosaicity as well as producing single diffracting crystals under 
conditions in which spontaneous nucleation yielded only useless crystals. 
Other porous materials, such as Sephadex beads of various sizes, carbon powder, alumino-silicates 
(Davis et al., 1989), mesoporous molecular sieves (Chen et al., 1993) and zeolites of various mesh 
sizes were generally unsuccessful (Chayen et al. 2001). In contrast to porous silicon, these materials 
exhibit minimal variation of pore size and shape. Cacciuto et al. studied, by numerical simulation, 
the nucleation of the hard-sphere model of colloids (Cacciuto et al., 2004). They observed that the 
model colloid crystallised on curved surfaces, including concave surfaces that may be considered as 
models for part of a pore. The concave surface acted as a nucleant, and its ability to do so depended 
on its curvature.  
The mechanism of heterogeneous nucleation is complex, but the nucleation potential is mainly 
defined by the surface properties and chemical composition of the nucleating agent. Hair, especially 
horsehair, has been used successfully for many years in macromolecular crystallisation, however, 
not as a nucleant per se, but in order to transfer crystal seeds (i.e. post-critical nuclei) into 
metastable solutions. The sharp microstructure of hair with its overlapping cuticles, which are 
particularly present in horse hair, is ideal for trapping the microfragments of a crystal (Bergfors et 
al., 2003). 
Recently, heterogeneous nucleation on fragments of human hair has been visualized by confocal 
fluorescent microscopy and atomic force microscopy, and the chemical and morphological 
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properties of the nucleant surface have been investigated by treatment with chemicals (Georgieva et 
al., 2007). The presence of keratin, but not lipids, was found to be essential for nucleation. 
Fragments of human hair combine most of the properties of the foreign substances used in the last 
thirty years as nucleant agents. They match important criteria required to an agent to be considered 
nucleant: surface ordered at the molecular level, ionisable groups, lipid layers, local concentration 
cavities, nano and mesoscopic structure. They have allowed to obtain macrocrystals and showers of 
tiny crystals under conditions that did not produce crystals in the absence of the nucleating 
substrate, not only in the case of model proteins but, more interesting, in the case of a polysaccarid-
specific Fab fragment and potato protease inhibitor. Moreover, Thakur et al. have shown how also 
others materials, such as dried seaweed, horse hair, cellulose and hydroxyapatite, can be used as 
nucleating substrates, able to increase the crystallisation success of several model proteins, 
especially when a combination with each other are used (Thakur et al., 2007). A number of 
different fibrous materials (rat whiskers, horse hair and dried seaweed) were successfully tested 
with glucose isomerase, lysozyme and trypsin (D’Arcy et al., 2003). 
Two kinds of layer silicate, semi-synthetic micromica and natural chlorite, have been tested as 
heterogeneous nucleant material (Takehara et al., 2008). Added as powder to a hanging drop, they 
were able to aid protein crystallisation. In particular, micromica powder has shown the potential to 
be used as universal nucleant for many proteins in the absence of precipitants. Micromica is a non-
swellable clay, originating from modification of a natural precursor-layered mineral (Utracki et al., 
2007). Natural  chlorite, another nanostructured material, suppressed nucleation in six out of the ten 
proteins tested, whereas it slightly increased the speed of crystallisation for two proteins and had no 
effect on the remaining two. Although the authors did not propose a detailed mechanism for the 
induction of nucleation by layered nanostructured material, such as these phyllosilicates, it can be 
speculated that this particular structure might promote nonspecific protein absorption. The 
differences in nanostructure between the two materials might explain their different effects. 
Also microporous synthetic zeolite Molecular Sieves have turned out to be candidates for universal 
hetero-epitaxic nucleant able to selectively facilitate new crystal forms which did not grow  
spontaneously from solution, acting as a crystallisation catalyst (Sugahara et al., 2008). Zeolite-
mediated crystallisation also improved the crystal quality in almost all of tested proteins (5 of 6). In 
these molecule sieves, the pores are much smaller than a single protein molecule, which led the 
authors to propose that nucleation followed an epitaxial growth mechanism that requires a regular 
arrangement of pores, such as those present on the zeolite surface. 
Poly vinylidene fluoride membranes with pore sizes of 400 nm have successfully used as 
heterogeneous nucleant surfaces: they promoted the growth of perfect lysozyme crystals allowing  
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to obtain two distinct forms (Zhanga et al., 2008)
 
. Nucleation of lysozyme crystals have been 
promoted also by using glass slide surfaces chemically modified with (3-
aminopropyl)triethoxysilane, poly(2-hydroxyethylmethacrylate) and poly-L-glutamic acid
 
(Liu et 
al., 2007). Moreover, polymer-induced nucleation has been used for production of high-quality 
lysozyme crystals and to induce selectively nucleation of multiple macromolecule crystal forms
 
(Grzesiak et al., 2008).  
The most recent studies have tested the effect, both in screening and as an additive for known 
crystallisation conditions, of polystyrene nanospheres on protein crystallisation with three 
commercial proteins, lysozyme, xylanase, xylose isomerase and with five research target proteins 
(Kallio et al., 2009). In screening, the addition of an aqueous solution of nanosphere to the 
crystallisation drop had a significant positive effect on crystallisation success in comparison to the 
control screen. As an additive, the nanospheres altered the crystal packing. 
The progression from the mineral crystals as nucleant agents that promote epitaxial nucleation in a 
highly specific manner, through the use of charged surfaces, towards a greater universality offered 
by porous and other natural or engineered microstructured materials has been explored. In addition 
to the already well known effects of epitaxy and electrostatic interactions, a rough and irregular 
structural pattern of terraces, hillocks, cuticles or pores on a solid substrate can enhance nucleation-
promoting properties, thus providing a new paradigm for the design of protein-crystal nucleants. 
In this contest, one topic of the thesis has been focalised on the development of crystallisation 
techniques able to promote and ease protein nucleation using functionalised surfaces. The aim is to 
evaluate the nucleant capacity of surfaces exposing chemical ionisable groups and understand the 
mechanism by which the surfaces control the protein crystallisation.  
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2.2 FUNCTIONALISED SURFACES 
 
Two surface have been used in the crystallisation experiments: Polystyrene films and mica sheets. 
Polystyrene films have been functionalised through a sulphonation reaction and are negatively 
charged, while mica sheets have been positively charged by a silanisation reaction in vapour 
diffusion (Tosi et al.,2008).  
 
2.2.1 Preparation and functionalisation of polystyrene films: Polystyrene films were prepared by 
dissolving polymer granules in 7% (w/v) 1,2-dichloroethane and 9 ml of the obtained solution was 
poured into a glass Petri dish (5.5 cm diameter) and left overnight under a chemical hood. The films 
were formed by solvent evaporation at room temperature, which was completed by incubating the 
films at 333K for about 12 h. Successively, they were sulfonated by immersion in concentrated 
H2SO4 (98% v/v) for different periods of time and then washed with distilled water to remove the 
residual acid. The different sulphonation times of polystyrene films are reported in Table 4 (page 
41).  
Eventually, the films were incubated for at least 2 h with the buffered solutions used for the 
crystallisation trials. The films released no material in solution. 
 
2.2.2 Preparation and functionalisation of mica sheets: Mica minerals are 2:1 layer silicates 
formed by a sandwich of two tetrahedral layers - sheets of linked [SiO4] tetrahedra - joined by a 
layer of Al
3+
 in octahedral coordination. The mica group of silicate (phyllosilicate) minerals has 
perfect basal cleavage and can be spited into thin laminae. Chemically, they contain complex 
silicate of aluminium and alkalies with hydroxyl. Muscovite (also known as Common mica, 
Isinglass, or Potash mica) is the most common mica.  
Muscovite is a phyllosilicate mineral of aluminium and potassium with formula 
KAl2(AlSi3O10)(F,OH)2, or (KF)2(Al2O3)3(SiO2)6(H2O). It has a highly-perfect basal cleavage 
yielding remarkably-thin laminæ (sheets) which are often highly elastic (Fig. 14).  
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Figure 14. Muscovite sheets. 
 
A perfect muscovite is made by repetition of 8 monolayers (4 O monolayers, 2 Si,Al monolayers, 1 
Mg, Fe, Al monolayer and one K monolayer) (Fig. 15) (Biino et al., 1998). 
Freshly cleaved muscovite mica surfaces have an outstanding even surface, are optically flat, clear, 
transparent, scratchless and free from fingerprints. They are very useful in electron microscopy for 
production of carbon support films, particle imaging, cell growing and thin film coating research. 
Muscovite mica surface are also suitable as substrates for high resolution atomic force microcopy 
studies such as DNA, DNA-protein and thin films. 
 
                             
Figure 15. The ideal crystal structure of muscovite. 
 
The hydrophilic properties of the mica samples were reduced by modifying their surfaces with a 
silanisation reaction (Luda et al., 1999). The mica sheets were immersed in 0.5 M HCl solution for 
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2 h (Fang et al., 1995) and then left to dry overnight in a nitrogen-gas atmosphere in a desiccator. 
The silanisation reaction was carried out in vapour phase for 18 hours in a desiccator containing 130 
µl of a silane mixture. Before each reaction the mica was carefully cleaved in air along its basal 
plane. To vary the density of the ionisable groups on the mica surface mixtures of two silanes, n-
propyltriethoxysilane and 3-aminopropyltriethoxysilane, in different percentages starting from 0 to 
100% of aminosilane, were used in the reaction. The composition of the five mixtures used for the 
silanisation reaction are reported in Table 4 (page 41). These mica sheets were incubated at least 3 
hours with the buffered solutions used for the crystallisation trials. No materials were released in 
solution as checked by atomic absorption for metal ions and chromatographic analyses. 
 
2.2.3 Characterisation of the functionalised surfaces: Studies of contact angles and roughness 
demonstrated that both surfaces are substrates suitable for macromolecular crystallisation: they do 
not allow topographic effects during nucleation, and their hydrophilicity still allows the deposition 
of a spheric drop. These surfaces are transparent to light and can be checked by an optical 
microscope. The conventional chlorinated organopolysiloxane-coated glass cover slip was used as a 
reference. 
Contact angles were determined using the sessile-drop method at room temperature. 5 ml of pure 
water was dropped onto the surface of the functionalised samples and onto the surface of the 
silanised glass cover slip, respectively. The drop was left undisturbed for about 1 min and its shape 
was then recorded with a digital camera.  
 
 
Figure 16. Diagram that shows the contact angle and interphase-energy between 3 phases: Solid-Liquid: 
γSL; Liquid-Gas: γLG ; Solid-Gas: γSG. 
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The contact-angle values reported in Table 4 (page 41) were the average of at least three 
measurements. The surface roughness was evaluated by means of atomic force microscopy. A 
Digital Instruments Nanoscope III atomic force microscope (AFM) was used to observe the 
topography of sulfonated polystyrene films, chemically modified mica sheets and silanised glass 
cover slips. All images were obtained in tapping mode using micro-fabricated silicon nitride 
cantilevers (Digital Instruments). The measurement of surface contact angles gives an evaluation of 
surface hydrophilicity (or hydrophobility). The mica silanised with neutral silane shows the same 
contact angle as the siliconised cover slip, used as control. An increase of the percentage of 
aminosilane in the reaction mixture causes a decrease of the contact angle, in agreement with the 
increase of the surface wettability due to a higher density of amino charged functional groups on the 
surface. As expected, surface hydrophilicity increases with the sulfonation time of polystyrene films. 
In a heterogeneous crystallisation experiment the roughness of the surfaces is a crucial parameter to 
address the crystal nucleation mechanism.  
The mean roughness, defined as the arithmetic average of the absolute values of the surface height 
deviation measured from the mean plane surface, was calculated over a square of 1 mm using the 
Nanoscope software. The values reported in Table 4 were the average of at least four measurements.  
The data reported in Table 4 show that the silanisation process increases the roughness of the mica 
surfaces, however mica surfaces showed a roughness that was always lower than that of the 
reference surface, irrespective of the silane mixture used in the functionalisation reaction. 
Polystyrene surfaces showed a roughness of the same order of magnitude as the reference surface, 
apart from that prepared with the highest sulfonation time (polyst. 48h). The low roughness of these 
two types of surfaces gives confidence that topographical factors should be almost absent in the 
crystallisation process. 
The distribution of charged functional groups on these surfaces has been studied. It has been 
reported that a mixture of silanes forms a monolayer on the mica surface in which silanes cluster in 
islands of different sizes (Lyubchenko et al., 1993; Crampton et al., 2005). In contrast, sulfonate 
groups are homogeneously distributed on polystyrene-film surfaces (Addadi et al., 1987). The 
increase in the number of ionisable groups on the film with the sulfonation time was checked by 
ATR-FTIR (Addadi et al., 1987) . After a period of 48 h, the peak corresponding to the sulfonate 
groups (1176.5) is saturated and its intensity does not increase by prolonging the treatment. 
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Figure 17. ATR-FTIR spectra of a) not sulphonated, b) 5min, c) 1h, d) 8h and e) 48h sulphonated 
polystyrene films. 
 
 
Table 4. The surface-contact angles and roughness of functionalised surfaces. (Standard deviations 
are given in parentheses). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
† Siliconized cover slip, on which chlorinated organopolysiloxanes are the exposed 
groups. * 3-Aminopropyltriethoxysilane. The values indicate the percentage of 
3-aminopropyltriethoxysilane in the 3-aminopropyltriethoxysilane/N-propyltriethoxysilane 
binary mixture. § Sulfonation time of polystyrene surfaces in sulforic acid. 
 
 
 
Surface 
functionalization 
Contact angle 
(°) 
Roughness  
(nm) 
reference
#
  104.4 (1.5) 0.50 (0.06) 
Mica - <10 0.11 (0.05) 
Mica A 0 % 3-apes* 104.4 (1.5) 0.25 (0.09) 
Mica B 30 % 3-apes 86.9 (1.9) 0.38 (0.17) 
Mica C 50 % 3-apes  83.0 (2.3) 0.29 (0.07) 
Mica D 70 % 3-apes 81.7 (2.5) 0.30 (0.12) 
Mica E 100 % 3-apes 81.3 (2.7) 0.29 (0.07) 
polyst.  - 97.5 (1.5) 0.35 (0.09) 
polyst. 5’ 5 min § 81.5 (2.0) 0.40 (0.09) 
polyst. 30’ 30 min 78.1 (2.2) 0.42 (0.15) 
polyst. 1h 1 h 76.4 (2.4) 0.38 (0.17) 
polyst. 8h 8 h 53.3 (2.5) 0.68 (0.18) 
polyst. 48h 48 h 35.1 (3.5) 1.5 (0.5) 
  40 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
- Chapter 2: The heterogeneous crystallisation - 
 
 41 
2.3 CRYSTALLISATION OF MODEL PROTEINS ON FUNCTIONALISED 
SURFACES  
 
The influence of the functionalised surfaces (sulfonated polystyrene films and aminosilanised mica 
sheets) on the crystallisation of insulin and ribonuclease A has been studied. The obtained results 
have been compared with previously reported work on the crystallisation of lysozyme, concanavalin 
A and thaumatin in the presence of the same type of surfaces (Fermani et al., 2001; Falini et al., 
2002). The capability of the surface to affect protein crystallisation was evaluated by comparing 
parameters such as the median waiting time, the density of crystallisation and the average crystal 
sizes (Tosi et al., 2008). In probability theory and statistics, a median is described as the number 
separating the higher half of a sample, a population, or a probability distribution, from the lower 
half.  
 
2.3.1 Set up of the crystallisation experiments: The crystallisation trials were carried out at 293 K 
by the hanging drop vapour diffusion method using a well tissue culture tray. The traditional 
hanging-drop vapour diffusion technique was modified introducing between the glass cover slip and 
the drop the surface opportunely functionalised (Fig. 18). 
 
 
 
Figure 18. The modified hanging drop technique. 
 
As reference, the conventional chlorinated organopolysiloxane-coated glass cover slips were used. 
Each well contained 750 µl of reservoir solution and the final volume of each drop was 5 µl, 
containing the protein and reservoir solutions in an equal ratio. All the experiments were repeated at 
least five times. In order to estimate the median waiting time (defined as the time spanning from the 
settling of the experiment to the observation of the first crystals using an optical microscope with 
 
Cover slip 
Functionalised 
surface 
Crystals 
Hanging drop 
Reservoir 
solution 
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crossed polarizers), all the experiments were monitored at least twice per day using an optical 
microscope. In each drop, the number and average size of the crystals were noted. 
The model proteins used were insulin and ribonuclease A, both from bovine pancreas. Insulin is a 
peptide hormone composed of 51 amino acid residues and has a molecular weight of 5808 Da. It is 
produced in the isles of Langerhans in the pancreas. Ribonuclease A (RNase A) is an endonuclease 
that cleaves single-stranded RNA. Bovine pancreatic RNase A (Mw 13.7 kDa) is one of the classic 
model systems of protein science. The pI (calculated using a ExPASy server tool) is of 6.2 for 
insulin and 9.9 for ribonuclease A. 
Both proteins were crystallised using the experimental conditions reported in the literature but 
slightly adapted to the used experimental setup. Insulin was crystallised in the presence of 0.01 M 
EDTA, 0.30 M Na2HPO4 pH 9.5 and 0.50% (v/v) xylene (Dodson et al., 1978) and ribonuclease A 
was crystallised in the presence of 55% (v/v) 2-methyl-2,4-pentanediol, 0.10 M sodium cacodylate 
pH 6.5 and 3.7 mM nickel chloride (King et al., 1956). The starting concentration of both proteins, 
insulin (20.0 mg/ml in 5 mM EDTA, 0.15 M Na2HPO4 pH 9.5 and 0.25% (v/v) xylene) and 
ribonuclease A (25.0 mg/ml in water) was lowered until no crystal growth was observed on the 
reference surface. 
 
2.3.2 Crystallisation of insulin on the functionalised surfaces: Insulin was crystallised on 
functionalised surfaces using a range of starting concentrations from 20.0 to 0.75 mg/ml. This 
protein has a high tendency to crystallise using starting concentrations above 2.0 mg/ml. Under 
these conditions, the influence of surfaces on crystallisation parameters can only be evaluated 
qualitatively. In Fig. 19a, a view of crystals grown on sulfonated polystyrene surfaces using a 
starting concentration of 10.0 mg/ml is shown. A large number of crystals formed on functionalised 
surfaces (Figs. 19a–e) with respect to the reference surface (Fig. 19f). Moreover, the crystallisation 
density increased proportionally to the density of sulfonate groups on the surfaces (Figs. 19a–e), 
with a concomitant reduction of the average crystal size. Similar behaviour was observed using 
silanised mica sheets. The waiting times, average sizes and crystallisation densities of insulin 
crystals grown on mica and polystyrene functionalised surfaces using starting protein 
concentrations of 2.0, 1.0 and 0.75 mg/ml are reported in Table 5.  
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Figure 19. Optical micrographs of insulin crystals grown on sulfonated polystyrene surfaces (a–e) and the 
reference surface (f). (a) polyst. 5’, (b) polyst. 30’, (c) polyst. 1h, (d) polyst. 8h, (e) polyst. 48h. The crystals 
were grown using a starting protein concentration of 10.0 mg/ml. 
 
 
Table 5. Waiting times (w.t.), average crystal sizes (D) and crystallisation densities (c.d.) for 
insulin. 
 
 
 2.0 mg/mL 1.0 mg/mL 0.75 mg/mL 
 
w.t. 
(days) 
D* 
(mm) 
c.d. 
(n. c./mm2) 
w.t. 
(days) 
D* 
(mm) 
c.d. 
(n. c./mm2) 
w.t. 
(days) 
D* 
(mm) 
c.d. 
(n. c./mm2) 
          
Control
#
 1 0.02  12  2 0.02  9 7
a 
0.03 6 
          
Mica A  1 0.02  34    0.5 0.03  10 3 0.02 8 
Mica B  1 0.03  35  1 0.02  20 2 0.03 10 
Mica C  1 0.06  34  1 0.01  30 2 0.03 15 
Mica D  1 0.01  46  1 0.02 35 1 0.02 35 
Mica E  1 0.01 48  1 0.01  35 1 0.02 50 
          
Polyst. 5’  1 0.01  45   1 0.01  12 6 0.02 6 
Polyst. 30’  1 0.09  50 2 >0.01  20 6 0.02 9 
Polyst. 1h  1 0.01  55 3 0.013  35 4 0.01 9 
Polyst. 8h  1 mass
b
 mass
b
 3 >0.01 50 3 0.01 12 
Polyst. 48h  1 mass
b
 mass
b
 2 mass
b
 mass
b
 2 >0.01 30 
 
* D: the value refers to the average length of the longest axis of the crystal calculated on a set of several dozen of crystals. 
# siliconised cover slip. 
a only in few experiments (less than 25%). 
b mass.: massive crystallisation. 
 
200 µm 
200 µm 200 µm 
200µm 200 µm 
300 µm 
f) 
a) 
d) e) 
c) b) 
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When a starting insulin concentration of 2.0 mg/ml was used, the waiting time was about 1 day  in 
the presence of both the functionalised surfaces and  the reference. At a concentration of 1.0 mg/ml 
the waiting time on the reference was almost double that on all mica functionalised surfaces while 
the waiting time on sulfonated polystyrene surfaces was unrelated to the density of sulfonation. 
Using a starting protein concentration of 0.75 mg/ml, on the reference crystals formed after about 
one week and only in a few experiments (less than 25%), while they always appeared after a 
waiting time of about 1 day and not longer than 5 days using amino-silanised mica sheets and 
sulfonated polystyrene films, respectively. Moreover, in the presence of functionalised polystyrene 
surfaces the waiting time decreased with the increase of the amount of sulfonate groups from about 
6 days on polyst. 30’ to about 2 days using polyst. 48h. The crystallisation density on the reference 
decreased as the protein concentration was reduced (Table 5). In the presence of surfaces with an 
increasing number of ionisable functional groups, an increase in crystallisation density was 
observed at each protein concentration. Interestingly, the crystallisation densities observed on mica 
and polystyrene functionalised surfaces were always higher than those observed on the reference. 
This effect was also present for mica A, which has a reference-like hydrophobic surface but differs 
in roughness and contact angle (Table 4). At a protein starting concentration of 2.0 mg/ml the 
crystallisation densities of insulin using silanised mica surfaces increased to a value of about 48 
crystals mm
2
. This value is close to the lowest crystallisation density observed in the presence of 
polyst .5’ (45 crystals mm
2
) at the same protein concentration. Under the same conditions the 
crystallisation density increased to 55 crystals mm
2 
in the presence of polyst.1h and appeared as a 
massive precipitation using polyst. 8h and polyst. 48h. When the starting protein concentration was 
reduced to 1.0 or 0.75 mg/ml a progressive decrease in crystallisation density was observed. This 
influence was more marked using sulfonated polystyrene films than with silanised mica sheets. 
Insulin precipitated in all the experiments, forming small crystals (around 10 mm along the main 
axis). As the density of charged functional groups on the surfaces increased, the average crystal size 
slightly decreased, while the crystallisation density increased. 
 
2.3.3 Crystallisation of ribonuclease A on the functionalised surfaces: Ribonuclease A was 
crystallised using a starting concentration between 25.0 and 2.5 mg/ml on mica or polystyrene 
functionalised surfaces. Crystal formation was not influenced by the presence of functionalised 
mica surfaces until the starting concentration was reduced to values equal or below 10.0 mg/ml 
(Table 6). 
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Table 6. Waiting times (w.t.), average crystal sizes (D) and crystallisation densities (c.d.) for 
ribonuclease A. 
 
* D: the value refers to the average length of the longest axis of the crystal calculated on a set of several dozen of crystals. 
# siliconised cover slip. 
a only in few experiments (less than 25%).  
 
At this concentration, using mica E functionalised only with hydrophilic silane, the waiting time 
was about 2 days, in contrast to waiting times that were at least doubled using the other silanised 
surfaces (Table 6). At a protein concentration of 7.5 mg/ml, the waiting time was about 4 days for 
crystals grown in the presence of mica A or the reference, both of which have a hydrophobic 
surface, about two weeks in the presence of mica surfaces functionalised with silane mixtures 
(micas B–D) and about 6 days in the presence of mica E. When the starting concentration was 
reduced to 2.5 mg/ml, crystals only grew on mica surfaces with a high content of amino 
(hydrophilic) groups (micas C–E). The density of crystallisation did not appear to be strongly 
influenced by the silanised mica surfaces. 
However, at each concentration the highest value of crystallisation density was observed in the 
presence of mica E. The average size of the ribonuclease A crystals was mainly controlled by the 
starting concentration and not by the type of mica surface used (Table 6). In the presence of 
sulfonated surfaces, ribonuclease A crystallised as large aggregates when starting concentrations 
above 10.0 mg/ml were used. Figure 20 shows crystals grown at a concentration of 20.0 mg/ml 
using polystyrene film sulfonated for 48 h and the reference surface. 
c) 
 
 
 
 10 mg/mL 7.5 mg/mL 2.5 mg/mL 
 
w.t. 
(days) 
D* 
(mm) 
c.d. 
(n. c./mm2) 
w.t. 
(days) 
D* 
(mm) 
c.d. 
(n. c./mm2) 
w.t. 
(days) 
D* 
(mm) 
c.d. 
(n. c./mm2) 
          
Control
#
 5 0.33 3 5 0.29  3 - - - 
          
Mica A 5 0.43  3 4 0.26 2 - - - 
Mica B 5 0.36  6 11 0.30  3 - - - 
Mica C 5 0.39  6 11 0.27  3 11
a
 0.17 0.5 
Mica D 4 0.26  5 12 0.16  2 9
 a
 0.16 0.5 
Mica E 2 0.43  6 6 0.21  4 35
 a 
0.17 1 
          
Polyst. 5’ 5 0.40  3 4 0.26 3 - - - 
Polyst. 30’ 5 0.30  3 4 0.24 6 - - - 
Polyst. 1h 5 0.29  4 6 0.32 5 4
a
 0.13 1 
Polyst. 8h 5 0.21  6 6 0.14 6 4
a
 0.14 1 
Polyst. 48h 2 0.34 9 2 0.14 10 4
a
 0.11  1.5 
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Figure 20. Optical micrographs at different magnifications of ribonuclease A crystals grown on the reference 
cover slip (a and b) and polystyrene surface with the highest content of sulfonated groups (c and d). The 
crystals were grown using a starting protein concentration of 20.0 mg/ml. 
 
The formation of these aggregates made difficult to evaluate the average crystal size and the 
crystallisation density. The waiting time was affected by the presence of sulfonated surfaces only 
when starting protein concentrations equal or lower than 10.0 mg/ml were used. At this 
concentration and for polyst. 48h the waiting time was shorter (2 days) than for other polystyrene 
surfaces (5 days). A similar influence of the surface was observed at a protein concentration of 7.5 
mg/ml. When the protein concentration was reduced to 2.5 mg/ml a waiting time of about 4 days 
was observed and, more importantly, crystals formed only in the presence of polystyrene films that 
had been sulfonated for more than 1 h. The average crystal size at the concentration of 10.0 mg/ml 
varied between 0.2 and 0.4 mm and was independent of the type of polystyrene film used. At a 
protein concentration of 7.5 mg/ml the average crystal size was around 0.25 mm using polyst. 5’–1h 
and about 0.14 mm for polyst. 8h and 48h. At the lowest starting protein concentration (2.5 mg/ml) 
an average crystal size of about 0.14 mm was observed. In the presence of these surfaces, the 
crystallisation density increased proportionally to the degree of sulfonation. It is important to note 
that at a starting ribonuclease A concentration of 2.5 mg/ml crystal formation was observed only in 
about 25% of trials for both surface families (more than ten on each surface). However, this 
100 µm 
400 µm 175 µm 
175 µm 
a) b) 
c) d) 
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observation does undermine the nucleating role of the functionalised surfaces as crystal formation 
was not observed on the reference surface. The ribonuclease A waiting time using functionalised 
surfaces showed a significant variability and in some experiments was longer than that observed on 
the reference surface (silanised surface with high hydrophobicity). A possible reason for this 
variability could be the presence of trace amounts of impurities in solution. Moreover, minimal 
protein degradation cannot be excluded in lengthy crystallisation experiments. 
 
2.3.4 Effects of both the functionalised surfaces on model proteins crystallisation: The results 
for the crystallisation of insulin and ribonuclease A in the presence of functionalised surfaces have 
been compared with findings obtained using lysozyme, thaumatin and concanavalin A on the same 
surfaces (Fermani et al., 2001; Falini et al., 2002). A summary of the variation of crystallisation 
parameters using functionalised surfaces with respect to the reference surface is reported in Table 7.  
Concerning the protein concentration the first and second values (reported in parenthesis) indicate 
the lowest starting protein concentration at which crystals formed in the presence of functionalised 
surfaces and the reference, respectively. 
In the Table 7, the symbol = indicates that the functionalised surfaces did not influence the 
crystallization process with respect the control; + indicates an increase of the crystal density (crystal 
per surface unit) with respect to the control; - indicates a reduction of the average size of the crystal 
with respect to the control. The observations refer to the lowest starting protein concentration when 
crystals were observed both on the functionalised surfaces and the control. The surfaces are those 
that gave the most evident influences on the crystallization process, usually the ones with the 
highest content of ionisable functional groups.  
Insulin and ribonuclease A have a net charge of about -9 and +8, respectively, at the pH values of 
the crystallisation conditions. Under the same pH conditions amino-silanised mica surfaces (micas 
B–E) are positively charged, whereas sulfonated polystyrene surfaces are negatively charged.  
Thus, electrostatic attractions or repulsions may be present as a function of the relative charges of 
the surface and the protein. Similar considerations can be performed for the other model proteins 
reported. It is possible to note that with the exception of lysozyme, charged surfaces always 
increased the crystallisation density and reduced the nucleation time (measured here as the median 
waiting time) with respect to the reference surface. 
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Table 7. Summary of the results of the model protein crystallisation experiments using the 
sulfonated polystyrene films and the silanised mica sheets that gave the most evident effects with 
respect to the reference. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Waiting times (w.t.), crystallization densities (c.d.) and average crystal size (d) are reported as relative values, equal 
(=), higher (+) or lower (-) in comparison to those for the reference. 
# The value refers to the lowest starting concentration of protein at which crystals formed on functionalised surface.  
* The protein net charge at the crystallization pH was calculated using the pI, MW, titration curve tool from ExPASy 
server. 
a The protein was crystallized at pH 6.0; b The protein was crystallized at pH 9.0.  
/ Crystallization trials have not been carried out. 
 
 
It has been demonstrated experimentally and theoretically that the interaction between proteins and 
surfaces promoting nucleation requires weak forces that concentrate proteins in the proximity of the 
surface (Chayen et al., 2006; Sear, 2007). While the physics and chemistry which govern 
homogeneous nucleation of proteins have been accurately investigated (Garcìa-Ruiz, 2003), 
research on the processes that control their heterogeneous nucleation is still in progress. Recent 
studies suggest that the heterogeneous nucleation of protein crystals cannot be described in the same 
way as the heterogeneous nucleation of ionic solids, in which an epitaxial mechanism of nucleation 
is commonly involved (Galkin et al., 2000; Sear, 2007). Protein crystals are stabilised by weak 
lattice energies (McPherson, 1999). Thus, the interaction between proteins and heterogeneous 
surface should be weak enough to let protein molecules be free to reorganise themselves in rotation 
and translation to associate in stable crystal nuclei. The ionisable functional groups present on the 
surfaces should allow protein–surface interactions by electrostatic forces. Since the superficial 
charge density can be modulated, the force of the electrostatic interaction can be also varied. When 
attractive interactions are present, protein molecules tend to concentrate close to the surface, locally 
Protein   
 
 
Sulphonated 
polystyrene films 
 Silanised Mica 
 Prot conc.# 
(mg/ml) 
Cryst. 
pH 
Prot. net 
charge* 
 w.t. c.d. D  w.t. c.d. D 
            
Lysozyme 5.0 (10) 4.5 + 2  = = =  -  = = 
Concanavalin Aa 3.0 (10) 6.0 - 9  / / /  - + - 
Concanavalin Ab 10 (10) 9.0 ~ 0  -  + -  / / / 
Thaumatin 2.0 (2.0) 6.8 + 5  / / /  -  + - 
Ribonuclease A 2.5 (7.5) 6.5 + 8  - +  -  = +   - 
Insulin 0.75 (1.0) 9.5 - 9  =  + -  - + - 
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increasing the supersaturation that favours crystal nucleation and growth. In addition to this effect, 
the surface can also stabilise already formed nuclei by interaction with a specific crystal face or it 
can favour the formation of crystal nuclei by clustering ordered motifs of protein molecules. It can 
be supposed (similarly to the concept used to explain the nucleation properties of glass substrates 
with pores of a wide range of sizes; Chayen et al., 2006) that surfaces with a random distribution of 
functional groups offer many different potential patterns of interaction with crystal nuclei. This can 
be described as a controlled mechanism with the surface playing an active role in the nucleation 
process. In the presence of repulsive forces, the protein molecule does not settle in the thin layer 
close to the surface. As a consequence, it can be supposed that the protein concentrates in the upper 
layer and its crystallisation can be achieved using a lower starting protein concentration. As the 
surface does not play a direct role in affecting the crystallisation process in this case, this 
mechanism is described as surface-induced. A schematic representation of these two mechanisms is 
shown in Fig. 21. 
                                                                                                                                                                                                    
 
Figure 21. Schematic representation of surface effects on protein crystallization. Crystallization can be 
controlled (left) or induced (right). In the first case protein nucleation occurs on the surface, which 
stabilises the nuclei. In the second case repulsive forces are present between the surface and the 
protein. These move the proteins out from the surface and increase their concentration in a thin 
layer in its proximity (dashed circles). In the scheme, drops and crystals are not shown on the same scale. 
 
In conclusion, it has been shown that functionalised surfaces are able to induce protein 
crystallisation at concentrations lower than those required by the reference surface. The random 
distribution of the functional groups on the surfaces results in a reduction of the waiting time 
occurring in some cases, which may suggest surface stabilisation of the crystal nuclei. Thus, it is 
conceivable to design surfaces suitable to control nucleation kinetics in order to resolve the conflict 
between the necessity of nucleation at low supersaturation and the need for a protein concentration 
sufficient to sustain crystal growth. 
 
 
 
 
 
 
 
 
  
 
 
 
 
Surface controlled Surface induced 
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2.4 PROTEINS CRYSTALLISATION ON FUNCTIONALISED SURFACES 
IN AN INNOVATIVE DEVICE: THE CRYSTALLISATION MUSHROOM 
 
The effect of sulfonated polystyrene films and silanised mica on crystal nucleation and growth of 
two model proteins, thaumatin and glucose isomerase, has been investigated together with a 
crystallisation device, the Crystallisation Mushroom (Triana S&T) (García-Ruiz et al., 2005). It 
offers the advantage to perform simultaneously crystallisation experiments under identical 
environmental conditions. Some of the experiments have been carried out in the Laboratorio de 
Estudios Cristalográficos of Professor Garzia Ruiz in Granada (Spain) thanks to the financial 
support of the bilateral project 0013890 CNR/CSIC (2007/2008). The groups of Bologna (Italy) 
and Granada (Spain) have a parallel experience in the studies of new strategies for macromolecular 
crystallisation. The bilateral project has been finalised to join the experiences of each group to 
design and realise a crystallisation system that has much as possible a “universal” applicability and 
allows to crystallise a wide number of uncrystallised proteins. For this reason, three months during 
the PhD period have been spent in Spain to the development of this new technique to promote and 
ease the protein crystals nucleation and growth. 
 
2.4.1 Set up of the crystallisation experiments: The crystallisation trials were carried out using 
the crystallisation mushroom (Fig. 22), a glass modified essicator to perform sitting drop vapour 
diffusion experiments under identical environmental conditions. It allows to follow the equilibration 
of 12 drops against a unique reservoir (5 mL). The final volume of each drop was 6 µl. Trials were 
set up at 293 K in an incubator.  
 
                              
Figure 22. The crystallisation mushroom. 
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The model proteins used for these experiments were thaumatin from Thaumatococcus daniellii and 
glucose isomerase purified from Streptomyces rubiginosus. Thaumatin is a low-calorie protein 
sweetener and flavour modifier, glucose isomerase (D-glucose ketoisomerase) is an enzyme that 
converts glucose to fructose.  
Firstly, several crystallisation mushrooms were set up for both model proteins in which 12 drops 
were made mixing the protein solution (three protein concentrations could be tested at the same 
time each experiment) and the reservoir solution in four different ratios: 1:1, 1:2, 1:3 and 2:1. 
Before to test the functionalised surfaces, it was needed to adapt the crystallisation conditions 
reported in literature for the used model proteins, thaumatin and glucose isomerase, to the new 
system, the crystallisation mushroom. A wide area of the diagram phase of each model protein 
could be screened in every performed experiment. The aim of this step was to identify the 
crystallisation conditions that gave at the same time countable number of crystals of sizes as big as 
possible. The screening of thaumatin diagram phase carrying out experiments in the crystallisation 
mushrooms showed that in this system countable number of crystals (less then 20) with big average 
sizes (0.40 mm) were generally obtained dissolving the protein in milliQ water at starting 
concentration of 40 mg/mL using 0.26 M Na/K tartrate and 0.1 M KH2PO4 pH 6.8 as reservoir 
solution. Thaumatin has theoretical pI 8.05 and at the crystallisation pH 6.8, net charge of + 4.7. 
Glucose isomerase was purchased as a crystalline suspension in an ammonium sulfate-rich solution, 
dialysed and successively concentrated in 100 mM HEPES pH 7.0. Glucose isomerase was 
crystallised at high and low ionic strength: in the first case, the best crystallisation condition was 
determined to be a reservoir solution of 0.8 M (NH4)2SO4 and 100 mM HEPES pH 7.0 with starting 
protein concentration of 35 mg/mL, while in the second case the reservoir solution was composed 
by 10% (w/w) PEG 1000 and 0.2 M MgCl2 and the starting protein concentration was 13 mg/mL.  
Glucose isomerase has theoretical pI 5.14 and at the crystallisation pH 7.0, net charge of -15.8. For 
both model proteins, theoretical pI and net charge at corresponding crystallisation pH were 
calculated using protein calculator v3.3 (www.scripps.edu). 
Once reservoir solution and protein concentration giving few and big crystals were determined, 
experiments in the crystallisation mushroom were performed using functionalised surfaces. In each 
experiment, one of the twelve positions in the crystallisation mushroom was used as reference (the 
device is made of siliconised glass and can be considered as a common siliconised cover slide used 
in the hanging drop technique) while the 6 types of sulfonated polystyrene films (with respect to the 
experiments previously described, also sulfonated polystyrene films at 24 h were tested) the five 
types of silanised mica were attached each at one of the eleven remaining positions with double-
steak tape. In a thirteenth position not sulfonated polystyrene film (polyst. 0’) was added and tested 
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(Fig. 23 a,b). The starting protein concentration of each protein was lowered until to reach the 
concentration at which no crystals appeared on reference. For each tested protein concentration of 
both model proteins, the experiments were repeated at least five times and the reported data were 
calculated as median of obtained results. In order to estimate the median waiting time, all 
experiments were monitored every day by optical microscopy and in each drop number and medium 
size of crystals were noted. 
 
  a) 
 
b) 
48h
8h
1h
30’
VAPOUR DIFFUSION
A
E
C
D
B
0’
24h
5’
Ref.
 
Figure 23. (a) the crystallisation mushroom with the functionalised surfaces; (b) schematic representation of 
crystallisation experiments with functionalised surfaces into the crystallisation mushroom. Reference, 
silanised micas and polystyrene films are represented in white, green and yellow, respectively. The letters A-
E indicate the different mixtures used in the silanisation of mica sheets. For sulfonated polystyrene films, the 
different times of sulfonation are reported. 
 
 
2.4.2 Crystallisation of thaumatin on the functionalised surfaces in the crystallisation 
mushroom: Thaumatin has been crystallised at different protein concentrations, from 40 mg/mL to 
15 mg/mL. At the latter concentration crystals always appeared using surfaces but never with the 
reference (Table 8). At high protein concentrations (about 30 mg/mL), there was not substantial 
difference between the use of reference or functionalised surfaces. In fact, median waiting time, 
crystallisation density, and average crystal size were in the same order of magnitude (data not 
reported). 
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Table 8. Median waiting time (w.t.), crystallisation density (c.d.) and average crystal sizes (D) for 
thaumatin grown on functionalised surfaces in the crystallisation mushroom. 
 
# siliconised glass of the crystallisation mushroom. 
† Number of crystals observed per surface unit (mm2).  
‡ The value refers to the average length of the longest axis of the crystal calculated from a set of several dozen crystals.  
§  Massive crystallization 
* days 
 
From starting protein concentration equal or lower than 30 mg/mL, the surfaces influence the 
crystallisation process differently from the reference. At 30 mg/mL, micas C, D, E, which have the 
highest contents of exposed hydrophilic ionisable groups, decreased the median waiting time of 
about 1 week with respect to the reference. Also polystyrene films at the highest degree of 
sulfonation (polyst. 48h) affected this parameter in the same way. Interestingly, not sulfonated 
polystyrene films halved the median waiting time. All micas exposing amino groups (mica B-E) 
drastically increased the crystallisation density compared with the reference, although the average 
crystal sizes did not significantly change for any mica excepted for mica B. At the lowest and 
highest times of sulfonation (polyst. 5’ and 48h), the crystallisation density was 33% higher than 
that one of reference, although crystals had same sizes. 
For the remaining kind of polystyrene films, the crystal density was double using  polyst. 1h and 
24h with crystal sizes slightly smaller (0.30 mm) or identical to reference (0.38 mm), respectively. 
On the contrary, on polyst. 30’ and 8h an amount of crystals identical to the reference grew but in 
this case the average dimensions of the crystals were strongly reduced to 0.23 mm. An influence on 
 30.0 mg/ml 25.0 mg/ml 20.0 mg/ml 15.0 mg/ml 
 
w.t. 
(d)* 
c.d.† 
(n.c./mm2) 
D‡ 
(mm) 
 w.t. 
(d) 
c.d.† 
(n.c./mm2) 
D‡ 
(mm) 
 w.t 
(d) 
c.d.† 
(n.c./mm2) 
D‡ 
(mm) 
 w.t. 
(d) 
c.d.† 
(n.c./mm2) 
D‡ 
(mm) 
                
refer.# 15 ~10 0.38  30 ~10 0.30  25 ~10 0.23  ----- ---- ---- 
                
mica A 13 < 5 0.30  14 ~10 0.38  11 < 30 0.26  24 ~15 0.11 
mica B 13 mass.§ 0.23  14 < 5 0.38  9 ~30 0.15  21 ~15 0.20 
mica C 9 mass.§ 0.38  14 < 5 0.38  9 ~30 0.30  21 ~25 0.30 
mica D 9 mass.§ 0.38  15 < 5 0.31  19 < 30 0.23  17 ~20 0.30 
mica E 9 mass.§ 0.38  22 < 5 0.56  7 < 40 0.19  17 ~20 0.30 
                
polyst. 0’ 7 ~20 0.23  15 mass.§ 0.15  - - -  - - - 
polyst. 5’ 14 ~15 0.38  19 < 5 0.60  18 ~10 0.30  17 ~20 0.34 
polyst. 30’ 13 ~10 0.22  19 ~10 0.23  18 mass.§ 0.15  21 ~15 0.26 
polyst. 1h 14 ~20 0.30  26 < 5 0.38  18 ~10 0.23  21 ~10 0.23 
polyst. 8h 13 ~10 0.23  14 < 10 0.38  18 ~10 0.38  21 mass.§ 0.15 
polyst. 24h 14 ~20 0.38  14  ~10 0.23  24 ~15 0.30  24 < 40 0.23 
polyst. 48h 9 ~15 0.38  20 ~10 0.23  14 mass.§ 0.15  24 ~15 0.26 
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the two parameters was present also using not sulfonated polystyrene films (about 20 crystals/mm
3
 
with size of 0.23 mm). 
At 25 mg/mL, the reduction of the median waiting time became much more evident for both 
functionalised surfaces, all micas and sulfonated polystyrene films, with respect to the reference. 
Micas A-D halved this parameter while for mica E the reduction, even if present, was less marked 
than that caused by micas A-D. At this concentration, the median waiting time using sulfonated 
polystyrene films was always lower than that of reference, but without a clear trend using from 
polyst. 5’-48h. On the contrary, polyst. 0’ halved the median waiting time compared with the 
reference, although it does not expose any chemical ionisable groups. At this concentration, high 
increase of the crystal density wasn’t observed for any functionalised surface, but it became 
substantial using not sulfonated polystyrene films, unique case in which also the average crystal 
sizes (0.15 mm) were strongly reduced with respect to the reference (0.30 mm).  
At 20 mg/mL the effect of the two functionalised surfaces was marked (Fig. 24) aswell the presence 
of exposed ionisable groups on the t surfaces became an important requirement to favour the 
nucleation event. This was confirmed by the fact that no crystals appeared on not sulfonated 
polystyrene films at concentration equal or below 20 mg/mL.  
With respect to the reference, the median waiting time was more than halved using mica A, the less 
charged mica, and reduced of three times and half using mica E, the most hydrophilic mica. Going 
from mica A to mica E, the crystal density increased showing values three times equal or greater 
than the reference. Only using mica B and E the average crystal sizes were slightly lower than those 
of reference. 
 
 
 
 
 
 
 
 
 
Figure 24. Optical micrographs of thaumatin crystals grown on (a) the reference, (b) mica E, (c) polyst. 48h. 
The crystals were grown using starting protein concentration of 20 mg/ml.  
 
 
 
 
a) b) c) 
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The median waiting time of reference (25 days) was reduced to 14 days on polyst. 48h, which also 
showed a strong effect on thaumatin crystallisation density compared with the reference. On it, a 
massive crystallisation occurred while on reference few crystals grew. Moreover, crystals grown on 
polyst. 48h were smaller (0.15 mm) than those grown on reference (0.23 mm).  
At 15 mg/mL, crystals did not growon reference, while they always appeared when functionalised 
surfaced were used. The median waiting time decreased going from mica A to mica E, but increased 
going from polyst. 5’ to polyst. 48h. All micas and sulfonated polystyrene films seemed to 
influence the crystallisation density at the same manner, excepted for polyst. 8h and 24h that 
resulted more efficient. The crystals with the smallest average crystal sizes grew on mica A and 
polyst. 8h. 
 
2.4.3 Crystallisation of glucose isomerase on the functionalised surfaces in the crystallisation 
mushroom: Glucose isomerase was crystallised using as precipitant salts or polymers in order to 
investigate the behaviour of the protein at high or low ionic strength. The presence of the salt in 
solution influences the nature of protein-surface electrostatic interactions and consequentially the 
entire crystallisation process. 
At high ionic strength it was possible only to determine the optimal crystallisation conditions for 
this protein in the crystallisation mushroom and at the moment experiments of crystallisation on 
functionalised surfaces are being carried out but no clear results have been obtained yet.  
On the contrary, at low ionic strength after identifying the optimal crystallisation condition of 
ribonuclease A in the crystallisation mushroom, experiments with functionalised surfaces-
mushroom were carried out.  Glucose isomerase was crystallised in a protein concentration range 
going from 13 mg/mL to 7 mg/mL (Table 9). 
At the highest protein concentration, crystals always appeared earlier on micas and polystyrene 
sulfonated films than on reference. In fact, all functionalised surfaces were able to decrease the 
median waiting time from 120 minutes (reference) to 30 minutes, except mica C, for which the 
median waiting time was of 1 h. With respect to the reference, not sulfonated polystyrene films also 
decreased of four times the median waiting time. The influence of functionalised surfaces on 
median waiting time was lost at concentration lower than 13 mg/mL.  
At 13 mg/mL, crystallisation density of all micas was always higher than that one of reference (Fig. 
25). Amongst the five tested micas, the two most hydrophobic (mica A-B) showed massive crystals 
growth. When the amount of amminosilane used to functionalised mica was higher than 30% (v/v) 
(micas C-E), the effect was reduced. The crystallisation density of mica C-E still remained much 
more higher compared with reference, increasing going from mica C to E. Also sulfonated 
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polystyrene films increased the crystallisation density with respect to reference, but no clear effect 
was observed. At the lowest (polyst. 0’) and highest (polyst. 48h) sulfonation times, the less marked 
influence on number of grown crystals was detected.  
At a concentration of 8 mg/mL, only few crystals grew on reference and not sulfonated polystyrene 
films (less than 5). While sulfonated polystyrene films seemed not to affect strongly the 
crystallisation density with respect to reference, completely hydrophobic (mica A) and hydrophilic 
(mica E) micas were able to induce the highest increase of the crystallisation density, especially 
marked for mica E. Moreover, for mica E the reduction of crystals sizes (0.08 mm) was well evident 
with respect to reference (0.14 mm). The sizes of crystals were also of 0.08 mm when polyst 30’,1h, 
8h and 48h were used as nucleant substrates. Lowering the concentration from 8 to 7 mg/mL, 
crystals did not appear anymore on reference.  
 
Table 9. Median waiting time (w.t.), crystallisation density (c.d.) and average crystal sizes (d) for 
glucose isomerase grown in the presence of PEG 1000 on functionalised surfaces in the 
crystallisation mushroom. 
 
 
# siliconised glass of the crystallisation mushroom. 
† Number of crystals observed per surface unit (mm
2
).  
‡ The value refers to the average length of the longest axis of the crystal calculated from a set of several dozen crystals.  
§  Massive crystallization. 
 
 
 13 mg/mL 8.0 mg/mL 7.0 mg/mL 
 w.t. 
(min) 
c.d.† 
(n.c./mm
2
)
 
D‡ 
(mm) 
 w.t. 
(min) 
c.d.† 
(n.c./mm
2
) 
D‡ 
(mm) 
 w.t. 
(days) 
c.d.† 
(n.c./mm
2
) 
D‡ 
(mm) 
            
refer.# 120 <10 0.20  240 <5 0.14  --- --- --- 
            
mica A 30 mass.§ 0.20  240 ~30 0.14  1 ~10 0.11 
mica B 30 mass.§ 0.20  12h ~20 0.10  1 mass.§ 0.11 
mica C 60 >50 0.20  24h ~10 0.14  1 > 20 0.15 
mica D 30 >100 0.18  240 ~10 0.14  1 mass.§ 0.15 
mica E 30 >200 0.20  240 mass.§ 0.08  1 ~10 0.18 
       .     
polyst. 0’ 30 15 0.20  24h <5 0.15  1 ~10 0.15 
polyst. 5’ 30 mass.§ 0.20  240 ~10 0.17  1 ~10 0.76 
polyst. 30’ 30 >50 0.18  240 ~10 0.08  1 ~10 0.38 
polyst. 1h 30 >100 0.18  240 ~10 0.08  1 ~10 0.38 
polyst. 8h  30 mass.§ 0.20  240 ~10 0.08  1 >50 0.38 
polyst. 24h 30 mass.§ 0.18  240 ~15 0.17  1 ~10  0.15 
polyst. 48h 30 15 0.20  240 ~10 0.08  2 ~10 0.15 
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At the most 10 crystals grew on micas A and E and all polystyrene films (except polyst. 8h), more 
than 20 on mica C and massive crystallisation occurred on mica B and D. The crystals sizes did not 
show a well defined trend and it was not possible to establish a correlation between the presence of 
chemical ionisable groups exposed on the surfaces and this parameter. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. Optical micrographs of glucose isomerase crystals grown on (a) the reference, (b) mica D, (c) 
mica E, (d), polyst. 30’ and (e) polyst. 8h. The crystals were grown using a starting protein concentration of 
13 mg/ml. 
 
2.4.4 The behaviour of functionalised surfaces on model proteins crystallisation in the 
crystallisation mushroom: For the first time, a modified essicator  has been used as alternative tool 
for the crystallisation of proteins. It offers the advantage to perform in the same physical-chemical 
environment different crystallization trials. Since the crystallisation process is influenced by 
uncountable variables and it is difficult to establish which of them will play the crucial role for the 
obtainment of crystals, performing experiments in identical conditions makes easier to compare the 
parameters affecting the process. That could be useful to completely understand the mechanism 
driving the crystallisation event. The crystallisation mushroom is a tool with promising and 
excellent potentialities in the field of crystallisation. The first step of the previously described work, 
that was the research of the crystallisation conditions for model proteins that it is well know to easy 
crystallise, has upfront highlighted the complexity of using this tool.  
  
a) 
b) c) 
d) e) 
300 µm 
600 µm 600 µm 
600 µm 600 µm 
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Both functionalised surfaces always decreased the waiting time of thaumatin and moreover, at the 
highest tested protein concentration (30-25 mg/mL), polyst. 0’, the surface not exposing ionisable 
chemical but only hydrophobic groups, showed the best capacity in affecting this parameter. At 
high protein concentration, it seems that the only presence of a foreign substrate can help the 
process regardless of the kind and amount of exposed chemical ionisable groups. As the protein 
concentration is decreased, the presence of ionisable groups linked to the surface becomes 
necessary to induce crystal growth and no crystal grew on not sulfonated polystyrene. Reached the 
limit concentration of 15 mg/mL, crystals stopped to grow also on the reference and between the 
functionalised surfaces no substantial differences in term of crystallisation density were detected. At 
this concentration mica E, the most hydrophilic and positively charged mica, and polyst. 5’, the 
polystyrene film with the lowest amount of hydrophilic exposed groups, were the most efficient 
surfaces in decreasing the waiting time, while the less efficient surfaces were mica A that is 
completely hydrophobic, and polyst. 48h with the highest content of exposed negative groups. The 
waiting time decreased together with an increment of exposed positive groups (going from mica A 
to mica E) and a decrease of exposed negative groups (going from polyst. 48h to polyst. 5’). In 
order to understand how the presence of ionisable groups on the nucleanting substrate influences 
and induces the nucleation event and the nature of relationships becoming established between 
protein and surface, it is necessary to study the behaviour of others model proteins in the system 
functionalised surfaces-mushroom. For this reason, the lysozyme will be used to carry out 
experiments that could elucidate the possible roles of ionisable chemical groups in the process of 
macromolecular crystallization. A deeper analysis of the system and of the interaction protein-
surface will be done by means of a comparison between the data obtained with thaumatin and those 
that will be obtained with lysozyme. The crystallisation pH of Lysozyme is 4.5 and at this pH the 
net charge is +2, very close to the neutrality (Table 7, page 50).  
Regarding glucose isomerase,  only at high ionic strength, some results, even if difficult to interpret,  
have been obtained. These results highlight that functionalised surfaces can influence nucleation 
starting from  the highest tested protein concentration at which decreased the waiting time and 
increased the crystallisation density with respect to the reference. At the low concentration of 7 
mg/mL, crystals did not grow on the reference but always on all the functionalised surfaces. The 
difficulty in interpreting and rationalising the obtained results, could be due to the presence of PEG 
in solution. 
PEG competes with protein for water and exert excluded volume effects (which vary according to 
the length of the polymer). However, unlike salts, PEG decreases the effective dielectric constant of 
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the solution and increases the effective distance over which protein electrostatic effects occur. 
These effects need to be explored carrying out further crystallisation trials. 
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CHAPTER 3: THREE-DIMENSIONAL STRUCTURE OF 
RIBOSOME INACTIVATING PROTEINS (RIPs) 
 
 
3.1 INTRODUCTION: classification, enzymatic activity, toxicity of RIPs 
 
At the end of 19th century, the toxic principle of castor bean was identified to be a protein, called 
ricin by Stillmark (Stillmark, 1888; 1889). The identification of ricin, from the seeds of Ricinus 
communis, was an important milestone in biochemistry because for the first time a well-defined 
biological activity was ascribed to a plant protein. Moreover, ricin and also abrin, a similar toxic 
protein from the seeds of Abrus precatorius, played an important role in the early development of 
immunology. In fact, they were used by Paul Ehrlich to immunise mice raising the first antibodies 
(Ehrlich, 1881a; 1881b). Seventy years later, the three-dimensional structure of ricin and abrin were 
resolved by Montfort  and Tahirov, respectively (Montfort et al., 1987; Tahirov et al., 1995). They 
were found to be composed of two polypeptide chains, an enzymatic A chain that damaged 
ribosomes, and a lectinic B chain, galactose specific, capable of binding to cell walls (Olsnes et al., 
1973(a,b); Olsnes 2004). Other and more numerous proteins were found that resemble the A chains 
of these toxins, in that they have a similar structure and the same activity on ribosomes. For these 
proteins were introduced the denomination of RIPs (Ribosome Inactivating Proteins) (Stirpe, 1982) 
and since then several reviews have provided lists of RIPs (Van Damme et al., 2001; Girbés et al. 
2004; Stirpe, 2004; Stirpe et al., 2006) (Table 10). 
The mechanism of the ribosomal damage was discovered by Endo et al. (1987), who found that 
ricin cleaved the glycosidic bond of a single adenine residue (A4324 in rat liver rRNA) (Fig. 26). 
This residue is adjacent to the site of cleavage of rRNA by α-sarcin, in a tetranucleotide GA4324GA 
in a highly conserved loop at the top of a stem, for this called α-sarcin/ricin loop (Endo et al., 1987; 
Wool et al., 1992; Barbieri et al.,1993). This observation was extended to other RIPs (Stirpe et al., 
1988), which were officially classified as rRNA N-glycosidases (EC 3.2.2.22). RIPs catalytically 
inactivate eukaryotic as well as prokaryotic ribosomes (Barbieri et al., 1993) by removing single 
adenine residues from the large rRNA (A4324 from rat liver 28S rRNA, A2660 of E. coli rRNA) and 
thus interrupting the interaction of elongation factors I and II with the ribosomes and ultimately 
arresting protein synthesis at the translocation step (Stirpe et al., 1992; Mehta et al., 1998; Tumer et 
al., 1999; Nielsen et al., 2001; Van Damme et al., 2001). At the cellular level, RIPs (Griffiths et al., 
1987; Bergamaschi et al., 1996; Bolognesi et al., 1996; Büssing, 1996; Narayanan et al., 2004) 
cause apoptosis and subsequently, or at higher doses, severe necrosis both in the organs of poisoned 
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animals and in cultured cells (Hughes et al., 1996). Some RIPs remove more than one adenine 
residue per ribosome (Barbieri et al., 1994). In addition to the N-glycosidase activity, some RIPs 
have DNAse, DNA glycosylase, and apurinic pyrimidinic lyase activities (Li et al., 1991; Roncuzzi 
et al., 1996; Nicolas et al., 1997; Nicolas et al., 1998; Nicolas et al., 2000; Hudak et al., 2000). 
However, it has been suggested that the sporadically observed nuclease activities are due to 
contamination by other enzymes (Day et al., 1998; Barbieri et al., 2000; Van Damme et al., 2001), 
whereas all RIPs tested remove adenine from DNA and some of them also from poly(A) (Barbieri 
et al., 1997). Their enzymatic activity though may be better described as adenine polynucleotide 
glycosylase in agreement with the nomenclature utilised for other depurinating enzymes involved in 
purine removal from DNA. RIPs depurinate also non-mammalian ribosomes, from insects (Zhou et 
al., 2000), plants (Iglesias et al., 1993), yeast (Roberts et al., 1986), and bacteria (Girbés et al., 
1993). 
 
 
 
Figure 26. 28S rRNA loop and the site of depurination by RIPs and α-sarcin. 
 
RIPs are classified type 1, type 2, and type 3 (Fig. 27) (Mehta et al., 1998; ). Type 1 RIPs, such as 
pokeweed antiviral protein (PAP), trichosantin and gelonin (Table 10), possess a single enzimatic 
polypeptide chain with an approximate molecular mass of 30 KDa. They are strongly basic proteins. 
PAP, (pokeweed antiviral protein) extracted from pokeweed leaves, was the first known identified 
type 1 RIP and it was found to inhibit protein synthesis by the same mechanism as the A chain of 
ricin (Irvin, 1983). 
Type 2 RIPs, such as ricin, abrin, modeccin and ebulin (Table 10) consist of two disulfide-bonded 
subunits, one of approximately 30 kDa with enzymic activity (A chain, functional homologue of 
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type 1) and one of approximately 35 kDa with lectin properties (B chain, a galactose-binding 
lectin).  
Type 3 RIPs have an N-terminal domain closely related to the A chain of RIPs and linked to an 
unrelated C-terminal domain with unknown function (Reinbothe et al., 1994). Type 3 RIPs, like 
type 1 RIPs, are single chain proteins that do not contain lectin-binding moiety, but differ from type 
1 because they are synthesised as inactive forms that require proteolytic processing of internal 
regions to form active proteins. A type 3 RIP, a 60-kDa protein (JIP60), has been identified in 
barley (Hordeum vulgaris) (Reinbothe et al., 1994).  
Generally, type 1 RIPs, being devoid of a B chain, enter with difficulty into cells and consequently 
are much less toxic than type 2 RIPs, but become highly toxic if they are introduced into cells by 
linkage to an appropriate carrier capable of binding to cells. The first demonstration of this was 
obtained with gelonin conjugated with concanavalin A, which resulted more toxic to cells than the 
free RIP (Stirpe et al., 1980). Type 1 RIPs can still be internalized by fluid-phase endocytosis. In 
the case of saporin obtained from Saponaria officinalis, it was reported that saporin first binds to 
the alpha2-macroglobulin receptor on human cells and is then internalised to cytosol.  
 
 
Figure 27. Schematic representation of the structure of ribosome-inactivating proteins. (Courtesy of 
Professor L. Barbieri). 
 
Some type 2 RIPs are potent toxins and they are regarded to be highly toxic by virtue of their 
carbohydrate-binding lectin chain, which interacts with cell membranes and facilitates the uptake of 
RIP into the cytosol space (Barbieri et al., 1993). This occurs through binding of the lectin site to 
galactosyl-terminated residues on most cells.  
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Table 10. Ribosome-inactivating proteins isolated from plant tissues. 
 
 
TYPE 1 RIPs 
 
 
TYPE 2 RIPs 
 
 
Agrostins from Agrostemma githago seeds  
Amaranthin fromAmaranthus viridis leaves  
Asparins from Asparagus officinalis seeds  
Hispin from Benincasa hispida seeds  
Beetin27 from Beta vulgaris leaves  
Betavulgin from Beta vulgaris seedling cDNA  
Bouganin from Bougainvillea spectabilis leaves  
Bryodins from Bryonia dioica leaves roots  
CCP 25 from Celosia cristata  
CAP30B from Chenopodium album plant  
CAP from Chenopodium amaranticolor leaves  
Camphorin from Cinnamomum camphora seeds  
Colocins from Citrullus colocynthis seeds  
CA-SRI protein from Clerodendron aculeatum leaves cDNA  
CIP-29, CIP-34 from Clerodendron inerme leaves  
Cucurmosin from Cucurbita moschata sarcocarp  
Pepocin from Cucurbita pepo sarcocarp  
Dianthin 29 from Dianthus barbatus leaves  
Dianthins from Dianthus caryophyllus leaves  
Gelonin from Gelonium multiflorum seeds  
Gypsophilin from Gypsophila elegans leaves  
Barley RIP and JIP 60 from Hordeum vulgare seeds  
H. crepitans RIP from Hura crepitans latex  
IRIPs from Iris hollandica bulbs  
Luffaculin from Luffa acutangola seeds  
Luffins from Luffa cylindrica seeds  
Lychnin from Lychnis chalcedonica seeds  
Mapalmin from Manihot palmate seeds  
Manutins from Manihot utilissima seeds  
MOR from Marah oreganus seeds  
ME 1,2 from Mirabilis expansa roots, cell cultures  
Mirabilis antiviral protein, MAP from Mirabilis jalapa seeds, roots, 
tissue culture  
Momordin II from Momordica balsamina seeds  
Momordins from Momordica charantia seeds  
Momorcochin from Momordica cochinchinensis seeds  
Momorsgrovin from Momordica grosvenori seeds  
Musarmins from Muscari armeniacum bulbs  
Petroglaucin from Petrocoptis glaucifolia whole plant  
Petroglandin from Petrocoptis grandiflora whole plant 
Pokeweed antiviral proteins, PAP from Phytolacca americana leaves, 
seeds, tissue culture, roots  
P. dioica RIPs Phytolacca dioica from seeds, leaves  
Dodecandrins from Phytolacca dodecandra leaves, tissue culture 
Insularin, PIP from Phytolacca insularis leaves, cDNA  
a- and b-sativin from Pisum sativum seeds  
Ebulin 1, ebulin f from Sambucus ebulus leaves and fruits  
Nigritins from Sambucus nigra fruits  
Sieboldin b from Sambucus sieboldiana bark  
Mexin Sambucus mexicana bark  
Ocymoidin from S aponaria ocymoides seeds  
Saporins from Saponaria officinalis leaves, roots, seeds  
S. cereale RIP from Secale cereale seeds  
Sechiumin from Sechium edule seeds  
SOP from Spinacia oleracea root, callus and leaves  
Stellarin from Stellaria aquatica leaves  
Trichobakin from Trichosanthes sp.Bac Kan 8-98  
Trichoanguin from Trichosanthes anguina seeds  
b-trichosanthin from Trichosanthes cucumeroides tubers  
Trichosanthins, trichokirin, TAP 29 from Trichosanthes kirilowii roots, 
seeds 
Trichomaglin from Trichosanthes lepiniate tubers  
Tritins from Triticum aestivum germ, seeds  
(pyramidatin)Vaccaria pyramidata seeds  
(YLP)Yucca recurvifolia leaves  
Maize RIP from Zea mays seeds  
 
 
Toxic ribosome-inactivating proteins 
 
Abrins from Abrus precatorius seeds  
Pulchellin from Abrus pulchellus seeds  
Modeccins from Adenia digitata roots  
Volkensin from Adenia volkensii roots 
P. californicum lectin from Phoradendron californicum leaves  
Ricins from Ricinus communis seeds  
Mistletoe lectin I, viscumin from Viscum album leaves  
VCA from Viscum album coloratum plant  
 
 
 
 
Non-toxic ribosome-inactivating proteins 
 
Cinnamomin from Cinnamomum camphora seeds  
Porrectin from Cinnamomum porrectum seeds  
Foetidissimin from Cucurbita foetidissima root 
EHL from Eranthis hyemalis bulbs 
IRA from Iris hollandica bulbs  
M. charantia lectin from Momordica charantia seeds  
PM RIP from Polygonatum multiflorum leaves 
R. communis agglutinin, RCA from Ricinus communis seeds 
Ebulin1 and ebulin f from Sambucus ebulus leaves and fruits 
Nigrin b, nigrin f and nigrin s from Sambucus nigra bark, fruits and 
seeds Sieboldin b from Sambucus sieboldiana bark  
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Ricin enters macrophages and liver sinusoidal cells by an alternative mechanism, through the 
mannose receptors of these cells, which bind the mannose residues present in the ricin molecule 
(Skilleter et al., 1981; Simmons et al., 1986; Magnusson et al., 1991).  
Some type 2 RIPs have low toxicity (Ferreras et al., 2000; Van Damme et al., 2001). Non-toxic 
type 2 RIPs and ricin-related proteins have been isolated from the bark, leaf and rhizome of 
elderberry trees belonging to the genus Sambucus (Girbés et al., 1993a, 1993b; Rojo et al., 1997). 
These enzymes, such as nigrin-b, sieboldin-b, ebulin-f and ebulin-r, have structure and RNA N-
glycosidase activity similar to those of ricin and showed the same binding specificity towards 
Gal/GalNAc residues, a potent inhibitory activity against the in vitro protein synthesis of rabbit 
reticulocyte lysate but little toxicity to cells and mice. Once inside cells, RIPs follow an intracellular 
pathway through which the RIP molecules in part go to the Golgi apparatus and from there to the 
cytoplasm, in part go to the lysosomes, where they are largely degraded, and in part are expelled 
from the cell (Sandvig et al., 2002). Differences in each of these destinations and processes could 
result in different cytotoxicity. 
RIPs are phylogenetically related. In general RIPs from close families share high amino acid 
homologies. The sequence homology varies from 17 to 75 % identical primary structure. Type 1 
RIPs and the A chains of type 2 RIPs from Magnoliopsida (dicotyledons) are closely related. RIPs 
from Liliopsida (monocotyledons) are at the same time closely related and distant from 
Magnoliopsida. In evolution, it has been proposed that type 2 RIPs were generated by the fusion of 
ancestral genes encoding a type 1 RIP and a Gal/GalNAc-binding lectin. The three-dimensional 
structure of several RIPs has shown that those proteins have a highly conserved “RIP-fold” and a 
structure composed of two domains, the N-terminal mainly formed by β-strands while the C-
terminal by α-helix regions. In a cleft between the N- and the C-terminal domain there is the active 
site with four highly conserved residues involved in N-glycosidase activity: two tyrosines, 
responsible for the substrate binding, a glutamate and an arginine directly involved in the catalytic 
reaction. The majority of RIPs are glycoproteins. The carbohydrate component does not seem to 
play any major role in the enzymatic activity of RIPs since: (i) some of either type do not contain 
carbohydrates (e.g. trichosanthin and abrin A chain), (ii) the sugar composition varies; (iii) gelonin 
and ricin could be partially deglycosylated without affecting their capability of inhibiting protein 
synthesis in a rabbit reticulocytes lysate; (iv) recombinant ricin chain A produced in E. coli is not 
glycosylated and is yet fully functional (Barbieri et al., 1993). 
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3.1.1 Distribution of RIPs: Ribosome-inactivating proteins (RIPs) are widely distributed 
throughout the plant kingdom as stable, highly basic proteins ranging in pI from 9 to 11 and occur 
in certain bacteria strains, like Shigella dysenteriae and pathogenic strains of Escherichia coli. They 
were initially detected mostly in Angiospermae, both mono and dicotyledonae, and also in 
mushrooms (Yao et al., 1998; Lam et al. 2001a,b) and in an alga, the Laminaria japonica (Liu et 
al., 2002). The highest number of RIPs has been found in Caryophyllaceae, Sambucaceae, 
Cucurbitaceae, Euphorbiaceae, Phytolaccaceae and Poaceae. However, there are no systematic 
screening studies to allow generalisations about occurrence (Girbés et al., 2004). Type 1 RIPs, in 
particular, have been found at various concentrations in many plants, including some that are eaten 
raw (e.g. spinach, tomato). The level of RIPs in plant is highly variable, ranging from trace to 
hundreds of milligrams per 100 g (Stirpe, 2004). In some plants, they are present in many or even in 
all tissues examined (roots, leaves, stems, bark, flowers, fruits, seeds, latex, cultured cells), whilst in 
others plants they are confined to a single tissue. Often different forms were found, sometimes even 
in the same tissue (Girbes et al., 2003). 
A toxic type 2 RIP, aralin, was found in the shoots of Aralia elata (Tomatsu et al., 2004), which are 
described as edible and presumably can be eaten safely because the RIP is destroyed by cooking 
and its concentrations are probably too low (0.32 mg/100 g) to be harmful when taken by oral route. 
The latter observation is of general interest, because it suggests that other unknown toxic type 2 
RIPs may be present in other, possibly many, plants, which have not been examined because they 
are non-toxic.  
 
3.1.2 Biological activities and possible uses of RIPs: RIPs are studied primarily because of their 
unique biological activities toward human and animal cells and the perspectives they offer for 
antiviral and antitumor activities in therapeutical applications. It is evident, however, that plants do 
not produce RIPs just to fulfill the requirements of modern humankind for antitumor and antiviral 
drugs. Despite detailed knowledge on the structure, activity, and action mechanism of RIPs, there is 
no unequivocal answer to the question of why plants synthesise and accumulate RIPs. Concerning 
the biological roles played by RIPs there are several hypotheses, but the current belief is that they 
could play significant roles in the antipathogenic (viruses and fungi), stress and senescence 
responses. In addition, roles as antifeedant and storage proteins have been also proposed (Girbés et 
al., 2004). Understanding the role of RIPs in nature must be important to justify the conservation 
through evolution of proteins which are energetically expensive to synthesise.  
They have antiviral, antifungal and insecticidal activity. The effect of RIPs on plant viruses led to 
transfection of plants with RIP genes, to improve their resistance to viral infections. Some 
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protection from some viruses was conferred to transfected plants by several type 1 RIPs and, 
although with less efficiency, by type 2 RIPs (Stirpe et al., 2006). They have shown broad spectrum 
antiviral activity against plant and animal viruses, RNA, DNA (Battelli et al., 1995; Wang et al., 
2000). For instance, the RIP from Mirabilis jalapa has antiviral activity against the tobacco 
(Nicotiana tabacum) mosaic virus, potato (Solanum tuberosum) virus X, potato virus Y, and viroids 
such as the potato spindle tuber viroid (Kubo et al., 1990; Kataoka et al., 1991; Kataoka et al. 1992; 
Vivanco, 1997). PAP protects tobacco and potato plants from viral infection, but high-level 
expression of PAP is toxic to tobacco (Lodge et al., 1993) and bentgrass plants (Dai et al., 2003). 
Some RIPs have specific DNA nuclease activity against supercoiled, covalently closed, circular 
plasmid DNA and single-stranded phage DNA (Roncuzzi et al., 1996). The mechanism of the 
antiviral activity is still not completely clear. Normally, in their own plants RIPs are segregated 
from the cytoplasm, being located in protein bodies (e.g. ricin), in the cell wall matrix or in 
vacuoles (e.g. PAP), in the intracellular space (e.g. saporins). It was thought that the segregation 
could be broken by the damage caused by viral infections, so that RIPs could come into contact 
with plant ribosomes, which would be inactivated, with consequent death of the infected cells and 
arrest of viral multiplication (Stirpe, 2004).  
The antiviral activity against animal viruses has led to numerous studies on the effect of RIPs, 
especially PAP and trichosanthin, in HIV-infected cells, after it was found that PAP inhibits HIV 
replication (Zarling et al., 1990). Other RIPs were studied as well, especially trichosanthin 
(McGrath et al., 1989) was given to HIV-infected patients, with very modest improvement of their 
conditions. The replication of HIV in cells was inhibited by several RIPs (Parikh et al., 2004), and 
investigations were started with the hope that RIPs could be used in the therapy of AIDS (Shaw et 
al., 2005). Unfortunately, besides the obstacle of the immune response against these foreign 
proteins, the few clinical trials made with trichosanthin gave disappointing results, and sometimes 
the administered protein aggravated the neurological (Garcia et al., 1993; Kahn et al., 1994) or 
mental symptoms and caused allergic reactions (Byers et al., 1994). 
Few type 1 RIPs have been shown to inhibit fungal growth (Roberts et al., 1986; Vivanco et al., 
1999; Park et al., 2002a, 2002b). Antifungal activity of the asparagus (Asparagus officinalis) RIP 
has been reported against Botrytis cinerea (Wang et al., 2001). Furthermore, two proteins, 
reportedly RIPs, from mushrooms Hypsizygus marmoreus and Lyophyllum shimeji, have been 
shown to be active against an array of fungi (Lam et al., 2001a, 2001b). Antibacterial and antifungal 
activity of type 1 RIPs have also been reported from Mirabilis expansa RIPs (ME; Vivanco et al., 
1999). Transgenic tobacco plants expressing an activated form of the maize RIP showed an 
enhanced resistance to the insect Helicoverpa zea (Dowd et al., 2003).  
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Biological effects ascribed to these proteins go back to ancient times. In the traditional Chinese 
medicine preparations of the root tubers of the Cucurbitacea Trichosanthes kirilowii containing 
trichosanthin had been used to induce abortion. Also other RIPs also were found to have 
abortifacient activity (Stirpe , 2004). Actually, RIPs are not abortifacient in the classical sense, in 
that they do not induce abortion by causing contractions of the uterus or a hormonal imbalance: 
rather, they cause the death of the fetus by killing syncytiotrophoblasts. These cells are highly 
sensitive to RIPs, presumably because, like macrophages, they have a high capacity of protein 
uptake, thus taking up a large amount of RIPs.  
RIPs cause immunological effects such as immunogenicity, allergenicity, and immunosuppression 
(Stirpe, 2004). RIPs are strongly immunogenic and their administration to animals gives rise to 
formation of antibodies, with cross-reaction only among RIPs from plants belonging to the same 
family (Strocchi et al., 1992). RIPs are also allergenic. Formation of IgE has been observed in mice 
after administration of several type 1 RIPs, in laboratory personnel working with RIPs, in HIV-
infected patients treated with trichosanthin and in patients treated with immunotoxins containing 
ricin or other RIPs. Since RIPs are present in plants that are eaten raw (Girbés et al., 2004; Barbieri 
et al., 2006), their allergenic properties may have a role in the pathogenesis of the allergies caused 
by some vegetables. 
RIPs have immunosuppressive effects and their administration prevents formation of antibodies and 
retards graft rejection. 
RIPs have been used to prepare immunotoxins or other conjugates, either by chemical linkage or as 
recombinant fusion proteins mostly with monoclonal antibodies but also with other suitable carriers, 
e.g. hormones (hormonotoxins), cytokines, neuropeptides. Most immunotoxins have been prepared 
for the experimental therapy of malignancies, treatment of cancer, especially haematological 
(Frankel et al., 2000), for immunosuppression and also for the therapy of viral diseases. For these 
purposes RIPs have been linked to antibodies against antigens expressed prevalently on cancer 
cells. 
Ricin has been considered as a possible weapon for warfare and terrorist attacks being a potent 
poison easy to obtain, utilisable for suicidal and homicidal purposes. Although less potent than 
other biological toxic or infectious agents, it can be prepared more safely from easily available 
material with relatively simple equipment and procedures, thus without the support of a strong 
organisation, and could be used for limited terrorist actions. Sources of other toxic RIPs are not as 
easily available as castor beans, but their toxins could be obtained by biotechnological techniques. 
Ricin and related toxins would be lethal in small amounts only if injected or inhaled but have a 
much lower toxicity by the oral route, and therefore could not be used to contaminate water supplies 
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or large amounts of food. Aggressions to single persons could be performed by injecting a toxin as 
occurred in London, when an expatriate Bulgarian journalist was killed with a microbullet 
containing ricin, as ascertained by the autopsy (Knight, 1979). 
Ricin was used in the famous “umbrella tip” assassination of Georgi Markov by the KGB and as a 
biological warfare agent by Iraq. Documents captured by British commandos in Afghanistan in 
2001 releaved that ricin had been adopted as a terrorist weapon by the al-Qaeda group (Robertus et 
al., 2004). For this, there is a considerable and increasing interest in developing antidotes to ricin 
and related toxins. Moreover, because of their possible and different applications in agriculture and 
in medicine RIPs have been receiving more and more attention by the scientific community. 
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3.2 STUDIED RIBOSOME INACTIVATING PROTEINS  
 
Three type 1 RIPs, momorcochin S, bouganin and lychnin and one type 2 RIP, stenodactylin, have 
been subjects of crystallographic studies in this thesis. 
 
3.2.1 Momorcochin S: It is extracted from seeds of Momordica cochinchinensis (Spiny bitter 
cucumber), a Cucurbitacea growing in India (Fig. 28). It is a glycoprotein with MW of approx. 30 
KDa, an alkaline isoelectric point (9.4) and can be considered as an iso-form of the previously 
purified momorcochin from the roots of Momordica cochinchinensis 
(Bolognesi et al., 1989). It is known only the N-terminal sequence of 
30 amino acids: DVTFSLLGANTKSYAAFITNFRKDVASEKK. 
Momorcochin S was linked to a monoclonal antibody against human  
plasma cells and the resulting immunotoxin was selectively toxic to 
target cells and had remarkably low toxicity to mice (Bolognesi et al., 
1989). This makes this protein worthy of consideration for the 
preparation of immunotoxins for experimental therapeutic purposes.  
 
3.2.2 Bouganin: It is a type 1 RIP isolated from leaves of 
Bougainvillea spectabilis Willd (Fig. 29) (Bolognesi et al., 
1997). It is synthesised as a pro-peptide consisting of 305 
amino acids: MGWWAIIVEP MLVMPSIVNK 
ETTSLGYNTV SFNLGEAYEY PTFIQDLRNE 
LAKGTPVCQL PVTLQTIADD KRFVLVDITT 
TSKKTVKVAI DVTDVYVVGY QDKWDGKDRA 
VFLDKVPTVA TSKLFPGVTN RVTLTFDGSY 
QKLVNAAKVD RKDLELGVYK LEFSIEAIHG 
KTINGQEIAK FFLIVIQMVS EAARFKYIET EVVDRGLYGS FKPNFKVLNL ENNWGDISDA 
IHKSSPQCTT INPALQLISP SNDPWVVNKV SQISPDMGIL KFKSSKLTQF ATMIRSAIVE 
DLDGDELEIL EPNIA. 
The first 26 (in yellow) amino acids act as a leader signal while the 29 C-terminal amino acids (in 
red) are cleaved during processing of the molecule (Den Hartog et al., 2002). The mature protein 
consists of 250 amino acids (the last residue is a Lys) with MW of 26.2 KDa and pI ~ 9.0.  
Bouganin has a very low in vivo toxicity as compared to its intrinsic enzymatic activity. 
Immunotoxins containing bouganin inhibit cell protein synthesis, induce apoptosis, and block the 
Figure 28. I Momordica 
cochinchinensis fruits. 
Figure 29. Image of flowers and leaves of 
Bougainvillea spectabilis Willd. 
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clonogenic growth of target cells, although with a different kinetics, suggesting the presence of 
different mechanisms of cell killing (Bolognesi et al., 2000).  
 
3.2.3 Lychnin: It is a type 1 RIP isolated from Lychnis 
chalcedonica seeds (Bolognesi et al., 1990) (Fig. 30). It had been 
previously studied in the Biomineralisation and Biocrystallography 
group of Bologna and in 2003 it was crystallised by the vapour-
diffusion method. Although the crystals diffracted at 1.7 Å, it was 
not possible to resolve the three-dimensional structure being the 
primary sequence not yet available at that time (Fermani et al., 
2003). In fact, only in 2006 Chambery et al. determined the 
complete amino acid sequence of lychnin which consists of 234 amino acid residues with an 
atypical primary structure and has a molecular mass of about 26 KDa (Chambery et al., 2006). 
 
3.2.4 Stenodactylin: It is a recently characterised type 2 ribosome-
inactivating protein (Stirpe et al, 2007), purified from the caudices of 
Adenia stenodactyla, Passifloraceae (Fig. 31) (Pelosi et al., 2004). It 
is found in eastern Africa, growing in a well drained soil with some 
water and some to lots of sun. 
Stenodactylin showed a high enzymatic activity both on ribosomes 
and hsDNA used as substrates and was extremely toxic to all cell 
lines tested, its cytotoxicity being higher than other toxins of this 
type (Stirpe et al., 2007). Stenodactylin was highly toxic to mice and 
it caused 100% death at a very low dose. The exceedingly high 
biological activity of stenodactylin makes it a good candidate for 
studies on structure/function relationship. The A chain of 
stenodactylin inhibited protein synthesis, as expected, whereas the B 
chain did not agglutinate erythrocytes, a surprising result since the B 
chain of modeccin and volkensin had hemagglutinating properties (Barbieri et al., 1980; Stirpe et 
al., 1985). The lack of agglutinating capacity can be due either to conformational changes or to 
aggregation of the B chain after separation from the A chain. Alternatively, it is possible that the B 
chain is monovalent, and that the whole toxin can agglutinate cells only after formation of 
aggregates, as other type 2 RIPs do (e.g. viscumin, Olsnes et al., 1982). 
 
Figure 30. Image of Lychnis 
chalcedonica. 
Figure 31. Image of Adenia 
stenodactyla showing a big 
caudex characteristic of this 
specie. The caudex, a perennial 
swollen base, can grow up to 30 m 
in diameter, and the vines up to 
1,5 m in length. 
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3.3 CRYSTALLISATION EXPERIMENTS 
 
The aim of the work was to crystallise momorcochin S, bouganin and stenodactylin and to obtain 
crystals of high quality that could allow to resolve the three-dimensional structures and successively 
to correlate molecular structures to biological activities. With regard to lychnin, being already 
known its crystallisation conditions, its three-dimensional structure was studied. All the RIPs used 
were extracted and purified by the group of Professor Bolognesi (Experimental Pathology 
Department, University of Bologna). 
 
 
3.3.1 Momorcochin S: The protein was dissolved in PBS buffer (5mM 
KH2PO4 pH 7.5 and 0.14 M NaCl) at a concentration of 11,3/11,6 
mg/mL. All experiments were carried out in vapour diffusion (hanging 
and/or sitting drop) at 293 K and the drops (5 µl) contained the protein 
and the reservoir solution (750 µL in each well) in equal volume. 
Hundreds of crystallisation conditions were tested and initially only 
fibres were obtained (Fig. 32). The crystallisation conditions tested 
were those reported by commercial screens sold by companies, such as 
Hampton research or Jena BioScience. After 18 months, crystals 
appeared in a drop in which the protein had been mixed with a reservoir solution containing 8% 
(w/v) PEG 4K(Fig. 33). 
 
          
Figure 33. Optical micrographs of momorcochin S crystals. 
 
 
 
 
 
200 µm 100 µm 
150 µm 
 
Figure 32. Optical 
micrographs of 
momorcochin S fibres. 
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3.3.2 Bouganin: The crystallisation trials were carried out at 293 K using the vapour diffusion 
method with the sitting drop technique. Drops contained 2 µl of protein, at a concentration of 12 
mg/mL in PBS (5 mM NaH2PO4 pH 7.5 and 0.14 M NaCl), mixed to an equal volume of reservoir 
solution. Single crystals of bouganin were obtained with a reservoir solution composed of 20% 
(w/v) 20 kDa PEG, in about two or three months. The crystals have a needle-like shape with 
maximum length of 0.5 mm (Fig. 34). 
 
    
Figure 34. Optical micrographs of bouganin crystals. 
  
 
 
3.3.3 Lychnin: Lychnin was dissolved in a solution containing PBS 
buffer (5 mM NaH2PO4 pH 7.5 and 0.14 M NaCl) at a concentration of 
10 mg/ml. Each drop was prepared mixing equal volumes (2.5 µl) of 
protein solution and reservoir and was equilibrated against 700 µl of 
the reservoir at 293 K. It was crystallised as previously described 
(Fermani et al., 2003). The best crystals (Fig. 35) grew in few days 
using a reservoir solution containing 30% (w/v) PEG 8K and 0.1 M 
NaH2PO4 pH 6.5-7.2.  
 
 
3.3.4 Stenodactylin: The conventional sitting drop vapour diffusion technique was used to 
crystallise stenodactylin and all the experiments were carried out at 293 K. The droplets (4 µl) 
contained the protein and the reservoir solution (750 µL in each well) in equal ratio. The best 
condition to grow single crystals was obtained using 1.4-1.5 M sodium malonate pH 6.8-7.5 as 
precipitant and a protein concentration of 5.76 mg/mL in PBS buffer (5 mM NaH2PO4 pH 7.0 and 
100 µm 100 µm 
200 µm 
Figure 35. Optical micrographs 
of lychnin crystals. 
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0.14 M NaCl) and 4 mM galactose. The crystals grew in about one month with maximum 
dimensions approximately of 0.3×0.2×0.1 mm (Fig. 36).  
 
 
    
 
Figure 36. Optical micrographs of stenodactylin crystals. 
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3.4 CRYSTALLOGRAPHIC STUDIES  
 
3.4.1 Momorcochin S: The obtained crystals were tested at the ESRF (European Synchrotron 
Radiation Facility) of Grenoble (France) but they did not diffract. Optimisation crystallisation trials 
are in progress in order to obtain crystals of quality suitable for X-ray studies. 
 
3.4.2 Bouganin: Diffraction data were collected at ESRF (microfocusing beamline ID13), from one 
crystal, irradiated in three different regions (beam size 5 µm × 5 µm). Crystal was soaked for few 
seconds in a cryogenic solution composed of 30% (w/v) PEG 8K and 20% (v/v) PEG 400 and 
positioned in the nitrogen stream at 100 K. Data were recorded at a wavelength of 0.976 Å, using an 
oscillation range of 1° and a crystal-to-detector distance of 100 mm. Data were processed and 
scaled using DENZO/SCALEPACK package (Otwinowski et al., 1997) and statistics are reported 
in Table 11. 
 
Table 11. Cell parameters and data collection statistics for bouganin.  
 
Space group P212121 
Unit cell a,b,c, β (Å, °) 40.84, 78.50, 79.38 
N° molecules in a.u. 1 
Resolution range* 35-1.8 (1.86-1.8) 
Measured reflections 79398 
Unique reflections 23985 
Completeness (%)* 98.9 (99.7) 
Redundancy 3.3 
Rsym* 0.104 (0.331) 
I/σ(I)* 15.9 (4.4) 
                                *Value in parenthesis refers to the last resolution shell 
 
Structure of bouganin was solved by molecular replacement (Navaza, 1994), using the structure of 
α-PAP-R (Ago et al., 1994; PDB ID code 1apa) as probe. The two proteins show 29% of sequence 
identity. Rotational and translational searches clearly indicate the presence of one molecule in the 
asymmetric unit as expected from Mattews coefficient calculation (Matthews, 1968). The 
correctness of the solution was verified by building the whole crystal packing. The model was 
refined with alternate cycles of simulated-annealing, energy minimisation, temperature factor 
refinement using the program CNS (Brünger, 1998), and manual rebuilding using O (Jones et al., 
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1991). Refinement was carried out in a resolution range of 8.0-1.8 Å, applying a sigma cut-off on 
amplitudes of 2.0, only in the initial stages of refinement, and selecting 5% of reflections for Rfree 
calculations. Water molecules were automatically added, and after a visual inspection they were 
conserved in the model only if contoured at 0.8σ on the (2Fo - Fc) map and if they fell into an 
appropriate hydrogen bonding environment. Refinement statistics for bouganin are given in Table 
12. Final model of bouganin has tight stereochemical restraints (Table 12). The Ramachandran plot, 
obtained using PROCHECK (Laskowski, 1993), shows that 88.0% of bouganin residues lie in the 
most favored regions, and the remaining ones in the additional allowed regions. In bouganin 
structure only Lys247, belonging to the C-terminal coil, is found in a generously allowed region, 
but the well defined electron density map confirmed its conformation. The root-mean-square error 
in the atomic positions, evaluated with the Luzzati method (Luzzati, 1952), is 0.17. 
 
Table 12. Refinement statistics for bouganin. 
 
No. protein atoms 1974 
No. water molecules 378 
R (%) 17.6 
Rfree (%) 20.2 
B mean (Å2) 12.8 
B (Wilson Plot, Å2) 8.1 
B protein atoms (Å2) 9.9 
B solvent atoms (Å2) 27.4 
rmsd bond length (Å) 0.005 
rmsd bond angles (°) 1.2 
 
 
3.4.3 Lychnin: Lychnin crystals were measured using synchrotron radiation (Eletttra X-ray 
diffraction beam line in Trieste, Italy) at 100 K. The crystals were soaked for few seconds into a 
cryogenic solution containing 30% (w/v) PEG 8 KDa and 30% (v/v) PEG 400 and rapidly exposed 
to a cold nitrogen stream (Oxford Cryosystem Cryostream). The diffraction data were collected to a 
resolution of 1.7 Å, on a MAR Research CCD using a radiation wavelength of 1.0 Å, an oscillation 
angle of 2.00° and a crystal-detector distance of 120mm. The diffraction data were processed and 
scaled for both proteins with the DENZO-SCALEPACK package (Otwinowski et al., 1997). The 
data reduction, including a search for systematic absences, clearly indicates that lychnin crystals 
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belong to the P21 space group. The unit cell parameters and the data collection statistics are listed in 
Table 13. 
 
Table 13. Cell parameters and data collection statistics for lychnin. 
 
Space group P21 
Unit cell a,b,c, β (Å, °) 35.25, 57.33, 52.23, 106.2 
N° molecules in a.u. 1 
Resolution range* 29-1.7 (1.76-1.7) 
Measured reflections 151602 
Unique reflections 21895 
Completeness (%)* 99.4 (98.3) 
Redundancy 6.9 
Rsym* 0.048 (0.084) 
I/σ(I)* 39.7 (14.2) 
                         *Value in parenthesis refers to the last resolution shell 
 
 
Matthews coefficient (Matthwes, 1968) calculations show the presence of one chain for asymmetric 
unit. The Vm value is 1.95 for lychnin with a solvent content of 36.4%. 
Several attempts to solve the structure of lychnin were made by molecular replacement, using the 
coordinates of different type 1 RIPs (saporin-S6, dianthin 30, PAP-R and α-PAP-R, ricin A chain), 
but no correct solution was found. Structure solution was achieved by the program AmoRe 
(Navaza, 1994) using bouganin, which shares the 29% of sequence identity with lychnin, as 
template. The (2Fo - Fc) map calculated after a rigid body refinement showed several regions with 
very poor electron density. These regions were deleted from model and rebuilt during the 
subsequent cycles as the electron density became clearer. The refinement was performed with CNS 
(Brünger et al., 1998) in a resolution range of 8.0-1.7 Å with a starting σ cut-off on amplitudes of 
2.0, which was later decreased to 0. A total of 10% of the data was randomly selected for Rfree 
calculations. The model was rebuilt with the graphic program XtalView (McRee, 1999). In the final 
stage of the refinement the solvent network was built: water molecules were added following the 
criteria used for bouganin structure. Refinement statistics are listed in Table 14. 
Final model of lychnin has tight stereochemical restraints (Table 14). The Ramachandran plot, 
obtained using PROCHECK (Laskowski et al., 1993), shows that 91.2% of lychnin residues lie in 
the most favored regions, and the remaining ones in the additional allowed regions. The root-mean-
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square error in the atomic positions, evaluated with the Luzzati method (Luzzati, 1952), is 0.15 for 
lychnin. 
 
Table 14. Refinement statistics for lychnin. 
No. protein atoms 1879 
No. water molecules 364 
R (%) 16.2 
Rfree (%) 19.6 
B mean (Å2) 13.6 
B (Wilson Plot, Å2) 13.8 
B protein atoms (Å2) 11.2 
B solvent atoms (Å2) 26.5 
rmsd bond length (Å) 0.005 
rmsd bond angles (°) 1.2 
 
 
3.4.4 Stenodactylin: Several crystals of stenodactylin were tested in X-ray diffraction experiments. 
Each crystal was briefly soaked in a cryo-protectant solution containing 2.0 M sodium malonate at 
the same pH of the reservoir solution and 20% (v/v) glycerol and transferred into a cold N2 gas 
stream (100 K) for data collection. Data were collected using an ADCD Quantum CCD detector on 
beam lines ID29 and ID14-1 at ESRF (Grenoble, France) using a wavelength of 0.976 Å and 0.934 
Å, a crystal-to-detector distance of 283.88mm and 265.31mm, respectively, and in both cases an 
oscillation range of 1°. The best crystal diffracted to a resolution of 1.9 Å, but the data were 
trimmed to 2.15 Å to achieve good values of completeness and I over σ(I) in the last resolution 
shell. The data were processed and scaled using DENZO and SCALEPACK programs (Otwinosky 
et al., 1997). All tested crystals showed a centred monoclinic space group with similar unit cell 
dimensions. The unit cell parameters and the data collection statistics obtained merging two data 
sets collected from different crystals are reported in Table 15. 
Matthwes coefficient calculations (Matthews, 1968) indicate the presence of two heterodimers in 
the asymmetric unit, corresponding to a VM of 2.61 Da
-1 and a solvent content of 52.5%. Molecular 
replacement procedures to solve the structure of stenodactylin are in progress, the structure of ricin 
is used as probe. 
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Table 15. Data collection statistics of stenodactylin. 
 
Space group C2 
Unit cell (Å, °) a = 220.54,  b = 64.26, c = 91.75,  
β = 105.68 
Resolution (Å) 50.0-2.15 (2.23-2.15) 
Observed reflections 612.719 
Unique reflections 64.284 
Mosaicity (°) 0.885 
Completness (%) 94.0 (72.9) 
I/σ(I) 18.7 (2.5) 
Redundancy 9.5 (7.0) 
Rmerge 0.183 (0.574) 
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3.5 RESULTS 
 
The three dimensional structures of two type RIPs, bouganin and lychnin, have been solved and 
compared with structures of other RIPs.  
 
3.5.1 Overall structures of bouganin and lychnin: The final model of bouganin lacks the last 
thirty-one residues of the sequence previously reported (Den Hartog et al., 2002). 29 C-terminal 
amino acids are proteolytically cleaved during the processing of the molecule from a precursor to a 
smaller mature protein, while Ser249 and Lys250 are disordered. All residues of lychnin sequence 
(Chambery et al., 2006) have been built in the high quality electron density maps. No glycosilation 
sites were found in either structure. 
Both bouganin and lychnin structures show the common ‘RIP fold’. The N-terminal domain (in red 
and magenta in Fig. 37a,b) is composed of a mixed β-sheet of seven strands (β1, β4, β5, β6, β7, β8 
and β9 in bouganin and β1, β3, β4, β5, β6, β7 and β8 in lychnin). Five strands in the centre are 
antiparallel and those at the edge are parallel to the near one. In both proteins an helix, α2 in 
bouganin and α1 in lychnin, followed by a short structural motif of two strands in bouganin (β2 and 
β3) or a strand plus a helix in lychnin (β2 and α2), connects the first two strands of the sheet, while 
a second helix, α3 in bouganin and α4 in lychnin, the last two. 
The C-terminal domain (in gold and green in Fig. 37a,b) is predominantly α-helical: eight helices 
are observed both in bouganin and lychnin. The C-terminal region of bouganin shows a loop, 
flanking helix α9, composed of two anti-parallel β-strands (β10, β11) connected by a short helix 
(Fig. 37a). In lychnin helix α11 is connected to the last helix α12 by a random coil (Fig. 37b). 
RIP family has five highly conserved residues, which have been identified by site-directed 
mutagenesis experiments to be the residues involved in N-glycosidase activity (Ready et al., 1991; 
Day et al., 1996; Poyet et al., 1998; Li et al., 1999a; Li et al., 1999b). These residues correspond to 
Tyr70, Tyr114, Glu165 Arg168 and Trp198 in bouganin, and Tyr69, Tyr119, Glu170 Arg173 and 
Trp203 in lychnin (Fig. 38). Only recently, a type 1 RIP, charybdin, with a natural substitution of a 
catalytic residue has been identified: a valine replaces the first (in numbering) tyrosine 
(Touloupakis et al., 2006). Moreover, it has been proposed that in PD-L4 a type 1 RIP isolated from 
leaves of Phytolacca dioica, a conserved serine, the fourth residue after the catalytic tryptophan 
(Fig.38), could be also involved into the catalytic mechanism (Chambery et al., 2007; Ruggiero et 
al., 2008). 
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Figure 37. Ribbon model of the crystal structure of (A) bouganin and (B) lychnin. The N-terminal 
and the C-terminal domains are differently colored. The secondary structure elements and the conserved 
residues of the catalytic site are indicated. The figure was produced by MOLSCRIPT (Kraulis, 1991) and 
rendered by RASTER3D (Merritt et al., 1997). 
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MOMORDIN        -------DVSFRLSGADPRSYGMFIKDLRNALPFREKVYNIPLLLPSVSG---AGRYLLM 50 
RICIN chain A   IFPKQYPIINFTTAGATVQSYTNFIRAVRGRLTTGADVRHEIPVLPNRVGLPINQRFILV 60 
DIANTHIN 30     -----ATAYTLNLANPSASQYSSFLDQIRNNVRDTSLIYGGTDVA--VIGAPSTTDKFLR 53 
SAPORIN S6      ----AVTSITLDLVNPTAGQYSSFVDKIRNNVKDPNLKYGGTDIA--VIGPPSK-EKFLR 53 
PAP             -----VNTIIYNVGSTTISKYATFLNDLRNEAKDPSLKCYGIPMLP---NTNTNPKYVLV 52 
LYCHNIN         --------RPSWTVDSDSAKYSSFLDSLREEFGRGTPKVCNIPVTK---KANNDKFVLVN 49 
BOUGANIN        -------YNTVSFNLGEAYEYPTFIQDLRNELAKGTPVCQLPVTLQ---TIADDKRFVLV 50 
                                   .*  *:  :*                            .:  
 
MOMORDIN        HLFNYDGKTITVAVDVTNVYIMGYLADT-----TSYFFN-----EPAAELASQYVFRDAR 100 
RICIN chain A   ELSNHAELSVTLALDVTNAYVVGYRAGN-----SAYFFHPD---NQEDAEAITHLFTDVQ 112 
DIANTHIN 30     LNFQGPRGTVSLGLRRENLYVVAYLAMDNANVNRAYYFKNQ---ITSAELTALFPEVVVA 110 
SAPORIN S6      INFQSSRGTVSLGLKRDNLYVVAYLAMDNTNVNRAYYFRSE---ITSAESTALFPEATTA 110 
PAP             ELQGSNKKTITLMLRRNNLYVMGYSDPFETNKCRYHIFNDISGTERQDVETTLCPNANSR 112 
LYCHNIN         LVLPFNRNTITLAFRASDAYLVGFQDRDSKTNKLRANFFSDEYRALSGKYKSIFTDAEVL 109 
BOUGANIN        DITTTSKKTVKVAIDVTDVYVVGYQDKWDGKDRAVFLDKVP-------TVATSKLFPGVT 103 
                        ::.: .   : *::.:                                     
 
MOMORDIN        RKITLPYSGNYERLQIAAGKP-----REKIPIGLPALDSAISTLLHYDS-----TAAAGA 150 
RICIN chain A   NRYTFAFGGNYDRLEQLAGNL-----RENIELGNGPLEEAISALYYYSTGGTQLPTLARS 167 
DIANTHIN 30     NQKQLEYGEDYQAIEKNAKITTGDQSRKELGLGINLLITMIDGVNKKVR---VVKDEARF 167 
SAPORIN S6      NQKALEYTEDYQSIEKNAQITQGDQSRKELGLGIDLLSTSMEAVNKKAR---VVKDEARF 167 
PAP             VSKNINFDSRYPTLESKAGVK----SRSQVQLGIQILDSNIGKISGVMS--FTEKTEAEF 166 
LYCHNIN         AP-ALPCASTYTDLQNKAGVS-----REKLSLGVSSLQTAFTAVYGKVFTG---KNVAKF 160 
BOUGANIN        NRVTLTFDGSYQKLVNAAKVD-----RKDLELGVYKLEFSIEAIHGKTING---QEIAKF 155 
                    :     *  :   *        *..: :*   *   :  :             *   
 
MOMORDIN        LLVLIQTTAEAARFKYIEQQIQERA--YRDEVPSLATISLENSWSGLSKQIQLAQGNNGI 208 
RICIN chain A   FIICIQMISEAARFQYIEGEMRTRIRYNRRSAPDPSVITLENSWGRLSTAIQES--NQGA 225 
DIANTHIN 30     LLIAIQMTAEAARFRYIQNLVTKNFP--NKFDSENKVIQFQVSWSKISTAIFGD-CKNGV 224 
SAPORIN S6      LLIAIQMTAEAARFRYIQNLVIKNFP--NKFNSENKVIQFEVNWKKISTAIYGD-AKNGV 224 
PAP             LLVAIQMVSEAARFKYIENQVKTNFN--RAFNPNPKVLNLQETWGKISTAIHDA--KNGV 222 
LYCHNIN         ALISIQMVAEAARFKYIEDQVINRGMY-SSFEAGARITLLENNWSKISEQYHKS------ 213 
BOUGANIN        FLIVIQMVSEAARFKYIETEVVDRGLY-GSFKPNFKVLNLENNWGDISDAIHKSSPQCTT 214 
                 :: **  :*****:**:  :  .        .      :: .*  :*             
 
MOMORDIN        FRTPIVLVDNKGNRVQITNVTSKVVTSNIQLLLNTRNIAEGDNGDVSTTHGFSSY----- 263 
RICIN chain A   FASPIQLQRRNGSKFSVYDVS--ILIPIIALMVYRCAPPPSSQF---------------- 267 
DIANTHIN 30     FNKDYDFGFGKVRQAKDLQMGLLKYLGRPKSSSIEANSTDDTADVL-------------- 270 
SAPORIN S6      FNKDYDFGFGKVRQVKDLQMGLLMYLGKPKSS-NEANSTVRHYGPLKPTLLIT------- 276 
PAP             LPKPLELVDASGAKWIVLRVDEIKPDVALLNYVGGSCQTTYNQNAMFPQLIMSTYYNYMV 282 
LICHNIN         -------CKLGGGQFTEEEMKLGLLLYN-------------------------------- 234 
BOUGANIN        INPALQLISPSNDPWVVNKVSQISPDMGILKFKSSKLTQFATMIRSAIVEDLDGDELEIL 274 
                :     :            :                               :      :: 
 
MOMORDIN        --------- 
RICIN chain A   --------- 
DIANTHIN 30     --------- 
SAPORIN S6      --------- 
PAP             NLGDLFEGF 291 
LYCHNIN         --------- 
BOUGANIN        EPNIA---- 279 
                          
 
Figure 38. Sequence alignment of different type 1 RIPs and ricin A chain. Residues highlighted in 
yellow correspond to conserved catalytic residues, positive and negative residues cited in the text are 
highlighted in light blue and red, respectively, and the C-terminal portion of the sequence proteolitically 
cleaved to obtain the mature form of the protein is highlighted in dark green. Disordered bouganin residues 
(Ser249 and Lys250) are indicated in green. Sequence homologies: bouganin-lychnin 29%, bouganin- or 
lychnin-momordin I 25% or 24%, bouganin- or lychnin-ricin A chain 27% or 23%, bouganin- or lychnin-
dianthin 30 22% or 26%, bouganin- or lychnin-saporin-S6 23% or 25%, bouganin- or lychnin-PAP-R 30% or 
27%. The sequence alignments have been performed with CLUSTALW (Combet et al., 2000). 
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Several mechanisms have been proposed to explain the RIP enzymatic activity (Mozingo et al., 
1992; Ren et al., 1994; Huang et al., 1995): in all of them the two tyrosines are responsible for 
substrate adenine binding through a stacking interaction, whereas the arginine protonates the N3 
atom of adenine and the glutamate stabilises the transition state. Alternatively, Huang et al. (1995) 
proposed that the N7 atom of adenine is protonated by an acidic residue not conserved in RIP 
family, corresponding to Asp96 in ricin A chain and Glu85 in α-momorcharin. In the same region 
of the three-dimensional structure, bouganin shows an aspartate (Asp113), while lychnin has a 
glutamate (Glu91) or an aspartate (Asp90) which could play the same role. Similarly to the other 
RIP structures the residues forming the active site are located in a cleft in the central part of the 
molecule, between the N- and the C-terminal domains. The cleft is formed by strand β6 and helices 
α4, the C-terminal portion of α7 and α9 in bouganin (Fig. 37a), and by strand β5 and helices α5, 
the C-terminal portion of α8, α9 and α11 in lychnin (Fig. 37b). In both structures the active pocket 
contains several ordered water molecules. Active site residues are involved in a hydrogen bond 
network including residues forming the cavity and water molecules. 
The electrostatic surface potential calculated for bouganin shows that the active site is a wide 
cavity, predominantly negative, except for a small positive zone determined by the catalytic residue 
Arg168 (Fig. 39a). Negative and positive well defined regions are observed around the cavity 
corresponding to Asp200, Asp203, Lys245 and Lys247 on the left, Lys116 on the right and Arg46 
on the bottom (Fig. 39a). The C-terminal region, corresponding to the structure motif β10-loop-β11, 
is mainly hydrophobic. 
The active site of lychnin structure is characterised by a deeper cavity with an electrostatic surface 
potential less negative than that one of bouganin (Fig. 39c). Two well-defined charged regions on 
the side part of the cavity are determined by the catalytic residues Arg173 and Glu170 and by 
Glu200 which strengthens the negative zone. The side chain of Tyr69 partially obstructs the access 
to the cavity. Several arginines and lysines come out from the surface of the protein, in regions far 
from the active site (N- and C-terminal regions) and around the catalytic pocket: on the left Lys205, 
on the bottom Lys39 and Lys98, on the top Lys132 and Arg195, and on the right Lys123 and Arg93 
(Fig. 39c). The electrostatic surface potential of saporin-S6 is also reported for comparison (Fig. 
39e). 
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Figure 39. Electrostatic surface potential of bouganin (A) at pH 7 and (B) at pH 4; lychnin (C) at pH 
7 and (D) at pH 4; saporin-S6 (E) at pH 7 and (F) at pH 4. The position of the residues cited in the text is 
indicated. The electrostatic surface potential at the two pHs has been calculated assigning to the side chain 
group of ionisable residues the charge present at the considered pH. This charge was evaluated from ExPASy 
server on the basis of the pKa of the residue. The values of electrostatic surface potential are expressed as a 
spectrum ranging from +10 kT/e (deep blue) through 0 kT/e (white) to -10 kT/e (deep red). At a temperature 
of 298.15 K, kT/e = 25.7 mV. The figure was produced by GRASP (Nicholls et al., 1991). 
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3.5.2 Comparison between structures: The backbone superimpositioning of bouganin and 
lychnin, which gave a root main square deviation (rmsd) of 1.306 Å for 192 superimposed Cα atoms 
(fitting was performed using McLachlan algorithm (McLachlan, 1982) as implemented in Profit 
V2.5.3), shows that the central portion of the molecules is well superimposable, while major 
differences are observed in the external regions (Fig. 40a).  
 
Figure 40. Structural comparison between different type 1 RIPs and ricin A chain. (A) 
Superimposition of the Cα atoms of bouganin (magenta), lychnin (cyan), dianthin 30 (green), saporin-S6 
(red), PAP-R (dark blue), momordin I (grey) and ricin A chain (gold). The regions showing the major 
differences are indicated with their secondary structure elements and zoomed (B), (C) and (D). The indicated 
secondary structure elements correspond to bouganin (magenta) or lychnin (cyan). The figure was produced 
by MOLSCRIPT (Kraulis, 1991) and rendered by RASTER3D (Merritt et al., 1997). 
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In the N-terminal domain strand β1 is longer in bouganin, while helix α3 is shorter than the 
corresponding α4 in lychnin and the subsequent strand is differently oriented in the two structures 
(Fig. 37a,b). The fold of the C-terminal region is absolutely different from bouganin to lychnin: the 
structural motif, composed of two antiparallel β-strands (β10 and β11), which connects helices α9 
and α11 in bouganin is completely absent in lychnin where the last two helices α11 and α12 are 
joined by a less bulky coil (Fig. 37a,b). 
Lychnin differs more than bouganin from the other examined RIPs: dianthin 30 (Fermani et al., 
2005), PAP-R (Mozingo et al.,1993), momordin I (Husain et al., 1994), saporin-S6 (Savino et al., 
2000) and ricin A chain (Mlsna et al., 1993). In the case of lychnin the rms deviations exceed 1.3 Å 
for all considered RIPs. The rms deviation for bouganin superimposition on PAP-R, ricin A chain 
and momordin I is around 1.1 Å (1.090 Å for 234 Cα, 1.147 for 233 Cα and 1.156 on 229 Cα, 
respectively) while it is higher for the superimposition on dianthin 30 and saporin-S6 (1.399 Å and 
1.340 Å on 210 Cα, respectively). Aside from the rmsd values, lychnin and bouganin are well 
superimposed to the considered RIPs in the central part of the molecule, which includes the active 
site (Fig. 40a). 
At the N-terminal region, the length and orientation of the loop connecting the fourth (β7 in 
bouganin and β6 in lychnin) and the fifth (β8 in bouganin and β7 in lychnin) strands of the mixed 
β-sheet, substantially differ among the considered RIP structures (Fig. 40b): it is longer in dianthin 
30 (green), saporin-S6 (red) and lychnin (cyan), but in the latter differently oriented; it is 
intermediate in bouganin (magenta) and PAP-R (dark blue); while in ricin A chain (gold) and 
momordin I (grey) the loop is much shorter with respect to the others. Variations in folding are also 
observed in the subsequent region composed by (i) an α-helix, common to all considered RIPs, with 
significant variability in length, and by (ii) a β-strand, found in bouganin, PAP-R, momordin I, ricin 
A chain and lychnin, in this last structure smaller in size and not superimposable to the others (Fig. 
40c). Dianthin 30 and saporin-S6 lack this last strand of the N-terminal mixed β-sheet. 
In all known RIP structures, the C-terminal region is characterised by a structural motif composed 
of two antiparallel β-strands connected by a loop or a small helix. These two strands are almost 
parallel to a long helix forming a wall of the catalytic cleft. In bouganin structure this motif is 
similar to those found in PAP-R, momordin I and ricin A chain (Fig. 40d). In dianthin 30 and 
saporin-S6 it is also observed, but it is much shorter than in the previous RIPs. Lychnin structure 
lacks this motif (Fig. 37b). 
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3.5.3 Differences at the active site: The positions of the residues involved in the catalysis are well 
conserved except for the orientation of one tyrosine (the first in sequence numbering, Fig. 38): the 
two aromatic rings are almost parallel, as required to form a stack interaction with the adenine of 
the substrate, in bouganin, dianthin 30, PAP-R, momordin I and saporin-S6, while in lychnin the 
aromatic ring of Tyr69 is perpendicular to that one of Tyr119, and oriented to form a double 
hydrogen bond with Ser117 (Fig. 41). Similarly, in ricin A chain structure the hydroxyl group of 
Tyr80 forms an hydrogen bond with the Gly121 carbonyl group (Mlsna et al., 1993). In bouganin 
and the other considered RIP structures, including ricin, the first catalytic tyrosine has a higher 
thermal factor (B) than the second one, indicating a greater mobility. In lychnin structure Tyr69 and 
Tyr119 are similarly ordered (mean B calculated on side chain atoms 15.4 Å2 and 17.8 Å2, 
respectively). 
 
 
 
Figure 41. Catalytic site of lychnin. The conserved important residues and Ser117, are showed in 
ball-and-sticks and the orientation of the side chain of the catalytic tyrosine, in other RIPs is also shown: 
bouganin (magenta), lychnin (cyan), dianthin 30 (green), saporin-S6 (red), PAP-R (dark blue), momordin I 
(grey) and ricin A chain (gold). Tyr69 interacts with Ser117 through two hydrogen bonds between the OH 
group of Tyr69 and O and OG atoms of Ser117. The figure was produced by MOLSCRIPT (Kraulis, 1991) 
and rendered by RASTER3D (Merritt et al., 1997). 
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3.6 DISCUSSION AND CONCLUSION 
 
Two novel structures have been added to the bank of RIP structures. Lychnin and bouganin have 
been chosen because of some peculiarities in their properties in experimental assays. In particular, 
bouganin has a very low in vivo toxicity as compared to its intrinsic enzymatic activity (data not 
shown) whereas lychnin has an atypical primary structure. The other representative RIPs chosen for 
comparison were dianthin 30, PAP-R, momordin I, saporin-S6 and ricin A chain, for which crystal 
and activity data were either available in literature or obtainable in our laboratory. 
Bouganin, lychnin, the different type 1 RIPs and ricin A chain structures share the typical “RIP 
fold”, conserved despite the sequence homology is around or less than 30%, except for dianthin 30 
and saporin-S6 (87%) (Fermani et al., 2005). 
Important structural differences are observed at the end of the mixed β-sheet of the N-terminal 
domain and at the C-terminal region (Fig. 40a), which are highly exposed regions. Segments 
connecting the final strands at the N-terminal domain show various arrangements between RIPs 
(Fig. 40b,c). It has been proposed that (i) this region, ranging from Tyr91 to Thr116 in ricin A 
chain, binds to monoclonal antibodies that neutralise the toxicity of these proteins (Lebeda et al., 
1999) and (ii) it forms the top of a putative recognition site for ribosomes (Mishra et al., 2004). At 
the C-terminal region, the structural motif composed of two antiparallel β-strands is absent in 
lychnin while it is shorter in dianthin 30 and saporin-S6 compared to the other considered RIPs 
(Fig. 40d). The core of the molecule, containing the active site, is highly conserved among RIPs 
(Fig. 41a). The side chains of catalytic residues are superimposable, except for the first tyrosine, 
which assumes different orientations in the considered RIPs (Fig. 41). Moreover, the high thermal 
parameters of this residue indicate that it is quite mobile and could work as a moving door for the 
adenine entering in the catalytic site. On the contrary, in lychnin structure Tyr69 shows a B value 
comparable to that one of Tyr119, and it is oriented to interact with Ser117 through two hydrogen 
bonds formed between the OH group of Tyr69 and atoms O and OG of Ser117 (Fig. 41). Similarly, 
in ricin structure Tyr80 forms an hydrogen bond with Gly121, but it keeps an higher B value with 
respect to Tyr123 (Mlsna et al., 1993). 
The observed structural differences between these proteins do not fully explain the differences in 
the amount of adenine released from various polynucleotides and the inhibitory activity in a cell-
free system (Table 15) (Fermani et al., submitted). The experiments on various substrates (hsDNA, 
poly(A) and rat ribosomes) were carried out by the group of Professor Bolognesi (Experimental 
Pathology Department of Bologna University).  
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Table 16. Adenine polynucleotide glycosylase activity (PNAG) and protein synthesis inhibitory 
activity of different type 1 RIPs and ricin A chain. 
 
 
 
PNAG activity 
(pmol A released)
$
 
Protein synthesis 
inhibitory activity 
(10
3 
U x mg
-1
)* 
  hsDNA Poly(A) Rat Ribosomes  
Group 1 Lychnin 29.5 (±6.3) n.d.
#
 7.2 (±1.2) 176 
 Momordin I 27.1 (±3.8) n.d.
 #
 3.9 (±0.2) 526 
 Ricin A chain 48.5 (±1.4) n.d.
 #
 6.2 (±1.4) 300 
Group 2 Bouganin 377.7 (±3.7) n.d.
 #
 4.8 (±0.9) 75 
 PAP 503.2 (±33.4) n.d.
 #
 5.1 (±0.5) 125 
Group 3 Dianthin 30 239.9 (±10.4) 5.4 (±1.7) 5.7 (±1.2) 96 
 Saporin-S6 376.1 (±15.8) >300 19.1 (±2.7) 813 
 
$ Glycosylase activity was determined with reaction mixtures containing 10 pmol of RIP, 10 µg of hsDNA and poly(A) and 10 pmol 
of rat ribosomes. Data are expressed as mean ± S.D. 
* One unit of inhibitory activity (U) is defined as the amount of protein causing 50% inhibition in 1 ml of reaction mixture. 
# Not determinable (less than the threshold of sensitivity of the analysis apparatus). 
 
There was no correlation between the inhibition of translation by mammalian ribosomes and the 
activity on simpler substrates. Depurination activity was measured at different pHs, including pH 
4.0, to maximise the amount of adenine released, choosing for each assay the optimal pH for RIP 
activity on any given substrate. In particular acidic pH allows for the detection of much lower 
amounts of adenine released from DNA. On the other hand (i) we can suppose on the basis of the 
high structure similarity between crystallised RIPs, that the global protein folding is not much 
altered by the ionisation of the surface groups at pH 4.0, and (ii) some intracellular plant cell 
compartments actually present acidic environments. 
The activity of assayed RIPs  indicates that saporin-S6 is the most efficient both in the protein 
synthesis inhibition and deadenilation of ribosomes (Table 15). 
Analysis of RIP activities on DNA and poly(A) allow to identify three possible groups: group 1, 
without measurable activity on poly(A) and with low activity on DNA (tens of adenines released), 
group 2, without activity on poly(A) and with high activity on DNA (hundreds of adenines released) 
and group 3, active on poly(A) and with high activity on DNA. Group 1 applies to lychnin, 
momordin-I, ricin A chain, group 2 to bouganin and PAP-R and group 3 to saporin-S6 and dianthin-
30, respectively. 
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The efficiency of saporin-S6 on ribosomes corresponds to a lower specificity: the molar ratio of 
adenine released indicates that this enzyme removes more than one base (almost two, in the given 
reaction time) for each ribosome, the Endo’s adenine and an additional one (Table 15). All other 
considered RIPs specifically release the Endo’s adenine from ribosome molecules (Barbieri et al., 
1993). It has been already proposed that beside their structural similarity, the higher efficiency of 
saporin-S6 on protein synthesis inhibition, with respect to dianthin 30, could be ascribed to a more 
negative electrostatic surface potential in the active cleft (Fermani et al., 2005) which may 
efficiently stabilise the oxacarbenium-like transition state.  
We can suppose that the previous observation  may justify the lower specificity on rat ribosomes 
and the higher activity on poly(A) of saporin-S6 compared to dianthin 30. It is not clear why 
dianthin 30 has a detectable activity on poly(A) respect to others considered RIPs. Evidently the 
stabilisation of the oxacarbenium-like transition state is not the unique factor determining the 
activity on this substrate. 
Bouganin shows a wide active site characterised by a negative potential with a small positive zone 
determined by Arg168 (Fig. 39a). However, its inhibitory activity on ribosomes is the lowest one 
and its deadenilation efficiency is almost negligible on poly(A) (Table 15). Similarly, lychnin is 
inefficient on poly(A), but shows a light increased inhibitory activity with respect to bouganin 
(Table 15). Various simulation models of ricin A chain X-ray structure bound to a modelled 
hexanucleotide CGAGAG loop or to a 29mer oligonucleotide hairpin (Olson,1997; Olson et al., 
1999), indicated that Arg134 and Arg213 formed a ion-pair with the phosphodiester backbone of 
the first cytidine and the subsequent guanosine, respectively. Arg134 (numbering correspond to 
ricin) is conserved in all RIP family, while Arg213 is replaced by lysine in lychnin, dianthin 30, 
saporin-S6 and PAP-R, by a non-polar residue (Gly194) in momordin I and by a residue with an 
opposite charge (Asp200) in bouganin (Fig. 39). Mutations R213A and R213D lowered the 
enzymatic activity respect to wild-type ricin, by 10-fold and over 100-fold, respectively (Marsden et 
al., 2004). It was also proposed that Asn78 in ricin (Olson et al., 1999) or the corresponding Asn70 
in PAP-R (Rajamohan et al., 2001) is involved in the interactions with the substrate, probably with 
the phosphodiester group between the target adenosine and the subsequent guanosine. This residue 
is conserved in all considered RIPs, except for bouganin and lychnin, which have an aspartate in the 
corresponding position (Fig. 38). The previous reported sequence substitutions could cause for 
bouganin and lychnin unfavourable interactions with the substrate, justifying the low efficiency in 
protein synthesis inhibition and deadenilation of poly(A) or the stricter specificity for the Endo’s 
adenine on rat ribosomes with respect to saporin-S6. Moreover, saporin-S6 structure shows in the 
region surrounding the active cleft, several lysines (46, 67, 91, 125, 134, 210, 220, 234) and an 
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arginine (209) pointing out from the protein surface (Fig. 39e). They could be accessible coupler for 
the substrate backbone phosphate groups. Lychnin structure shows six hypothetic anchoring points 
(Lys39, Arg93, Lys98, Lys123, Arg195, and Lys205) (Fig. 39c), but the catalytic reaction could be 
hampered by the electrostatic surface potential at the active site, not highly negative as in saporin-
S6. No other of considered RIPs shows a comparable number of positive exposed residues. 
Moreover, in lychnin the orientation of Tyr69 aromatic ring almost perpendicular to Tyr119 (Fig. 
41), is not suitable to form a stack interaction stabilising the target adenine. The correct positioning 
of Tyr69, which partially hinders on the right side the access to the active cavity, would require the 
break of a double hydrogen bond with Ser117 followed by a rotation of the aromatic ring. 
The above considerations can not be addressed to explain the activity of RIPs on hsDNA. The 
experimental conditions (pH 4) affect the electrostatic potential on the protein surface. All type 1 
RIPs have an highly basic isoelectric point (equal or higher than 9) and at pH 4 the surface becomes 
almost all positively charged (Fig. 39b,d,e). Only bouganin, saporin-S6 (Fig. 40b,f) dianthin 30 and 
PAP-R (not shown), corresponding to the toxins showing a high activity on DNA (Table 15), still 
maintain in these acidic conditions a negatively charged zone in the active cleft corresponding to 
the catalytic glutamate. Supposing that the deadenilation of DNA occurs with the same mechanism 
proposed for ribosomes (Mozingo et al., 1992; Ren et al., 1994; Huang et al., 1995), the reaction 
can proceed only if the catalytic glutamate, responsible for the nucleofilic attack on the positive 
transition state or the polarization of a water molecule, has a negative charge.  
In conclusion, the higher protein synthesis inhibitory activity and efficiency of saporin-S6 in the 
deadenilation of various polynucleotides, as rat ribosomes, poly(A) and hsDNA, compared to other 
RIPs can be ascribed to an efficient interaction between the enzyme and the substrate, guaranteed 
by several exposed arginines or lysines surrounding the active site cleft, and to the negative 
electrostatic surface potential into the active cavity, which stabilise the positively charged transition 
state. These two conditions are not present at the same time in any other of the considered RIPs: 
bouganin shows a negative potential at the active site, but the interaction with the substrate could be 
prevented by the negative charge of some surrounding residues, while in lychnin the interaction 
could be as efficient as in saporin-S6, but the position and the interactions of Tyr69 and the 
electrostatic surface potential at the active site probably do not favour the adenine removal. 
Moreover, the structural differences observed in the exposed regions of the N- and C-terminal 
domains may influence the enzyme-substrate interaction and probably the RIP enzymatic activity. 
The gained information from this research show that although the structures give some useful 
indications to explain RIPs’ action on polynucleotides and protein synthesis, the high complexity of 
the enzyme/substrate system still prevents the complete evaluation and final understanding of all the 
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parameters that could influence RIP activity. Moreover, the wide range of heterogenous substrates 
on which they acts with different activity enhances the interest on their biological function. 
Knowledge of structural differences between type 1 RIPs is of great importance for their 
pharmacological and medical applications. Our results also encourage the extension of 
crystallographic investigations on other RIPs from diverse sources to elucidate important 
differences that can be linked to their biological activities on various substrates. 
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CHAPTER 4: LOOKING AT THE INTERACTIONS BETWEEN 
CISPLATIN AND METAL IONS WITH PROTEINS 
 
4.1 INTRODUCTION  
 
This research aimed at the structural characterisation, through X-ray technique, of platinum drugs, 
copper and other biologically relevant ions complexed to proteins involved in copper trafficking.  
The ability of anticancer drugs to enter cells and to reach an adequate concentration within the 
appropriate intracellular compartments is an important determinant for the efficacy of a 
chemotherapy. Platinum coordination compounds have been successfully applied in cancer 
chemotherapy for more than 25 years since the introduction of the parent compound for this class of 
antitumor agents, namely, cis-[diamminedichloroplatinum(II)], known as cisplatin (DDT) 
(Rosenberg, 1999). They are the most effective antineoplastic agents for a number of malignancies 
(e.g., testicular, ovarian, head and neck, and bladder cancer) (Samimi et al., 2003).  
Over decades, a great deal of effort has been devoted to synthesis and testing of the tumor-
inhibiting profiles for new metal complexes, with the major impetus toward development and 
implementation of novel anticancer drugs. These are anticipated to have superior efficacy, increased 
selectivity for tumor tissue, reduced toxicity, a wider spectrum of activity, lack of tumor cell 
resistance, and improved pharmacological characteristics (e.g., possibility of oral administration) as 
compared to cisplatin. Still, of thousands of tested compounds, only a fraction (about 30) have 
entered clinical trials and merely three Pt drugs (cisplatin, carboplatin and oxaliplatin) have 
eventually been approved worldwide in 1978, 1993, and 2002, respectively (Wong et al., 1999; 
Galansky et al., 2003; Timerbaev et al., 2006). The cytotoxicity of DDT is related to the amount of 
drug that enters the cell, the extent to which that drug reaches the nucleus and reacts with DNA, and 
the ability of the cell to repair or tolerate DDP adducts (Andrews et al., 1990). Pt who becomes 
cationic species in the plasma and in the intracellular fluid, can form cross-links with DNA and 
acting as strong nucleophile links selectively amino acids containing sulfur, like cysteine and 
metionine. The major mechanisms of resistance that have been identified thus far involve reduced 
drug uptake, increased cytoplasmic detoxicification, and increased DNA repair (Perez et al., 1993; 
Johnson et al., 1997; Fink et al., 1998). Among these, reduced cellular drug accumulation is the 
most universally identified correlate of acquired DDT resistance (Andrews et al., 1990). DDT and its 
analogues are highly polar molecules and do not cross lipid bilayer membranes easily. It enters cells 
relatively slowly compared with most anticancer agents. Until short time ago, platinum-based 
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anticancer drugs were thought to enter the cell mainly by passive diffusion. However, recently it has 
been demonstrated that the Cu homeostasis system can regulate the uptake, intracellular 
compartmentalization and efflux of DDT, carboplatin and oxaliplatin. (Katano et al., 2003; Samimi 
et al., 2004; Safaei et al., 2005).  
Accumulation and export of these anticancer drugs can be regulated by two copper-transporting 
ATPases, the Menkes (ATP7A) and Wilson (ATP7B) proteins, respectively; thus suggesting that 
platinum drugs can be taken up, distributed into various intracellular compartments, and exported 
from tumor cells by the system of membrane transporters and soluble trasporters ("chaperones") 
that evolved to manage copper homeostasis. ATP7A and ATP7B are important constituents of the 
Cu homeostasis system that has evolved to deliver Cu to Cu-requiring proteins while protecting the 
cells from toxic effects of Cu (Culotta et al., 1999). ATP7A is expressed in most tissues other than 
liver, whereas ATP7B is expressed predominantly in the liver. Very little is known about the 
mechanism by which these copper-transporters shuffle the Pt drugs, while the copper transport 
mechanism has been extensively studied and clarified. The observation that ATP7A- and ATP7B-
transfected cells accumulate high levels of DDP in their vesicular compartment after exposure to 
low concentrations of the drug suggests that DDP also may be a substrate for these transporters 
(Katano et al., 2003; Samimi et al., 2003). In particular, consistent with a possible role for ATP7A 
in the export of DDP, ATP7A was found to be overexpressed in some ovarian carcinoma cell lines 
with acquired DDP resistance (Katano et al., 2002). 
Although several studies indicate that ATP7A and ATP7B are capable of transporting copper only 
in its reduced form [copper(I)], data from other P-type ATPases, such as Znt, indicate that this class 
of enzymes may be capable of transporting other heavy metals when the metals are present in high 
concentrations (Liu et al., 2006). DDP is a substrate for ATP7B but is transported at a much slower 
rate than copper (Safei et al., 2008).  
The major Cu uptake transporter is the copper transporter 1 (CTR1), which delivers Cu to pathway-
specific chaperones such as ATOX1, CCS and COX17 for delivery to the secretory compartment, 
cytosol and mitochondria respectively (Culotta et al., 1999). An important feature of Cu 
transporters and chaperones is the presence of specific histidine-, methionine-, and cysteine-rich 
metal binding domains that selectively bind Cu(I) and exchange it with other Cu homeostasis 
proteins (Huffman et al., 2001).  
It has been shown that most of the DDT injected in a patient is protein bound (Deconti et al., 1973).   
Therefore the study of Pt-protein adducts is important both for drug’s activity and undesired side 
effects (Espinosa et al., 1995). Unraveling the interactions between DDT and metal ions with 
proteins allows to determine specific structural parameters and chemical features (effect of the 
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charge, steric hindrance, flexibility) that may influence the reactivity and modulate the metal 
binding properties of the complex to the transport proteins. A detailed description of the molecular 
architecture and metal-binding features of these macromolecular systems could help to shed light on 
the mechanisms of cellular transport of not essential metal ions and compounds, like platinum and 
may open new avenues for the design of potentially active anticancer agents with tailored uptake 
and efflux properties. Thus, these studies may represent an initial step towards the design of new 
anticancer drugs active towards tumors resistant to DDT (Timerbaev et al., 2006). Moreover, 
through the optimisation of interactions with specific molecular targets, it could be also possible to 
minimise side effects, sometimes rather severe, that represent a big limitation in the use of these 
drugs and vary from individual to individual. Indeed, the diverse response of individuals, all 
subjected to the same chemotherapeutic treatment, originates from different cellular processing of 
loaded drug, which involve proteins interacting, and sometimes interfering with the drug itself.  
 
4.1.1 Model proteins object of structural invastigation: The aim of our work has been the 
crystallisation and structure determination of adducts between model proteins and platinum-based 
anticancer drugs or, generally, metal ions. Proteins naturally involved in copper homeostasis have 
been used as model. Such proteins have also been shown to be responsible for platinum drugs 
transport (see section 4.1). Among these proteins we have used human Hah1 and CopC. Hah1 is a 
metallochaperonine protein implicated in copper delivery to the Menkes and Wilson disease 
proteins. CopC is a bacterial protein that transports copper and shows a methionine rich domain 
with a sequence similar to those observed in other proteins involved in copper homeostasis in cells. 
It was planed to investigate by single crystal X-ray crystallography the interaction of Hah1 and 
CopC with selected platinum substrates. The aim was to characterise the sites of attack of the 
platinum drugs and the consequent conformational alteration of the protein. 
Also human ubiquitin and superoxide dismutase (SOD) have been selected both for their biological 
relevance and their full characterisation in the native state. 
The knowledge of the interaction between the metal and its transport protein represents an 
important step of the overall understanding of the metal trafficking through the cell. 
 
4.1.1.1 Hah1: Hah1 is a 68-amino acid protein (Hung et al., 1998). It is a copper transport protein, 
whose structure has been deeply studied. Hah1 is part of a family of copper-binding proteins that 
share a similar MT/CXXC Cu(I) binding motif that is also present in its target proteins.  
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The Hah1 metallochaperonine protein is implicated in copper delivery to the Menkes and Wilson 
disease proteins (ATP7A and ATP7B). This small protein has a sequence similar to the six copper 
(I)-binding domains present both in ATP7A and ATP7B (Werimont et al, 2000).  
A sequence analysis of numerous metal-transporting ATPases by Arnesano and coworkers revealed 
sequence homology between Atx1 and Ccc2, the yeast homologs HAH1 and MNK, respectively. 
The primary structure similarity of the two proteins suggested that their complimentary tertiary 
structures could be important to inducing or facilitating Cu(I) transfer (Arnesano et al., 2001). 
Furthermore, since no crystal structure of the donor-target complex exists, Larin et al. used the 
solution structure of MNK4 and the crystal structure of HAH1 to artificially create a complex 
whose structure was compared to the X-ray structure of the HAH1 homodimer by rmsd that showed 
a high level of structural homology to the HAH1:MNK4 heterodimer (Larin et al., 1999). A similar 
docking study was undertaken by Arnesano in which the artificially docked Atx1:Ccc2 heterodimer 
was compared to available crystal structures of Atx1, Ccc2 and HAH1 (Arnesano et al., 2004). In 
this study, it was noted that the Atx1:Ccc2 complex, the yeast homolog to the human HAH1:MNK4 
complex, is remarkably similar to the crystal structure of the HAH1 dimer as a whole and with 
respect to the geometry of the Cu(I) binding region of the heterodimer. In light of these studies, the 
use of the HAH1 homodimer structure as a model of the HAH1:MNK4 heterodimer is considered 
valid. 
Wernimont et al. elucidated the structure of Hah1 using X-ray crystallography (PDB ID 1FEE), and 
determined the protein to be dimeric in the crystalline state, with one Cu(I) ion bound per dimer in a 
near-tetrahedral configuration (Wernimon et al., 2000). The crystal structure of Hah1 was 
determined in the presence of Cu(I), Hg(II), and Cd(II). The structure of CuHah1 revealed a copper 
ion coordinated by Cys residues from two adjacent Hah1 molecules. The CuHah1 crystal structure 
is the first of a copper chaperone bound to copper and provides structural support for direct metal 
ion exchange between conserved MT/HCXXC motifs in two domains. The structures of HgHah1 
and CdHah1also revealed metal ion coordination by two MT/HCXXC motifs. Although it was clear 
that Cu was bound by residues from each monomer, the data from the crystal structure supported 
either a four-coordinate or three-coordinate Cu(I) state with a loosely-bound fourth residue 
(Rosenzweig et al., 2001). A four-coordinate Cu(I) site would also produce an electrostatic 
environment with a net charge of -3 in the active site, which is unfavourable (Wernimon et al., 
2000). NMR studies performed by Anastassopoulou et al. concluded that Atx1, the yeast homolog 
of HAH1, exists as a monomer in solution, binding one Cu(I) ion per monomer in a nearly linear 
two-coordinate fashion (PDB ID 1TL4) (Anastassopoulou et al., 2004). 
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We planed to investigate by single crystal X-ray crystallography the interaction of Hah1 with 
selected platinum substrates. The proposed crystallographic studies could allow to characterise the 
sites of attack of the platinum drugs and the consequent conformational alteration of the protein. 
 
4.1.1.2 CopC: CopC is a small soluble protein consisting of 102 amino acids expressed in the 
periplasm of Pseudomonas syringae pathovar tomato as part of its copper resistance response (cop 
operon) (Zhang et al., 2006). Bacterial resistance to copper conferred by plasmids has been 
described not only in Pseudomonas (Cooksey, 1994) but also in Xanthomonas (Lee at al., 1994), 
and E. coli (Brown et al., 1994; 1995). These systems are highly homologous (Brown et al., 1994; 
Cooksey, 1993; 1994) and contain the same genes. The plasmid is able to confer copper resistance 
to the host strains of Gram-negative bacteria and protects the cells by sequestering the excess of 
copper in the periplasm and in the outer membrane (Cooksey, 1994).  
For Pseudomonas sp., the two regulatory genes are called copR and copS, and the four structural 
genes copABCD (Fig. 42). The four structural 
proteins determining copper resistance are the 
inner membrane protein CopD, the outer 
membrane protein CopB, both membrane-bound 
copper pumps, and two soluble proteins CopA 
and CopC present in the oxidizing environment 
of the periplasm (Fig. 42). CopA and CopC are 
blue copper-binding proteins containing 11 and 
1 Cu2+ ions, respectively (Cha et al., 1991). The 
operon COP encoding the four proteins, 
CopABCD, acts under the control of a copper 
inducible promoter requiring CopR and CopS 
that form part of copper sensing and gene 
induction systems (Mills et al., 1993). Storage of excess copper in the periplasmic space is 
considered to protect the cell from toxic copper. How the membrane proteins CopD and CopB are 
involved in movement of copper across the outer and inner membranes is not understood.  
CopC protein is proposed to be a copper carrier but in contrast to known cytoplasmic copper 
chaperones, it contains no cysteine residue (Zhang et al., 2006). While Cys-rich sites are 
characteristic of copper(I) carriers in the reducing cytoplasm, His/Met-rich sites seem to be 
important in oxidizing environments (Huffman et al., 2001; Tottey et al., 2005). CopC shows a 
Figure 42. Copper transport and resistance in Pseudomonas. 
Om idicates outer membrane; im inner membrane. 
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region containing four methionine residues arranged as a [M(X)nM]m motif, in analogy with other 
proteins involved in copper homeostasis in eukaryotic cell, like hCtr1 (Arnesano et al. 2003).  
CopC can mimic the action of the copper transporter hCtr1 and the use of CopC as model is 
justified since hCtr1 is not a protein easily available, being its expression and purification very 
difficult. 
NMR and EXAFS structural data revealed a β-barrel topology and two copper binding sites, 
separated by 30 Å (Arnesano et al., 2003; 2004). One site is specific for Cu(I) while the second is 
specific for Cu(II). A full solution structure analysis is reported for Cu(I)-CopC. The copper(I) site 
is constituted by His-48 and three of the four Met residues (40, 43, 46, 51), which are clustered in a 
Met-rich region. Oxidation of Cu(I)-CopC or reduction of Cu(II)-CopC causes migration of copper 
from one site to the other. This behavior indicates that CopC can exchange copper between two 
sites activated by a redox switch. 
Since copper transport mechanisms have been studied and clarified , very little is known about the 
mechanisms by which copper-transporters shuttle platinum. We have investigated the interaction of 
CopC with selected platinum substrates to characterise the sites of attack of the platinum drugs and 
evaluate analogies/differences with the sites of interaction of copper. 
 
4.1.1.3 Superoxide dismutase: There are three major families of superoxide dismutase, depending 
on the metal cofactor: Cu/Zn (which binds both copper and zinc), Fe and Mn types (which bind 
either iron or manganese), and finally the Ni type which binds nickel. In humans (as in all other 
mammals and most chordates), three forms of superoxide dismutase are present. SOD1 is located in 
the cytoplasm, SOD2 in the mitochondria and SOD3 is extracellular. The first is a dimer , while the 
others are tetramers. SOD1 and SOD3 contain copper and zinc, while SOD2 has manganese in its 
reactive centre. 
Cytosolic Cu, Zn superoxide dismutase (SOD1; EC 1.15.1.1) is a critical component of the cellular 
defence against reactive oxygen species and catalyses the dismutation reaction of the superoxide 
radical anion to hydrogen peroxide and oxygen via the cyclic reduction and reoxidation of copper 
(Fridovich, 1975). On the other hand, SOD1 exhibits peroxidase activity and oxidizes various 
substrates in the presence of hydrogen peroxide (Hodgson et al., 1975).  
It is composed of two identical subunits, each containing 153 amino acids of known sequence 
(Barra et al., 1980; Hallewell et al., 1985) together with a Cu(II) and Zn(II) (Carrico et al.,, 1970). 
The recombinant human enzyme has been expressed at high levels, purified, and characterised from 
both Escherichia coli (Hallewell et al., 1985) and yeast (Hallewell et al., 1987). Both recombinant 
proteins have normal specific activity when compared to the enzyme purified from human 
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erythrocytes, but recombinant CuZn superoxide dismutase from E. coli lacks the N-acetylation 
found in the eukaryotic enzyme.  
The overall fold in each SOD1subunit is described as an eight-stranded antiparallel β-barrel 
connected by three external loops (Tainer et al., 1982; Rakhit et al., 2006). Two of these loops, the 
Zn loop and the electrostatic loop, form the walls of a channel from the enzyme surface to the active 
site. The third loop region provides the Greek key connection across the β-barrel. Several charged 
residues within the electrostatic loop as well as the catalytically important Arg143 are involved in 
the electronic guidance of the substrate to the active site and so contribute to the high-level 
specificity of SOD1 for the superoxide substrate (Getzoff et al., 1983). The Zn loop is so named 
because it contains ligands for the Zn ion. The metal ions in SOD1 are bridged by the imidazole 
ring of residue His63, which acts as a ligand to both metals. The catalytic copper is bound by four 
histidines, His 46, 48, 63 and 120, in a distorted tetrahedral binding geometry in the oxidised 
(Cu(II)) form and in a distorted trigonal planar geometry, bound by His 46, 48 and 120, in the 
reduced (Cu(I)) form, while the Zn is bound by His 63, 71, 80 and Asp 83 acting as a monodentate 
ligand, is thought to play a structural role and act as a positive charge sink. (Getzoff et al., 1983; 
Rakhit et al., 2006). There is structural evidence from crystallography and EXAFS that the Cu-
His63-Zn-bridge in SOD1 is broken upon reduction to Cu(I), leaving an approximate trigonal planar 
Cu coordination (Strange et al., 2003).  
The first atomic-resolution structures for human SOD1, the first structure of a reduced SOD1, and 
the first structure of a fully Zn-substituted SOD1 enzyme have been solved by Strange et al. 
(Strange et al., 2006).  
Morover, crystals of cisplatin-treated bovin SOD were obtained by Calderone et al. (Calderone et 
al., 2006). Structural data revealed a preference for platinum binding to His19 compared to Met115 
or Cys6 residues. This preference was at least partially ascribed to the fact that the access to either 
Met115 or Cys6, the only free sulfur-containing groups of beSOD is somehow sterically hindered. 
In SOD, both metal ions, Cu and Zn, can be selectively removed and replaced by other metals to 
obtain different metal ion derivatives which are useful for studying various aspects of 
metalloprotein chemistry (Valentine et al., 1981). For this reason, human SOD1has been chosen as 
model protein to invastigate the interaction with cisplatin. In particular, SOD exhibits great stability 
under physiological-type condition and has several potential binding sites for platinum. Sulfur-
containing side chains are known to represent preferred binding sites for platinum compounds. 
SOD1 has four cysteine residues, Cys6, Cys57, Cys111, and Cys146. An internal disulfide bond 
exists between Cys57 and Cys146 (Tainer et al., 1982; Parge et al., 1992), which contributes to the 
high stability of the SOD1 protein. This disulfide bond is highly conserved in SOD1s from various 
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organisms, including yeast, plants, flies, fishes, and mammals. In contrast, two free cysteines, Cys6 
and Cys111, are not conserved: Only human and great ape SOD1s among mammals have the highly 
reactive free cysteine residue, Cys111, at the surface of the SOD1 molecule . Actually, yeast, fungi, 
and spinach (plants) have no free cysteines, and residue 6 is Ala and residue 111 is Ser in these 
organisms (Fink et al., 2002). More evolved organisms, such as flies, fishes, and mammals, 
including the Japanese monkey, have only one free cysteine, Cys6. 
It was demonstrated that Cys111 is a primary target for oxidative modification and plays an 
important role in oxidative damage to human SOD1, including familial amyotrophic lateral sclerosis 
mutants (Fujiwara et al., 2007).  
 
4.1.1.4 Ubiquitin: Ubiquitin (Ub) is a small protein of 76 residues (MW 8565 Da) folded in a 
compact globular structure in which a mixed parallel/anti-parallel β−sheet packs against an α-helix 
generating a hydrophobic core. Not found in bacteria, this protein is ubiquitous in eukaryotes and 
has highly conserved sequences, the human and the yeast proteins differing by only three residues 
(Vijay-Kumar et al., 1987). The remarkable degree of sequence conservation underscores its 
important physiological role (Hershko et al., 1998). Ub becomes attached to lysine residues of 
proteins to be degraded and targets them to the proteasome, the complex molecular machinery 
where the ATP-dependent process of degradation takes place. Besides protein degradation, Ub is 
known to activate cell signals in several pathways: tolerance to DNA damage, inflammatory 
response, protein trafficking, and ribosomal protein synthesis (Pickart et al., 2004). The presence of 
Ub-positive protein aggregates is a biomarker of neurodegeneration (Ciechanover et al., 2003), but 
the molecular mechanism underlying their accumulation is unknown. Protein aggregation is 
believed to be favored by metal ions, such as Cu(II) and Zn(II), whose levels are increased in brains 
of patients with Parkinson’s and Alzheimer’s diseases, the two most common neurodegenerative 
disorders (Sigel et al., 2006). Ub has been widely used as model for stability, folding, and structural 
studies (Jackson et al., 2006) and carefully characterized both in solution (Di Stefano et al., 1987)and 
solid state (Vijay-Kumar et al., 1987).  
However, despite the plethora of structural investigations, only few studies concern the interaction 
with metal ions. Recently, binding of Cu(II) to Ub has been shown to destabilise the protein 
decreasing the thermal stability both in terms of unfolding temperature and enthalpy, while other 
metal ions, including Zn(II) and Cd(II), have no effect on the unfolding temperature (Milardi et al., 
2007). Crystallisation experiments with hUb and cisPt or Cu(II) have been carried out to investigate 
and compare the binding site(s). In the present study, also adduct formation between human 
ubiquitin (hUb) and group-12 metal ions Zn(II), Cd(II), and Hg(II) has been investigated by X-ray 
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crystallography. While Zn(II) is an essential element involved in several important cellular 
functions (Burdette et al., 2003) Cd(II) and Hg(II) are toxic metal ions released into the 
environment by human activities, which may bind to adventitious sites, thus compromising protein 
functions (Valko et al., 2005). The characterisation of metal-binding sites and the patterns of metal 
ion-induced crystallisation of human ubiquitin (hUb) can provide structural insights into the early 
aggregation mechanism of folded systems.  
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4.2 CRYSTALLISATION EXPERIMENTS 
 
The aim of our work has been the crystallisation and structure determination of adducts between 
model proteins and platinum based anticancer drug or, generally, metal ions. Crystals of protein and 
cisplatin or other metal ions were preparated by co-crystallisation or soaking of already formed 
native crystals. The proteins are commercially available and human Hah1, CopC had been 
purchased by Protera srl while human SOD by Sigma-Aldrich. The cis-Pt based anticancer drugs 
had been supplied by the Laboratory of Prof. Natile, University of Bari, Italy. 
 
4.2.1 Human Hah1: Hah1 cloned from human cDNA (residues 1-68, swissprot O00244), 
expressed in E. Coli, were used. Crystallisation experiments were performed in anaerobic 
conditions, being this protein sensitive to O2. Crystallisation experiments were carried out at 293 K 
by the hanging drop method mixing 1.5 µl of protein with 1.5 µl of reservoir solution (750 µL in 
each well). To prepare metal- protein adducts, cisPt or Zeise ‘s salts (K[PtCl3(C2H4)]), were used. In 
co-crystallisation experiments, the protein was dissolved at different concentrations in different 
metal solutions: 
-5 mg/mL in 3.33 mM cisPt and milliQ water (protein-metal molar ratio 1:5). 
-5 mg/mL in 3.33 mM cisPt and 20mM 2-[N-morpholino]ethanesulfonic acid (MES) pH 6.5 
(protein-metal molar ratio 1:5). 
-7.5 mg/mL in 1.92 mM cisPt and milli Q water (protein-metal molar ratio 1:2). 
-7.5 mg/mL in 1.92 mM Sali di Zeiss and milli Q water (protein-metal molar ratio 1:2). 
When Hah1 was tried to be co-crystallised with cisPt, the adduct was left to interact at least for 2 
days before to set up crystallisation experiments, while only 1 day was enough for Zeise’s salts 
being its hydrolysis time shorter than that of cisPt. 
As reservoir solution, those reported in literature by Wernimont et al. and variation of them, 
including variation of precipitant concentration and/or buffer pH, were tested (Wernimont et al., 
2000):  
a) 0.1 M MES pH 6.5, 1.8 M (NH4)2SO4, 0.2 M MgCl2, and 5 mM dithiothreitol (DTT). 
b) 0.1 M MES pH 6.5, 0.1 M MES pH 6.5 and 1.5 M Li2SO4. 
c) 1.0 M Li2SO4, and 5 mM DTT. 
It was not possible to obtain any crystal of Hah1-metal adducts although dozen and dozen of co-
crystallisation experiments were set up. Also attempts to obtain crystals of native protein were 
always unsuccessful. 
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4.2.2 CopC: Recombinant CopC, from Pseudomonas syringae, expressed in Escherichia coli, were 
used. It is in the apo form and consists of residues 25-126 (Swissprot accession C32018). 
Crystallisation experiments were carried out by the hanging drop method at room temperature by 
mixing the protein solution (1.0/2.0 µL) with an equal volume of reservoir solution (750 µl in each 
well). The tested reservoir solutions were those reported in literature and variations of them, 
including variation of precipitant concentration and/or buffer pH: 
a) 2.0 M ammonium sulfate, 0.1 M sodium HEPES, pH 7.5, 2%(w/v) PEG 400 (Zhang et al., 2006). 
b) 4.4−5.2 M ammonium nitrate, 0.1 M sodium acetate, pH 4.6−4.8 (Zhang et al., 2006). 
c) 4.3 M NaCl, 0.1 M sodium HEPES, pH 7.5 (Wernimont et al., 2003). 
In the co-crystallisation experiments, to prepare metal- protein adducts, cisPt, transPt and Zeise’s 
salts (K[PtCl3(C2H4)]) were used: The adducts with cisPt or 
transPt were left to interact at least 2 days before to set up 
crystallisation experiments while those with Zeise’s salts 1 
day. The adducts were performed dissolving the protein in a 
metal aqueous solution containing the metal in molar ratio 
1:3 with respect to the protein. The tested protein 
concentration ranged from 30 to 7 mg/mL. Co-
crystallisations experiments did no produce crystals at all. 
Crystallisation experiments to obtain crystals of native 
protein were also unsuccessfully carried out.  
In literature, the CopC was reported to be crystallised in the 
presence of Cu but not in the apo-form. So, we tried to 
dissolve the protein (14 mg/mL) in 2.66 mM CuSO4 
(protein-Cu(II) molar ratio 1:2) and we could obtain crystals 
(Fig. 43) in about one month, when 2.0 M Am2SO4, 0.1 M 
sodium HEPES, pH 7.5, 2% (w/v) PEG 400 were used as 
reservoir solution. Before to set up the crystallisation experiments, the CopC-Cu(II) adduct was left 
to interact one day.  
 
4.2.3 Human superoxide dismutase: Superoxide dismutase from human erythrocytes (Catalog 
Number S9636) (hSOD) were crystallised either in hanging or sitting drop vapour diffusion at 
293K. Crystallisation experiments to obtain native crystals of hSOD suitable for soaking 
experiments into solution containing cisPt and co-crystallisation metal-protein experiments were 
performed. The droplets (5µl or 10µl) contained protein and reservoir solution (750µL in each well) 
Figure 43. Optical micrographs at 
different magnifications of crystals of 
CopC grown in the presence of Cu(II). 
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in equal ratio. The conditions to grow single crystal were selected from those reported in literature 
for hSOD: 
a) 2.2-2.4 M ammonium sulphate, 50 mM TRIS pH 7.5, 50 mM NaCl, 10-4 MEDTA, 0.01% (w/w) 
NaN3 (Parge et al., 1986). 
b) 35-25% (v/w)PEG 8K, 50mM TRIS pH 7.5, 50mM NaCl, 10-4 MEDTA, 0.01% NaN3 (Parge et 
al., 1986). 
c)15% (w/v) PEG 3350, 0.2 M calcium acetate, 0.1 M TRIS pH 8.0 (Strange et al., 2003). 
d) 2.1 M ammonium sulphate, 0.8 MNaCl, 50 mM TRIS pH 7.5 (DiDonato et al., 2003). 
e) 2.5 M ammonium sulphate, 0.1 M NaCl, 50 mM TRIS pH 7.5 (Strange et al., 2006). 
f) 3.0M ammonium sulphate, 0.1M NaCl, 50mM sodium acetate pH 4.75 (Strange et al., 2006). 
Hundreds of experiments were performed starting from those six conditions searching for the best 
one to growth single crystals. In each experiment, parameters such as precipitating concentration 
and pH of the buffer were changed one at the time or at the same time. The tested protein 
concentrations went from 20 to 8 mg/mL. When experiments to obtain crystals of native protein 
suitable for soaking into a platinum solution were set up, the protein was dissolved in 50 mM 
KH2PO4 pH 6.8.  
In this case, the crystals 
generally always grew 
using condition a, b, d, 
e independently of the 
protein concentrations. 
In most case, 
aggregates of crystals 
were obtained (Fig. 44). 
When 2.1 M 
ammonium sulphate, 
0.8 M NaCl, 50mM TRIS pH 7.5 or 2.5 M ammonium sulphate, 0.1 M NaCl, 50mM TRIS pH 7.5 
were used as reservoir solution, after approximately 6 months single native crystals appeared (Fig. 
45 a and b, c respectively): 
All native crystals were used for soaking experiments: in these experiments crystals were soaked 
into a drop (5µl) containing the precipitating agent and the buffer in which they had grown, and 
cisPt. 
 
 
500 µm 100 µm 
Figure 44. Optical micrographs at different magnifications of aggregated native human 
SOD crystals (20 mg/mL in 50 mM KH2PO4 pH 6.8) grown in the presence of 
ammonium sulphate. 
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a) 
200 µm 
b) 
250 µm 
c) 
200 µm 
d) 
250 µm 
 
 
 
 
 
 
 
 
 
 
Because of the low solubility of cisPt, it was generally possible to prepare a soaking solution in 
which the concentration of cisPt corresponding at most to a protein-metal molar ratio 1:0.2. 
Although the low amount of cisPt, crystals dissolved in few minutes once introduced into the 
soaking solution.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 46. Optical micrographs of single human SOD crystals (20 mg/mL in 1.27 mM cisPt (protein-cisPt 
molar ratio 1:1) and 50 mM KH2PO4 pH 6.8) grown in the presence of (a) 15% (w/v) PEG 3350, 0.2 M 
calcium acetate, 0.1 M TRIS pH 8.0, (b) 2.2 M ammonium sulphate, 50 mM TRIS pH 7.5, 50 mM NaCl, 10-4 
M EDTA, 0.01% (w/w) NaN3, (c) 2.3 M ammonium sulphate, 50 mM TRIS pH 7.5, 50 mM NaCl,     10
-4 M 
EDTA, 0.01% (w/w) NaN3, (d) 2.4 M ammonium sulphate, 50 mM TRIS pH 7.5, 50 mM NaCl, 10
-4 
MEDTA, 0.01% (w/w) NaN3. 
 
Experiments of co-crystallisations were also tried. For these experiments hSOD-cisPt adducts were 
prepared dissolving protein and cisPt in 50 mM KH2PO4 pH 6.8 in molar ratio 1:1. The adducts 
250 µm 
a) 
250 µm 
b) 
250 µm 
c) 
Figure 45. Optical micrographs at different magnifications of single native human SOD 
crystals (20 mg/mL in 50 mM KH2PO4 pH 6.8) grown in the presence of (a) 2.1 M ammonium 
sulphate, 0.8 MNaCl, 50 mM TRIS pH 7.5 and (b,c) 2.5 M ammonium sulphate, 0.1 M NaCl, 
50 mM TRIS pH 7.5. 
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were left to interact 1 day before to set up crystallisation experiments. In 3/6 months, crystals 
generally grew in all the tested literature conditions.  
Crystals tended to grow aggregated even if in the same drop also single crystals was possible to 
observe (Fig. 46a,b,c,d). In particular, in the same drop crystals with different morphology were 
often observed, especially when the used precipitating agent was ammonium sulphate (Fig. 46 
b,c,d). 
 
4.2.4 Human ubiquitin: Crystals of human ubiquitin and cisplatin or other metal ions such as 
Cd(II), Cu(II), Hg(II), and Zn(II) were prepared by co-crystallisation or soaking of already formed 
native crystals (Falini et al., 2008). The crystallisation of metal ion-hUb adducts was carried out by 
the hanging drop method at 293 K. The drops (5µl) were formed by mixing equal ratio of protein 
and precipitating solution. The volume of the reservoir solution was 750 µl. The tested reservoir 
solution were those reported in literature: 
a) 28% (w/v) PEG 4K 50 mM Na cacodylate pH 5.6 (Cook et al., 1979). 
b) 25% (w/v) PEG 1450K, 200 mM cadmium acetate, 50 mM HEPES pH 7.0 (Martin et al., 2003). 
c) 25% (w/v) PEG 8K, 200 mM cadmium acetate, 50 mM HEPES pH 7.0 (Martin et al., 2003). 
d) 60% (v/v) MPD, 20 mM Na citrate pH 4.0/4.2 (Igumenova et al., 2004). 
e) 31% (w/v) PEG 4K, 50 mM Na citrate pH 5.6 (Benitez-Cardoza et al., 2004). 
Hundreds of experiments were set up. The protein was dissolved in milliQ water at a concentration 
of 25 mg/mL. The metal ion was added to the protein solution up 
to a concentration close to that of precipitation. Hg-hUb crystals 
grew only in the presence of Hg-hUb molar ratio 1:1 and the 
reservoir was composed of 25% (w/v) PEG 1450, 50 mM HEPES 
pH 7.0, and 2.92 mM Hg(CH3COO)2. Orthorhombic crystals 
appeared within one month (Fig. 47). 
Single crystals of Zn-hUb were grown in the presence of 25% 
(w/v) PEG 1450, 50 mM HEPES pH 7.0, and Zn(CH3COO)2 at a 
concentration ranging from 200 to 25 mM.  Orthorhombic crystals formed in about two weeks at the 
lowest zinc concentration (Fig. 48a), while cubic crystals formed in a week at the highest 
concentration (Fig. 48b,c). At intermediate concentrations around 75 mM both crystalline forms 
precipitated.  
 
 
 
c) 
Figure 47. Optical micrographs    
of Hg-hUb crystals. 
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Figure 48. Optical micrographs of hUb crystals grown in the presence of (a) 75 mM Zn(CH3COO)2 and (b,c) 
200 mM Zn(CH3COO)2. 
 
Cd-hUb was crystallised using a precipitating solution composed of 25%(w/v) PEG 1450, 50mM 
HEPES pH 7.0 and 200mM Cd(CH3COO)2. Cubic crystals grew within two weeks (Fig. 49).  
 
      
 
Figure 49. Optical micrographs of Cd-hUb crystals. 
 
Crystals of native hUb were obtained in the presence of 30% (w/v) PEG 1450 in approximately 1 
month (Fig. 50). 
 
 
 
 
 
 
 
 
Figure 50. Optical micrographs of native hUb crystals. 
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Since any attempt of co-crystallisation cisPt-hUb or Cu-hUb failed, soaking experiments with 
native crystals grown in the absence of metal ions (the reservoir solution contained only PEG and 
the protein was dissolved in milliQ water) were tried. The hope was that cisPt or Cu(II) entered into 
crystals allowing to identify their binding site(s). 
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4.3 CRYSTALLOGRAPHIC STUDIES  
 
4.3.1 Human Hah1: Since the crystallisation conditions of Hah1 have been reported in the 
literature (Wernimont et al., 2000), we were confident that Hah1 single crystals would be obtained. 
Although several crystallisation experiments were performed, no crystals were obtained neither of 
native protein nor of adducts with platinum. Currently, experiments have been performing to 
identify a reservoir solution that produces native crystals of Hah1 suitable for soaking experiments. 
 
4.3.2 CopC: The crystals grown in the presence of Cu(II) were tested at Elettra (Trieste, Italy; beam 
line XRD1). They were soaked for two hours in a solution composed of 2.0 M ammonium sulphate, 
10% (w/v) PEG 400, 6.65 mM Zeise’s salts (protein-cisPt molar ratio 1:5) and positioned in the 
nitrogen stream at 100 K. Diffraction data were collected at Elettra (Trieste, Italy; beam line XRD1) 
and recorded at a wavelength of 1.0 Å, using an oscillation range of 1°, and a crystal-to-detector 
distance of 160 mm. The collected data have been elaborating to resolve the structure of the protein 
and verify if the platinum is entered in the crystal substituting the Cu(II) at the active site. 
 
4.3.3 Human superoxide dismutase: A lot of crystals were tested at synchrotrons of Trieste 
(Elettra), Grenoble (ESRF) and Paris (Soleil). Although crystals , either of native protein or adducts 
with cisPt, diffracted at a good resolution (2-3Å), it was never possible to index the data.  
Acrylamide gel electrophoresis revealed heterogeneity in their purity. A SOD1 modified form on 
Cys111 has been crystallised and the structure is under refinement. 
 
4.3.4 Human ubiquitin: The crystallographic structures of ubiquitin and group-12 metal ions 
Zn(II), Cd(II), and Hg(II) have been resolved by X-ray crystallography (Falini et al., 2008). 
A single crystal of Hg-hUb was soaked for few seconds in a cryogenic solution composed of 25% 
(w/v) PEG 1450K, 2.92 mM Hg(CH3COO)2 and 20%(v/v) PEG 400 and positioned in the nitrogen 
stream at 100 K. Diffraction data were collected at Elettra (Trieste, Italy; beam line XRD1) and 
recorded at a wavelength of 1.2 Å, using an oscillation range of 1°, and a crystal-to-detector 
distance of 100 mm.  
Prior to data collection Zn-hUb crystals were briefly transferred into a cryo-protectant solution 
(25% (w/v) PEG 1450, 200 mM or 25m M Zn(CH3COO)2, 15% (v/v) PEG 400). Data from Zn-hUb 
cubic and orthorhombic crystals were collected at Elettra (Trieste, Italy; beam line XRD1), at a 
wavelength of 1.0 Å, using an oscillation range of 1°, and a crystal-to-detector distance of 130 mm. 
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Cd-hUb data were collected from single crystals at 100 K at beam line ID21, ESFR (Grenoble, 
France) using a wavelength of 0.997 Å, an oscillation range of 1°, and a crystal-to-detector distance 
of 150mm.All data were processed and scaled using DENZO/SCALEPACK package (Otwinowski et 
al., 1997) and the statistics are reported in Table 17. 
The structure of orthorhombic Hg-hUb and orthorombic crystals of Zn-hUb were solved at 1.8 Å 
resolution. Cubic crystals of Zn-hUb adduct were also obtained in the presence of high 
concentration of Zn(II). They diffracted at the maximum resolution of 3.6 Å with cell parameters a 
= b = c= 105.143 Å. Data collection statistics gave Rsym = 0.154 and mosaicity equal to 1. These 
data did not allow a resolution of the structure with the required accuracy. 
The crystal structure of Cd-hUb was solved at 3.0 Å resolution in a cubic form.  
The structures were solved by molecular replacement, using the structure of native ubiquitin 
(1UBQ) as probe. The metal ions were added in the regions with high electronic density (contoured 
more than 5σ on the (2Fo - Fc) map) in the electron density maps, having a distance from the protein 
donor atom(s) shorter than the sum of the Van der Waals radii and a correct geometry. The 
refinements were performed with CNS (Brunger et al., 1998) with a starting σ cut-off on 
amplitudes of 2.0, which was later decreased to 0. A 5% of the total data was randomly selected for 
Rfree calculations. The models were rebuilt with the graphic program XtalView (McRee, 1999). In 
the final stage of the refinement of Hg-hUb and Zn-hUb the solvent network was built. Water 
molecules were automatically added, and after a visual inspection they were conserved in the model 
only if contoured at 0.8σ on the (2Fo - Fc) map and if they fell into an appropriate hydrogen 
bonding environment. Only few water molecules were manually added to the Cd-hUb structure. 
The high thermal factors of this structure (Table 18) with respect to those of Zn-hUb and Hg-hUb 
are probably due to the low data resolution and to an intrinsic crystal disorder enhanced by the high 
crystal symmetry. All the refinement statistics are listed in Table 18.  
The Ramachandran plots of the solved structures, obtained using PROCHECK (Laskowski et al., 
1993), show the majority of the residues lying in the most favored and allowed regions, and the 
remaining in the additional allowed regions. The C-terminal region of the protein showed a high 
degree of disorder, only the amino acids clearly visible in the electron density maps were included 
in the structure and refined. 
For Cu(II), the best results were obtained when native crystals were soaked for not more than 1 hour 
into a solution composed of 25% (w/v) PEG 1450, 50 mM HEPES pH 7.0, 7 mM Cu acetate (hUb-
Cu(II) molar ratio 1:2). Data from one crystal were collected at Soleil (Paris, France, beamline 
PROXIMA1) and recorded at a wavelength of 1.377 Å, using an oscillation range of 1°, and a 
crystal-to-detector distance of 199 mm. Crystal diffracted at 2.0 Å. Data have been elaborating.  
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Table 17. Cell parameters and data collection statistics for ubiquitin crystallised in the presence of 
metal ions. 
 
 Zn-hUb Cd-hUb Hg-hUb 
Space group P212121 P4332 P212121 
Unit cell a, b ,c, (Å) 44.36, 50.95, 93.32 105.253 28.02, 42.83, 50.37 
N° molecules in a.u. 3 2 1 
Resolution range* 32.5-1.8(1.84-1.80) 74.5-3.0 (3.1-3.0) 24.5-1.8 (1.85-1.80) 
Measured reflections 70229 348 734 29 818 
Unique reflections 19140 4357 5484 
Completeness (%)* 94.8 100 (100) 93.7 (58.8) 
Redundancy 3.7 80 5.4 
Rsym* 0.114(0.513) 0.078 (0.70) 0.074 (0.162) 
I/σ(I)* 11.7(1.3) 76.5 (10.4) 32.5 (15.0) 
    *Value in parenthesis refers to the last resolution shell 
 
 
 
 
 
Table 18. Refinement statistics for ubiquitin crystallised in the presence of metal ions. 
 
 Zn-hUb Cd-hUb Hg-hUb 
No. protein atoms 1706 1166 575 
No. metal atoms 1 12 1 
No. water molecules 127 7 105 
R (%) 22.2 27.9 23.5 
Rfree (%) 27.1 30.1 29.3 
B mean (Å2) 25.8 74.1 20.9 
B (Wilson Plot, Å2) 17.2 73.8 20.1 
B protein atoms (Å2) 24.0 74.3 19.3 
B metal atoms (Å2) 44.1 64.2 28.4 
B solvent atoms (Å2) 45.4 58.7 29.8 
rmsd bond length (Å) 0.005 0.012 0.005 
rmsd bond angles (°) 1.2 1.9 1.2 
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For the experiments with platinum, two soaking solutions were tested:  
1) 25% (w/v) PEG 1450, 10% (v/v) glycerol, 1 mM cisPt (hUb-Pt molar ratio 1:0.5).  
2) 30% (w/v) PEG1450, 50 mM HEPES pH 7.0, 7 mM Zeise’s salts (hUb-Pt molar ratio 1:2.5).  
Crystals were left into soaking solution in both cases 1 hour before to collect data. 
Data were collected at Soleil (Paris, France, beamline PROXIMA1). For the crystal soaked into 
cisPt solution, data were recorded at a wavelength of 1.071 Å, using an oscillation range of 1°, and 
a crystal-to-detector distance of 120 mm. Orthorhombic primitive crystal diffracted at the maximum 
resolution of 2.0 Å with cell parameters a = 28.31, b =42.68, c= 50.82 Å. The structure of adducts 
has been resolving. Preliminary data suggest the possible presence of cisPt ions close to His68. 
For the crystal soaked into Zeise’s salts solution, data were recorded at a wavelength of 1.071 Å, 
using an oscillation range of 1°, and a crystal-to-detector distance of 195 mm. Crystal diffracted at 
the maximum resolution of 1.8 Å. At the status of art, those collect data have been not processed 
yet. 
 
4.3.4.1 Characterisation of human ubiquitin-metals adducts: Crystals of hUb were grown in the 
presence of different concentrations of Zn(II), Cd(II) or Hg(II) acetate. Zn-hUb adducts crystallize 
in orthorhombic or cubic form depending upon the metal/protein molar ratio used (8:1 and 70:1, 
respectively). Crystallisation of a Cd-hUb adduct takes place only at high metal/protein molar ratio 
(70:1), while crystals of Hg-hUb were obtained only at very low Hg(II)/protein molar ratio (1:1). 
The structure of orthorhombic Hg-hUb was solved at 1.8 Å resolution. The asymmetric unit 
contains one protein molecule and one Hg(II) ion. Inspection of the electron density maps shows 
other regions which could host metal ions with low occupancy factors (i.e. the fraction of sites 
occupied by metal ions) and high thermal factors, these ill-defined metal sites were not considered. 
His68 binds Hg(II) through NE2 of the imidazole ring. The metal ion completes its linear 
coordination geometry by binding NE2 of Gln31* of a symmetry-related molecule (Fig. 52a and 
Table 19). This site has an occupancy factor of 0.77 and the bond distances for Hg1–NE2 His68 and 
Hg1–NE2 Gln31* are 2.2 and 2.4 Å, respectively. 
Orthorombic crystals of Zn-hUb (1.8 Å resolution) contain, in the asymmetric unit, three hUb 
molecules (A, B, and C) and one Zn(II) ion, which interacts with two protein molecules (A and B) 
by coordination to NE2 of His68 residues (Fig. 51B). This site has an occupancy factor of 0.50 and 
the bond distances for Zn–NE2 His68A and Zn–NE2 His68B are 2.5 and 2.4 Å, respectively. The 
Zn(II) ion interacts weakly also with two water molecules. His68 of the third protein molecule (C) 
in the asymmetric unit does not appear to have metal ions in its proximity.  
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Figure 51. hUb metal binding sites Me1 (A, B, C) and Me2 (D). (A) Structure of the Hg-hUb adduct; (B) 
structure of the orthorhombic Zn-hUb adduct; (C, D) structure of the cubic Cd-hUb adduct. The distances are 
reported in Å. 
 
The crystal structure of Cd-hUb has been solved at 3.0 Å resolution in a cubic form. In the 
asymmetric unit there are two protein molecules (A and B), each one interacting with several Cd(II) 
ions. The metal binding sites are the same for the two protein molecules, but the occupancy factors 
are different (Table 20). One cadmium ion (Cd1) is anchored to NE2 of His68 and completes its 
quasi-tetrahedral geometry by binding the carboxylate group of Glu64* of a symmetry-related 
protein molecule and two water molecules (Fig 51c). A second Cd(II) ion (Cd2) is anchored to the 
carboxylate group of Glu16, which undergoes a remarkable displacement from its position in native 
hUb (PDB code: 1UBQ (Vijay-Kumar et al., 1987), Fig. 52a). Cd2 also binds the NH2 and CO of 
Met1, the carboxylate group of Asp32* of a symmetry-related molecule, and a water molecule (Fig. 
51d).  
Binding of Cd2 appears to weaken the hydrogen bond between CO of Met1 and NH of Val17, the 
distance between these two groups increasing from 2.5 Å in the native form to 3.4 Å in the adduct 
(Fig. 52A); however, the local fold of hUb does not change significantly, due to the persistence of 
the hydrogen bond between NH2 of Met1 and CO of Val17. Donor atoms for the third Cd(II) ion 
(Cd3) are the carboxylate oxygens of Glu18 and of Asp21* and Glu18* of a symmetry-related 
molecule (Fig. 52B). 
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Table 19. Metal ion – protein donor atom distances below 3.5 Å in the most relevant metal binding 
sites of hUb. 
     *indicates that the residue belongs to a symmetric molecule 
 
 
 
 
Figure 52. (A) Superposition of the structures of native hUb (white) and Cd-hUb (blue) in the region of the 
binding sites Cd2 and (only partially) Cd3. The interactions between the metal ions (Cd2 and Cd3) and donor 
atoms are indicated by dashed lines. The Met1 CO — Val17 NH and Met1 NH2— Val17 CO interactions are 
indicated by dotted lines. (B) Cd3 metal binding sites in Cd-hUb. The three symmetry-related hUb molecules 
(coloured in different blue tones) are linked by a bond network involving three Cd2 and three Cd3 ions (light 
blue spheres). 
Me-hUb 
adduct 
 
Metal ion 
sites 
Chain A 
  
Chain B  
   Protein residues Dist. 
(Å) 
 Protein residues Dist. 
(Å) 
        Hg-hUb  Hg1 His68 
Gln31* 
Gln31* 
NE2 
NE2 
OE1 
2.2 
2.4 
2.7 
    
          
Zn-hUb  Zn1 
 
His68  
W1 
W2 
NE2 
O 
O 
2.5 
3.2 
2.8 
 His68 NE2 2.4 
          
Cd-hUb  Cd1 
 
 
Glu64 
Glu64 
His68*  
W1 
W2 
OE1 
OE2 
NE2 
2.3 
2.5 
2.5 
2.6 
2.5 
 Glu64* 
Glu64* 
His68 
 
OE1 
OE2 
NE2 
 
2.6 
2.3 
2.3 
 
  Cd2 
 
Glu16 
Glu16 
Asp32* 
Asp32* 
Met1 
Met1 
W3 
OE1 
OE2 
OD1 
OD2 
NH 
CO 
 
2.5 
2.3 
2.6 
2.7 
2.7 
2.5 
2.4 
 Glu16 
Glu16 
Asp32* 
 
Met1 
Met1 
W5 
 
OE1 
OE2 
OD2 
 
NH 
CO 
 
2.5 
2.4 
2.6 
 
2.8 
2.6 
2.3 
 
  Cd3 
 
Glu18 
Glu18 
Asp21* 
Asp21* 
Glu18* 
W4  
OE1 
OE2 
OD1 
OD2 
OE1 
2.7 
2.3 
2.6 
2.6 
2.7 
3.4 
 Glu18* 
Glu18* 
Asp21 
Asp21 
W6 
W7 
OE1 
OE2 
OD1 
OD2 
 
2.8 
2.4 
2.6 
2.5 
2.9 
2.5 
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Table 20. Occupancy and thermal factors of Hg(II), Zn(II), and Cd(II) ions in the binding sites of 
Me-hUb adducts. 
 
    
 
  * Occupancy factor defines the fraction of crystallographic sites occupied by metal ions 
 
Similarly to Glu16, also Glu18 undergoes a remarkable displacement from its position in native 
hUb (Fig. 52a). Cd2 and Cd3 bridge, 
in pairs, three protein molecules of 
different asymmetric units (Fig. 53a), 
thus playing a crucial role in the 
molecular packing. Other Cd(II) ions 
are localized on the protein surface 
and bound to carboxylate groups, 
however their occupancy factors are 
generally low. 
Cubic crystals of Zn-hUb adduct 
were also obtained in the presence of 
high concentration of Zn(II). 
Unfortunately, their low quality 
prevented an accurate determination 
of the crystallographic structure 
which, however, appeared to be 
similar to that one of cubic Cd-hUb.  
In general, the observed metal ion–
protein donor atom distances are 
slightly larger than the average for 
Me-hUb 
adduct 
Metal ion 
sites 
Chain A 
 
 Chain B 
 
 
  occupancy  
factor* 
thermal 
factor (B) 
occupancy 
factor* 
thermal 
factor (B) 
Hg-hUb 
 
Hg1 
 
0.77 
 
28.4 
 
 
 
 
 
 
 
Zn-hUb 
 
Zn1 
 
0.50 
 
44.1 
 
 
 
 
 
Cd-hUb 
 
 
Cd1 
Cd2 
Cd3 
0.70 
0.85 
0.85 
67.1 
59.4 
58.4 
0.20 
0.45 
0.75 
63.9 
64.5 
61.2 
Figure 53.Packing of molecules in cubic Cd-hUb (A, B) and orthorhombic 
Zn-hUb (C, D) crystals. hUb molecules are coloured in cyan and yellow, 
respectively. In (A) and (B) hUb molecules forming one trimer are shown in 
more intense colour; Zn(II) or Cd(II) ions are shown as red spheres, while 
the Zn(II) or Cd(II) ligands are shown as blue sticks. Regions containing 
poorly wrapped backbone hydrogen bonds (dehydrons) are shown in red. 
Conserved contacts between two hUb molecules within the trimer are 
shown in detail in (B) and (D). Residues at the interface are shown as 
green and blue sticks and pointed out by arrows. The metal binding sites 
are indicated for one hUb molecule. 
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inorganic compounds. This is not unexpected since the donor atoms are linked to the protein frame 
and thus are more subject to spatial constraints.  
The three structures (superimposed in Fig. 
54) allow a hierarchy among protein 
metallation sites to be established. 
At low metal/protein ratio the surface 
exposed His68 appears to be the dominant 
anchoring site. By increasing the metal ion 
concentration, the carboxylate side chains 
of Glu16 and Glu18, located near the N-
terminus of hUb, can also load a metal ion. 
Binding to His68 and to the N-terminus has 
been already observed, respectively, in a 
Ub variant crystallised in the presence of 
Cd(II) ions (Bang et al., 2006) and in a Ub-
like protein crystallised in the presence of 
Zn(II) ions (Rao et al., 1998). His68 and 
Met1 are also the sites of copper ion 
binding. Specifically, Met1 was found to be 
the primary site of attack by Cu(II) ion, which attains a tetragonal geometry by coordinating the 
nitrogen of Met1 and three oxygen donor ligands (Milardi et al., 2007). In contrast, when three 
copper coordination positions are held by a tridentate ligand (such as iminodiacetate, IDA), the 
imidazole nitrogen of His68 becomes the preferential site of attack (Nomura et al., 2004). 
Hg-hUb and Zn-hUb show preferential coordination to His68, thus resembling the hUb-Cu(IDA) 
system. It is most likely that, in the solid state, an adjacent hUb molecule plays a similar role like 
the IDA ligand in solution experiments, that is to provide additional donor atoms to the metal ion. 
Binding of Cu(II) to Met1 of hUb was shown to cause a destabilization of the protein, such a 
destabilization is not observed in the case of Cd(II) in agreement with previous calorimetric 
determinations (Milardi et al., 2007) This could be a consequence of the different coordination 
mode of Cu(II) with respect to Cd(II). While Cu(II) is bound to a single hUb molecule, Cd(II) binds 
to Met1 and Glu16 of one hUb molecule and completes its coordination shell by binding to Asp32* 
of a symmetry-related molecule and to water molecules of crystallisation. Moreover, the 
coordination geometry of Cd(II) is generally tetrahedral or octahedral, but not tetragonal as for 
Cu(II). It is also worthnoting that, notwithstanding the several attempts, all trials to crystallize hUb 
Figure 54. Superposition of the three Me-hUb adduct 
structures. Only the C trace of the protein molecules is shown 
in different colours. Zn-hUb is shown in green, Cd-hUb is shown 
in blue and Hg-hUb is shown in gold. Metal ions are shown as 
spheres of different colours: brown indicates Zn(II), light blue 
indicates Cd(II) and violet indicates Hg(II). The N-terminal (N-
term) and C-terminal (C-term) regions of the protein are also 
indicated. 
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in the presence of copper were unsuccessful, even when using very small amounts of Cu(II). This 
could be a consequence of Cu(II) destabilizing the protein structure and hampering crystallisation.  
At NMR studies, the primary binding of Cu(II) ions was identified to be a specific site at the N 
terminus of Ub, involving the Met1 nitrogen and three oxygen donor ligands in a tetragonal 
geometry (Milardi et al., 2007). Potential oxygen donor ligands are Met1 and Val17 (carbonyl 
groups), and Glu16 and Glu18 (carboxylate groups). At physiological pH the N-terminal group 
(pKa 9) of uncomplexed Ub is completely protonated and Cu(II) has to compete strongly with 
protons for coordination to this site. Since the residues close to the N terminus are involved in the 
formation of a strand, Cu(II) binding may destabilize the protein starting from its N-terminal 
region. Furthermore, in native Ub, the first residue, Met1, is involved in two key hydrogen bonds 
(Vijay-Kumar et al., 1987): one occurring between the N-terminal group and the CO of Val17 and 
the other between the side chain sulphur atom of Met1 and the amide NH of Lys3. Therefore Cu(II) 
binding to Ub might hamper the proteins' turnover and other in vivo signalling events regulated by 
Lys63-linked polyubiquitination (Pickart et al., 2004; Eddins et al., 2006). 
The Cu(II) affinity of the primary site of Ub appears to be competitive with that of amyloidogenic 
proteins involved in prion, Alzheimer s, and Parkinson s diseases. In all cases the affinity is in the 
submicromolar range, a fact that may have important biological implications (Rasia et al., 2005). 
The analysis of molecular packing shows that, in cubic crystals of Cd-hUb, helix α1 (residues 23-
31) of one hUb molecule packs against the N-terminal region of another molecule and comes in 
contact with residues 18-20 (located in the loop between β2 and α1) and with the side chain of 
Lys63. Each of the two hUb molecules, in turn, establishes complementary contacts with a third 
molecule, thus giving rise to a symmetric trimer stabilized by three Cd2 and three Cd3 ions (Fig. 
53a).  
Interestingly, a similar trimeric arrangement of hUb molecules is also found in orthorombic crystals 
of Zn-hUb, where Me2 and Me3 ions are missing, thus suggesting that such an intermolecular 
interaction involving helix α1 of one hUb and the N-terminal region of another hUb does not 
necessarily require support from metal ions (Fig. 53c). 
Instead, a series of electrostatic intermolecular interactions (H-bonds and salt bridges) are 
established (Glu18/Lys29, Ser20/Asn25, Ser57/Glu24, and Lys63/Gln31; Fig. 53b and d). Helix α1 
of native hUb contains a large number of poorly wrapped backbone hydrogen bonds (Fernandez et 
al., 2007) called dehydrons, which are generally correlated to the aggregation propensity of a 
protein (Fernandez et al., 2003). Mapping on the Zn-hUb and Cd-hUb structures reveals that 
dehydrons are clustered in the core of the trimer (Fig. 53a and c). Therefore, such "structural 
defects" in isolated hUb molecules may be partially offset in the crystals by intermolecular 
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interactions at the trimeric core. From this analysis it is also inferred that bridging metal ions may 
enhance the aggregation propensity of surface regions of hUb, thus shifting the equilibrium towards 
the formation of oligomeric species. 
In conclusion, we have shown that hUb can bind group 12 metal ions at different sites, His68, 
Glu16/Met1, and Glu18 being, in the given order, the preferred anchoring residues. Metal binding 
to the second and third site causes a polymorphic transition and stabilizes a trimeric arrangement of 
hUb molecules characterized by the clustering of dehydrons.  
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